var title_f34_61_35792="Chest radiograph of complete AV canal defect";
var content_f34_61_35792=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F87173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F87173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of complete atrioventricular canal defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph of complete atrioventriculare canal defect in an infant demonstrating the characteristic findings of cardiomegaly and increased pulmonary markings.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_61_35792=[""].join("\n");
var outline_f34_61_35792=null;
var title_f34_61_35793="Pityriasis rosea with herald patch";
var content_f34_61_35793=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pityriasis rosea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules and oval plaques are present on the trunk. A larger herald patch is on the right midback.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_61_35793=[""].join("\n");
var outline_f34_61_35793=null;
var title_f34_61_35794="Internal podalic version2";
var content_f34_61_35794=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Internal podalic version",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upward pressure on head is applied as downward traction is exerted on feet.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &copy;1980 McGraw Hill. p.1078.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_61_35794=[""].join("\n");
var outline_f34_61_35794=null;
var title_f34_61_35795="Atelectasis: Types and pathogenesis in adults";
var content_f34_61_35795=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Atelectasis: Types and pathogenesis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/61/35795/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35795/contributors\">",
"     Paul Stark, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/61/35795/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35795/contributors\">",
"     Nestor L Muller, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/61/35795/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35795/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/61/35795/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atelectasis describes the loss of lung volume due to the collapse of lung tissue. It can be classified according to the pathophysiologic mechanism (eg, compressive atelectasis), the amount of lung involved (eg, lobar, segmental, or subsegmental atelectasis), or the location (ie, specific lobe or segment location).",
"   </p>",
"   <p>",
"    The classification of atelectasis according to the pathophysiologic mechanism is reviewed here, as are the mechanisms of each type of atelectasis. Radiologic manifestations of atelectasis are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7255?source=see_link\">",
"     \"Radiologic patterns of lobar atelectasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF ATELECTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atelectasis can be divided pathophysiologically into obstructive and nonobstructive atelectasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Obstructive atelectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive (ie, resorptive) atelectasis is a consequence of blockage of an airway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35795/abstract/1\">",
"     1",
"    </a>",
"    ]. Air retained distal to the occlusion is resorbed from nonventilated alveoli, causing the affected regions to become totally airless and then collapse. The rate at which this occurs depends upon several factors, particularly the amount of collateral ventilation and the composition of inspired gas.",
"   </p>",
"   <p>",
"    Obstruction of a segmental bronchus is less likely to result in segmental atelectasis than obstruction of a lobar bronchus is to produce lobar atelectasis. This difference is the consequence of collateral ventilation between segments within a lobe. Collateral ventilation occurs via three distinct channels (the pores of Kohn, canals of Lambert, and fenestrations of Boren) and all of these channels must be obliterated for obstructive atelectasis to occur. Such collateral ventilation does not occur between lobes, unless the interlobar fissures are incomplete (which is the case in &ge;50 percent of normal persons) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35795/abstract/2\">",
"     2",
"    </a>",
"    ]. Of note, collateral ventilation is age-dependent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children have poorly developed collateral pathways and, therefore, obstructive atelectasis can occur readily. This is why atelectasis is common in children who have aspirated a foreign body. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2585?source=see_link&amp;anchor=H8#H8\">",
"       \"Airway foreign bodies in children\", section on 'Radiologic evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast, elderly adults with emphysema have extensive collateral ventilation through fenestrae of Boren, which are larger than the pores of Kohn. This explains why an obstructing lesion, such as a tumor, may have a long latent period in adults before it causes atelectasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35795/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who are breathing gas with a high fraction of inspired oxygen (FiO",
"    <sub>",
"     2",
"    </sub>",
"    ) develop atelectasis more rapidly than patients who are breathing gas with a lower FiO",
"    <sub>",
"     2",
"    </sub>",
"    . Under normal conditions, the ambient air contains 79 percent inert nitrogen, which is in equilibrium with the nitrogen that is dissolved in pulmonary arteriolar and capillary blood. After complete occlusion of a bronchus, intraalveolar oxygen distal to the obstruction is rapidly reabsorbed along a steep pressure gradient into deoxygenated mixed venous blood. The pressure gradient forcing nitrogen into the mixed venous blood is minimal. Thus, nitrogen disappears slowly and acts like an alveolar splint or scaffolding, delaying the formation of atelectasis for several hours. In contrast, in patients who inhale gas with a high FiO",
"    <sub>",
"     2",
"    </sub>",
"    , the alveolar nitrogen is washed out. With less nitrogen in the alveoli at the moment of bronchial obstruction, atelectasis develops more rapidly, sometimes within minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonobstructive atelectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonobstructive causes of atelectasis include loss of contact between the parietal and visceral pleurae, parenchymal compression, surfactant dysfunction, replacement of lung tissue by scarring or infiltrative disease, and strong vertical acceleration forces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Relaxation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relaxation (ie, passive) atelectasis ensues when contact between the parietal and visceral pleurae is eliminated (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83302 \" href=\"mobipreview.htm?17/44/18118\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35795/abstract/2\">",
"     2",
"    </a>",
"    ]. While this is usually due to a pleural effusion or pneumothorax, a large emphysematous bulla can have a similar effect. In this case, the visceral and parietal pleurae separate as the residual physiologic elastic recoil of normal lung parenchyma retracts the normal lung away from the bulla.",
"   </p>",
"   <p>",
"    Normal lung usually preserves its shape, even when its volume is decreased. This quality is called form elasticity and is the reason why relaxation atelectasis is more likely to be generalized than localized. Less frequently, the lobes of the lung may behave independently. As examples, the middle and lower lobes may shrink more than the upper lobe in the presence of a pleural effusion, while the upper lobe may be affected more by a pneumothorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35795/abstract/4\">",
"     4",
"    </a>",
"    ]. The loss of contact between the visceral and parietal pleurae may be local in this setting, which may cause local rather than generalized atelectasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Compressive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compressive atelectasis occurs when a space occupying lesion of the thorax (eg, loculated pleural effusion, elevated hemidiaphragm, or solid mass of the chest wall, pleura, or parenchyma) presses on the lung and causes the lung volume to diminish to less than the usual resting volume (ie, the functional residual capacity) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35795/abstract/1\">",
"     1",
"    </a>",
"    ]. Compressive atelectasis has a lot in common with relaxation atelectasis (ie, both eliminate contact between the pleurae), except compressive atelectasis is more likely to be local [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35795/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Adhesive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adhesive atelectasis is a consequence of alveolar instability due, in part, to surfactant dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35795/abstract/1\">",
"     1",
"    </a>",
"    ]. In the normal lung, surfactant reduces the surface tension of alveoli and decreases the tendency of alveoli to collapse. Decreased production or inactivation of surfactant leads to alveolar instability and collapse. Adhesive atelectasis is a significant problem in respiratory distress syndrome of premature infants, acute respiratory distress syndrome (ARDS) in adults, acute radiation pneumonia, and posttraumatic lung contusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35795/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cicatrization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cicatrization (ie, cicatriceal atelectasis) results from diminution of lung volume due to severe parenchymal scarring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35795/abstract/1\">",
"     1",
"    </a>",
"    ]. Common underlying etiologies include granulomatous disease (eg, sarcoidosis), necrotizing pneumonia, and radiation pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35795/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Replacement atelectasis occurs when the alveoli of an entire lobe are filled by tumor (eg, bronchioloalveolar cell carcinoma), with ensuing loss of volume.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14133513\">",
"    <span class=\"h3\">",
"     Acceleration atelectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;This type of atelectasis has been described in pilots subjected to very high, vertical accelerative forces between 5G and 9G: at 5G, up to 50 percent of pulmonary airways are distorted and closed due to gravitational forces. The atelectasis is exacerbated by breathing a high fractional concentration of oxygen. Decreases in vital capacity are a reflection of this type of atelectasis in pilots. Acceleration atelectasis can cause symptoms like chest pain, coughing, and dyspnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35795/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Rounded",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rounded atelectasis (also called folded lung, Blesovsky&rsquo;s syndrome, or atelectatic pseudotumor) is a distinct form of atelectasis associated with pleural disease, particularly following asbestos exposure. It is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7255?source=see_link&amp;anchor=H14#H14\">",
"     \"Radiologic patterns of lobar atelectasis\", section on 'Rounded atelectasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/1/32785?source=see_link\">",
"       \"Patient information: Atelectasis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5442404\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atelectasis describes the loss of lung volume due to the collapse of lung tissue. It can be classified as obstructive or nonobstructive. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obstructive (ie, resorptive) atelectasis results from the blockage of an airway. It is more common after obstruction of a lobar bronchus than of a segmental bronchus and it occurs more rapidly among patients who are breathing gas with a high fraction of inspired oxygen (FiO",
"      <sub>",
"       2",
"      </sub>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Obstructive atelectasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonobstructive causes of atelectasis include loss of contact between the parietal and visceral pleurae (ie, passive atelectasis), parenchymal compression (ie, compressive atelectasis), surfactant dysfunction (ie, adhesive atelectasis), replacement of lung tissue by scarring (ie, cicatriceal atelectasis) or infiltrative disease (ie, replacement atelectasis), and strong acceleration forces in pilots and astronauts. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nonobstructive atelectasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rounded atelectasis is a distinct form of atelectasis associated with pleural disease, particularly following asbestos exposure. It is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7255?source=see_link&amp;anchor=H14#H14\">",
"       \"Radiologic patterns of lobar atelectasis\", section on 'Rounded atelectasis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35795/abstract/1\">",
"      Woodring JH, Reed JC. Types and mechanisms of pulmonary atelectasis. J Thorac Imaging 1996; 11:92.",
"     </a>",
"    </li>",
"    <li>",
"     Muller, NL, Fraser, RS, Colman, NC, et al. Radiologic diagnosis of diseases of the chest, Saunders, Philadelphia 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35795/abstract/3\">",
"      Thurlbeck WM, M&uuml;ller NL. Emphysema: definition, imaging, and quantification. AJR Am J Roentgenol 1994; 163:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35795/abstract/4\">",
"      Stark P, Leung A. Effects of lobar atelectasis on the distribution of pleural effusion and pneumothorax. J Thorac Imaging 1996; 11:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35795/abstract/5\">",
"      Tacker WA Jr, Balldin UI, Burton RR, et al. Induction and prevention of acceleration atelectasis. Aviat Space Environ Med 1987; 58:69.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6978 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_61_35795=[""].join("\n");
var outline_f34_61_35795=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5442404\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF ATELECTASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Obstructive atelectasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonobstructive atelectasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Relaxation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Compressive",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Adhesive",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cicatrization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Replacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14133513\">",
"      - Acceleration atelectasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Rounded",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5442404\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6978\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6978|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/44/18118\" title=\"diagnostic image 1\">",
"      Passive atelectasis three views",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/1/32785?source=related_link\">",
"      Patient information: Atelectasis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7255?source=related_link\">",
"      Radiologic patterns of lobar atelectasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_61_35796="Primary sclerosing cholangitis";
var content_f34_61_35796=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary sclerosing cholangitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 239px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADvAV8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzfTwxs5m8xpUlJGCT8oyQSAenBzjmmLtaxuSrs8ODbrF1w/zcgHAHBHPP0rWSzt4LOG7z5twg5QsDtzwV9M/j2qrLcFbjzIljiUqpbaTvyecdSOP69xRe+x9LypqyKmnWNzBcW7xz72hUoElB+XOOuCQT9DV/UbgeXFAoEsgb5UPGSQTyenQGlG37Gl2QqNu/dqV2pyeDgc4PB/Gq6Wgu7uWe9McULNhj5jRkkKMYyRjvQn1Yr6WQs7pOBYur21ztQObcABAWGec+/OOxq5YWbwMsNqXnd2JMkr/d46ZxnH4UR3dvdsI0iRWB8yJthw6jowPI9R2OB071mTPa21+xmed45AcLEcgkH3/HGKN1ZDUla9yW51B3lMMELwxRP5TGLG0nIwAMjHbnHfoKUwDyriJZUiWIkMyg/MP0x93rg/SkWOKHdPDbtEkxOPMRtyc4GNuQoPHXB61eluZotMGmG4xaN86ow+Y4GAQVGTwKe2xKlLoZ2l2Esiov2l12T70CnG8E8A+oPHXFSyWtwbXfe3kMag7VVg+70GCN3NRSBp7L7BFbyloyWV1BXKsOxJGTnt1q5fpcNZWk1o4+0Qb5SIXK7V6Yc8DJB7HB+btUta7hzOK0JYpHQCOeJDcPA+xpIwxJyANrbuG6YJxVZ2nt9sMdu0zmMo0kkg5XJHXrnIHtVSylmt3uEkks4ZGblC+UI2jjGTyavXUcbeatysjKXIzHux6hiRwT0HGfpmq5VFiuV2RSiLEtu0Ibjzo/vHB4AGeOp5xyPelt4J476KS1nkW52jFs5woUZCkkHGSuCcenboKYs/KuGj1G1jVAo8qJQ7RnB6nqc/M3ep5LVInvpBdOsaMyFZHZiBjCsrAFQck9xjHQUm7MiT12LqtPc6iZo0CIQElE53x9Tu+Uc4wffvx62xbiE3zQpuCqEkjjICEFdylAcdfM7+nPrWdpyyW0ohnRUtA+8s0hcgAYJPJwenseetP1C38xjJazbZgw8tRLsjkUkEZxgZKnvjrQ1qXdrUva3qEWraK+nfagLhHWcNGXDOqhuCSuOQw71X0+R2t49kVs81vD5QdlIcdxludx4HpVGzwscAWM7nbZKJY2JjHP3BjjJx7dM9quWxSGORAgYtKYyFjwxBzgtwOPekoJKyCEEtWLdXD6gstvJ5RCggyRoVcEjsST2asuL7NDJgM01smcSSruwxxwB9Pb1rbS0srJsQoqyIMLk5ZV9M9axrCZ7e7ln1O3SSMjIjcYWToPUHjFVHRaI1Uepb8QWaarfpMHdJZiiMgOUG0ZJx/wH171FpdveaZMFs5cCSR33tlsrgYVhleO+OxAqS6vDPDHLh3kMTAzuDyhZsLuHPGQB6ACi11C+k0pAsYkuInV0SdVYEFSDy3GPTJ9aT2tYHCPY3HjO2eZEtkkkfeRFHsjBz0C9QMY71X03SA9surRXIWGZ8pvJHIJxtABxyO+OtVbeRpXksbtohJ5jbAuNrL1BP8AeIx+OOc1WijuYE8hPJ+xwjMDPtG4Ajknp+IxU8rSsn/wwO+iRqm2azniuppwodn3OCfm+cnHTPTufyqrrCiS2guXcKkcplAZeevA4zx/hTHa5utPjD7SEcthNrA8nGAcjOP51bt5A9qGE8wmRwzvIBjO7odwxjtx+dOzWoXlazIrSyu45o381Xt0yoNwTIxyQSB0x09+1Up5vs+r+Wshw2C+WPQ+gx9O9XrqdobzCzQMrJ8wZwuPpnHOP60pktVn2rNDd7CFLHb5o5xnBAP3jjIGOaE7PXqLn6XMm5sIo9sRklZFGJJBgYHZW7nkA8DrVy01CO7j8qALE4+WMMu5Tt9hj+lWntI3lWeOcKFBw0RBxnHXII/zxUlgZHuLgeSDswIChXMjEHcWUHk9O3rVOWmpOiM3UmmuYrSGW3iidyFQOd2ScAdPcirWm2CW+y0tikly7MxVVwzSfxKCcDaMcZ96R7+W4V7e1a+iQwsguD8nzZXoep+6AcD7rN60zRftWnme5Km4JQqXyctjcOeR61Du1oCbbuuiNO/0qPTbeKWSSZ4IYypLYAfgcnGc5x3A6546VkwSxX16bmBskKEWMjbuTPrz/EGGP8lXM0l3JICsTy8ySlfLkLZGAONvXgcdMVQjt/8AQYYJoo1vYpvMkeY7WCj+L5Tg43DBOe4qop21epneWxchu/JkaANGkiIZW3IWJKtt+Zgefu9MfjV/wvFPdxzQK7yztIGV5Dxnb0XnjgfrWXNNvtVtBMkpIDzNMxRWxyQSMcYAz07966jwwRYahfzW5HkQxqUyxYhmKg8nnuP1qajcYuy1CUnvuzqoGh1C3S3t5jtRQh4I4X5T+NbihVUBFVVHAAGAKzdFtorWxM7qsbSZlc8KFU8/gMAH8653XddF83lWUjpZAfvHYbBKc8AE/wAJ/DOQOeleV7N1Z8sdked7N1Z8sdkWvF/iO3t7ebTY1lkuZo2XK8BfUZPtXFwX7JMlsYlN3t3xxr8oQ7c/O/8AF1HQVptLbQRhpniVM5Ck4zz2A6896zrm6iS5lEbLNdAnCK4LE9RgKcdPX+delRpRhHlSPQpUo01yxY+b7Z57ulvDPNJEN8Zb5Nw6Yzjk5PJqeztkS7gt7aCKKSULGNigNyByT/nrVT5jciSa3aN3hVwVYBnPAIZc9uOcd+tW9JbUUvblo0hgZNql7lwhCMCHAOc5OeM+1XLROxUrRVzR1nw9MYnnF0pLYkYwsUYKDtAXI6ZJJGepzXNzzR2+svb3ELuZOHaNgqhiu7AUg+nXNa+oXqR6ZJHayQSxHBk8twznngHBxjJ7Vk3tzqaX0j6faW08Bf5AVHpznJGecjn2pU1K1pO+/l2FBNLuVE+ytG8E4MdjErYK8FhzwMk5IGe/X9ILiNLzT4HVQ9jbS4ijlJUOOcEkcg4GOpqM6WbZluZC7XOGO0y7l2qD/s8HGO55qzd3Mw0aI3AjNt5of7u5QQgIBUkc4bGR2UdOlaLcG1b9ClG0cKWgtmYiFisTou9YsnOOvJyABn0rX1DRZCscWpJNHJAxb5YyofcB0z6cUzQL1p9c0+RYoMW+LhrdcgA7RxjGMZOR6YFaN5ey6pqLCSVYriGNWkkkLfdyQowNxPLnv2/OG5c2uwOavaK0M61gjtreMQbja52hCclM9d3oeoxn0rNg1O4MpubuGWRlxDu4ztGSFAAAPJJz1rVju5pNPW4u7m3kkOQsMCPlMEjJZsDg56A8YxWdAbgWk0d7MzQSOH8y4G84/hwAx49vpWis9wbejiRTrLqF3Ck88dy0h2wsVxHgMT1U9jnPXpWmbma1v47X7aJrdSrySKi7RJ8yD8MM3U96rmKw+wtduswkjkGxYY1RVGEyQcnDc8gAgkdechbdPOnt1EM08cjLMgkCZbbz90tggg92H6cy2mrGabd3YdfTRS/ML608yKR5VSVgp3AkArg88jvn6dqlsTIsdtMjZuLg/PExHIAPC8Z3Hg4IPQ1JdpBNeubW3sJZ/s/2byLmD5AxZjnjIByQuASMDrTJofKvJ3v7GCGxkeNz5cahQx5YAAk/eOAcfWpu9gVSSd/6+ZY0+3utRnmnstRCqg2t5oT5R1wSB369q0NJni1C+mtLi7WxMMJkZoyrKxwOQzf72cY6D8a5/V7ibKWVtcIJwwIOGjzntxn1HpVuxvJ7yyMkkZw+YyIpMNvHQgnoOBx9eaThdadf6+ZrJuS3KJgMdlPaW6q8MrLiFlOyU8k/MDuyNoPH40+a1urex+wrBsbmKREYnATG0qCpJXHqQeG5OM1Z0WQ2sx1CytxNNkhyZsbTgDg7QTxjPT8cVeu76LxAizNa+aIzuVNqlssclSzHG3jpj15OaqTlzarT9SW237vUydMgTTM3JEo3QhFQ4+8SDgZHPQflWhAzfZLqWPess7LKyxrksVA28HODx27YPeoWneATzzvHHbeUI0gi3AZLDgjGOAMcdsilN5K1uHaKNYjGvzxuUaNckKduDu6eo+gqnd7o0TXUuzAkxFiscbsDMW/u4JwPfP0qMiEwvDp1zsWUs3zqNwbJUnGTkdKclti8lnkaUmcK4G4FYyMHgdQfp71LcGNpdzj/AFSZLhAWPtnPTjOMd6k01vcpCBIbWXN1AklwxDyA5UcYxgn/AGR361Kwa303bZqtxIjYVA2DknkcA9uayrie3luHS3kZ5h84i27UJPQZ+pBrXt/L8m6tJL6409jtklurfKmJQcAcZLBiwBHHIB7U5NpalSfLFuJViu4bS1WI728uMLtYAYGcY684J9qjtrPT/s91IJJIM4YtM6gHJ5x+OPWr5M0mktCfKW2Q+bG0KEO8YOQuCQBn9PSqoFy0BWzstsjnbtd1JIXkkYwMZK9SD7cUJ/IFZrXcqust2higSGO0ZnSYxFnBJONyk9MjGQSe+MdoLuKR7+3SRjILg7mKjhOAQD+JH1xVrT7cpaNJIvkyjOxYjgM33sk+uGXP8zUUVwbjR4YbeWaO68vccnLFQRk54BPI7jqaqwua2t/67GjDItlCY9zzGAZKIoyp5PrUd4sN5bGJjKsRJk2AD97tOeO/vx2qpbXZSSDz7WS4liXlmKgLyMHBJ9OcGtImVwZ54UeJPmVEwWHY5J4PPTpSs0Dd15GXdWkGszA3ksyiBciUqBv78dBgf5xjmeCwMAFxNMH8iMozouSw+8NnIHcdQelLby20d7udlVp3VEeNThz0GOMjHTmsyeN23yy3DtawyGSSEOWyQcbsEAHqBjrgU7PboZOy17m3Ff2l/b3MEzxtBN8kkBcBiqsrdQc7t2zPbANZFzYwyR296ysJocSEAHBxIwLAZ5+6fTgDpk1LFb2llDPBLEHM7GVZAozsyvT0B9K1NIvLi2trOxKhniX5pA52xDHy5HVs4wcEY9+lK7S90mVO6u0Vlnlnit7+5vPPaNkjIwvyhuMcAf3jV3Vkt5rS3WW5j8nfuaI8yMAVI2DIycjv6fWlnM5vGto188uPlLHnO4ZySeSAM54rQgtLT+yLm5mmBubaTZNE8Wdp+UDB9cHOf8KhtRsOXupRMC4jS4kimhJuTHgiWIbhDnHzNg4wuOc9x9addwXqztdyWczxhTA07xsDtIBO3A2noevcHn0WazWO2ea2eQpA2ZMPgt83O7jkAg8c5xUtrrCTPK32kr56mELHuaMEgcDOCPy9auz3RL08jT1uGx05Vt4WM0KQ5EnVcsxOMhupLZx71b0mS3tneGQMIZU2bicEMDu5P0BrO0+B9O0x4b9VfycqU+/nAHGTgEVWmVJbY2kkCxyRKJWjiI3AlsDBxjpmslFNct7+f6js+WzOk8QeIY7tv7IsijxNhJpt45UAkgYz7DPrkcda5rVreOzF5sgjRpis74kbDvlsM+ei9emOT7YOlo4tJNsETgFmOVWPGW28kn1x3/Sq934hi066uEurKR1dirSPtOcHpjJyKVOPJ7sF/wAHzM1TjD3Ujk7O1bUrtoVeCKLOHn3EhSSW2p2OGJHJ713sViryWrxRr9ntoyBINxyOMfNnHJUdu31znf29ayxGMW9zBZyKGl+zbIwuehIyd3Yjjis26uzfSzCxmaaUyb1SMFEwCSGdmIJ6DgL3b8dGpzd3oPysdDJaac97HJqDiFTkB/MCkkkcDPB6Ht2qlaWFlp1zNqNkzC8uiybz8xA5VflzjoR+VZt293dae1jPNFbyRp5jOpYhi27K8fhz7H2qXT0ljkjhuY7e0tbMiRXiYkTEo2Q4C8gE4HHelyNLf5eQnvqJ4d0SPR4nkmeBJLgeWwhcsFUHP8XcnH5Vo3W1hI8rN5BAAXgAHjnP04qG5mJuDPeW8USxphHQ5VcnnjGR26etYn2mSS5ktbNgxlzIx3FMHdzjg8cVUYuT5mbxSiki3d3lxJvkjiYRlwY0SJlwuf4yOgA64NNgk1BIFNiYXmlZhK+792FLNhQWPJHpyc560y0s3vGW2WUWfl8yoy5MvORtBOeOpIz2zU2o7Vn+ywTI7wQhmWT1Ax04IJx1JI9qWl7IzbbdjWe302zuJ5PtSyylBvMKfMTgcsdoOB7c9KwJtInk0hkRYTdyYYtNvEbfNjBB+fIA44xU1nILpRb3TpGI4gkUZ+VxtA3qQTk4KgZwOla2myMLhLp7cSq5KvFJOpDDHUOu0ZzjpmkrxV/6/QyS6XepFrmnWVjYW0mm6Va3tzGiJK9zHICxwc7OVHXGB160QaHb38UdtbiUXceZVikKxMU4G0cAMqnHr1PJpHi1XSrAxh86MzmJnZVXbG/Byx7ZJ5rN89GWWS8lSSGI4iaOFxvQkD1OQOMkf3l6ZGZipW0l89/69CYxUVpuSazpl/HqcH2yyfyUGAbiASHAH97BXr1wetVoHjjurxbeciVRKEAkTzFkIPBI+bZuCZA5OOldJFe3d74cewcuowIfLVAU2IRwzY+UgZPJB5Fc99sa3mkNzIsexW82GN1OXH3QH5CjdxyD1Gc5FVByknF20/r+vzLlzNPntfyJbSacWitq7Rvp8ZLeZsctvCqW5YcAEv1wOlR2stvc3s4WJ/Ito1W5UyH5CVGR87cKMPnH90dalt9T+0wf6PH5VtJMizF5VkbdghuQF3HA4VQOnc1OtxqDrI8xkuIIwDHH5B3RDHJwvJHc5HYdO71XkTFNq9yustlYxTRXVvPb7m8yNWRgCQMDA6Zzn24596qubAwQp5gDSAKXcPHvJJKrtJO3OfzIPPFQyXLzypOIUuIrdvMRwGGMYJbIOMDjtStPEttbG2SH7NgJCBcqPmyfl5OT39/eqUblqXVE7xXVhZ2ziEPqm5gJIizBR7knPQ45zVvRY59ZhkOqRIJ4mCxyxwlFI6gkkc47Y5qTT9ZlgmHkSxxkwlhyoz8+Dy3Hp/k1Ol7/AGes3nFyI/3jSGMhTu5JzjGOtKXNfbUrqQWz29uk5urqSG4hlEciKoOGJ77VIOSpGTU3mQs5uLSV5ZWQ4i3YdiMjgcdwenpRNqUa3EIiv9yl1ieIIHznOFyBkd6u3DRmFEgtzE6KzFyGJYk7hgHp+vWk7316jV09zLaSRGljuvLghEZLHcd3bPJJ4xuqvaSRrHdSW4iMB+WOQPkOuM8nPqWqZ4rkyANKkrxsoEap/q1PUtg8ZHQnFOvIIxAYUVpBvDlVycMQT26Dk/41d0bp31RiR/aQZJoI4JIzEUlJOVMueRjPTAHXmtRtQnkud11cSC4KsBKmdoHy8BehHX+E8mpbOxRdE+03bwwyrKSG3jywfXOcZ68Zqy1hc3Wlz6jo8yiGLCq0qDEmWAI5K4x+tS5Rb1E5xhHV6jWTfbwTQpcPcMF3uX6AjBAUnAx9OnvVeS6xMwmKRzsSkbTlBvUcn7n0B554qjZavLcOlkYDcqxwWRxnBPsPTml0WzSG+aVoTHDjEe1vMyT3OOnGetVy8urEnfYt3V3bokMduruViYxsxO3cQeME+w7cZqkjrdTyxobcpsKKEO0qMYI4xxnHIrSuB5mB5Mrl5HyucbSMdeO/BH14pNGiji1QRXKy2qttjj+UvlOMqRjI/hOTjp3zSvZXLuormWxSe1liSFEsIRGI9jTse2TnBDc/UjtVy31CxluGsnup4Z9ozGhCCM5G0cc85xjnrWtNp1tCbqMAzRTMeuRuBJ/oarQLpsl4Nk+bm3ZWZDIMxnII4xxnHfNS58yuZt6aGfeZhnEiSyPbRYZ5tx3jHJw3TOPX2qG2jtLqU3M8csbmT928aYk3dQ24Aj8zjPbpXQ22JJXjjiLKFJkZG3YPGMgdBjP5VlQSxSukelzl48kShAHCDJJJ44IOOvHbHNO/QTs9BsNpa3Gmf6b9q3qFU4dSQQOuOfU+9OE1pFcRJJbzXcDxLIJRGrlgu4jJ6k8DFVdTElrK97d4MqOHiQEfdbcOgycc8H/I1dJgabRspGYoZJWwhB3L8qE8n3z2olort7he++xTP224S4kkEEZjnIjeMMF2gjOc98dD0pUVLh4bq9e2nhtgzbyNxQrk56Y4wv5cU/xCVstOWeHy2lZREqseiN1xzycAn3xVfTbcpayy2kDea0aMHbLKWK/3ePyz3p3uroE1qma0FjbwW7C2hURuQ5Ug4IJ3Zx+NQ6msTi1tYAUuGJeQpDhBzgDO3BGDz1pbV7lHfzLnzY1dQuFVduT+nPTPpjmtHVoksbeM2fm3MjuBluCOvzdMDGO4rK7UlfUl2TSaOd1K4h01ZraK7Ju5v3jbz9/PHzMAOOAcZ6gVqaVZxa5cSW0cc32ADzJ5IoyWZ+AoG8FccenapR9mEf70tNcA7GflQc+nY9QOKwtaltbS5jlktjO8iZO6baVwcYCgZx71duZWWj/r0CSut7DtWstRtXu7W2FtHp8fSAgAleOo6Z/+tWpuvPs+y5geMOu0BkVlPHTjIA+tRaLfAPLLbvhV3KqDBHTI6jP/AOv1q9NrNpdWd6NQmC4t/wDRXQ8b8MewPonB9aJya3jf8wleC11MtEtY51ge1hkuB+8zEigI3Vc9CM4HOPxp9ne3sc4jMO10UmTyogIy3BG0+3NVNJ1ieGCVZ5m2HlSFH7xRkjt/LFaMuqws2yVJFhQNIHIJZgo5GAOCfXH4U2ns0GiVx0V5M8TyX93GoRnkYvyUUHA6AngD8/wrJXULuRrqMzWVz5EiuqwSEEISSGJJAPG09f8ACor29e8Yy2MSeWVJ/eE5EfQnnHOR6fhWnbwxmFiLeTMkXy4bJYAc9uB7mnyqOtikmmmnoLqN05SGJYxPO43BWUkFMn8Oqn8qxWfU7qDMblTvwVgkRlAAxhck9+1WpZg+mS20pVG4Qlvk2qGDAYPXksc+9RWbyR6MJWntY3knLvIzqUAIwADuxnp3zVKNkNS6NGjBfx2qG8ZAYQnz+U5VEUsNrBSuTnjjjqacZJNRuRdWKCWCMbZEKBGGQrjq2DkH8Px4W8kSCGEFI4LYyj5WLoyDBPQHqTjrkcnNQ28NzBcRzlp3tXdikPy8gkENxgEYzjnOMcVjZbo5mzSsdN1eQH7O1pIyIRGs0RXDH7zHDnAyDjHPI9xU0vkabeKb18yWsm5reHPJZCAMkYxg5/KuV+16hmaN5hPs5dVQ9dp+VWwOD2wc8DmkFvLNKDJcOwYHZLZzAtjjI3H5sgr09G/IdNp+89CWzqL/AE+WSxh1RJitq0YdII/lBQ5I46Ac9PWsjXLO8u5YIDaG1cKZW2yK0rAcYyCFxk+v4d6bDfRS2lqjteSRrktHGVKAhiqgHO9T93GCMHGMCpJnkttUaW7uYBZ+WSq3cqDILdYyMA/w8Mc4ycdDSV47vuJT094rrppn0+Z9Rdvt9skUWWUNkySFMlsn5j03D0XPpTPs7WFzcvf3Kqd5G2SI4QA5fZtZsYH54Ax3BuWW6jgdpW2gJ+/RWIySOGAwrcYGCM4Xr1KK7/a4xpq77FP3QkVmd423LlQckrlAQM46npgkWuZbvQVrbEurTQ29tpxsVSNrqVWW68v5ps9MEEEY7bgOSear2V3cTeIrrM801uIz5tmDiJAQFBClsHGcn8cZq8t2DYXYs1mk1NTLCMYaVQSdrcHPBAG4c8DvVG2klurpUaGGF4QdsKiZcsBjbk/dII4AIGQM5pdLW/r+v6QW1JVuYTaeZeW9rDDJGRGY7QPGXYsBxvB52NzgdD6g0kEkV3JcWoup4b7DIYQxw7gZYgYwOAQMt2H0qq92zxqJoUF1HKqu5zHEiEZyQSDnpyBnANVZYnt7ie2EyMpLAsYlZlcru2M+3Zw5G7njBquW2lwk+jNKWaKa7itpcJHNl4E2YEhAw3QnH44+6Oe1XLuZEvbzS723ii1H/V5Rd00Z29Afutxz99cbj1xzlNdzeV9oZbURtgM0LjySee0Tbi3C9On51ot5b+US0k9q7uxjzHvLrySmcEAfL1OeDSt/X9fl1NE2/QshLq3g2MV3+Tx53zY44JAP3s+5+pqnZ36WqyeYCtywkcOxymIwWY8DIGdxA55NW9O1K6jWS2gW1FnKN8Us0ZySOVAYcZwBwOueKgv4rp2ZrOaSKUYecRA7Zi3HQAtkYIA4xx709dmi5StqkdXd6BNdaf8Ab3lhgi8oT7hktt25ycD0/niuOutQtPNSGLy7p1cbnZSDgEjcMj68V20PiQX2im2UxrKFEEu1lIBJ24+8cE471zyxadJdJEbKQtG53umQM7uQ2DyuSecY681jQlNJ+06BTnVs+YZqNpbvpZjuFW2VONqLvUY5yBxWbIkmkQXtpc313cwQ7GnjnX5VJIwcB2B6r0yfyroLixjt82xEsNvDOYisw4YYOFDEHIJII5yao3H2aOWa1kOy3G3bseQFe/zHOR7VpCV7W1RV7tNFGaMCxUxxQReS8ayvCnlsMleM88bWGetT2eo2dzOVtUiRQwiZyCCzYY9NvcKScnsKsT6fDqllKEk2qOCUmTqBkEgEkY46jPAqSc/ZFEl81usKuWUlArdMBf3YGRyT3NVdPTqV1umO+zyfZLpZUBdgQixYVZBzjg98YzkjmqkLSQRzxX5T7NCrO3y5O3k+pzjjsPpUNrqlvEWcNPO4c75JCEXAA5K5Xjr0GePWpYNQjbUJba5uFLqvmDyR+7UDBIORnBB7+9LlY00loGhXcU929pYSrM8j+YgnZlAQ4wFwp9R1x1pEjm1JJ7WaIukYaRZUcAvtPoenbv8AlVmQSuJJ9MmhgMvyHy0GJExjkEHnIPpUkB8t4ba2WWGFGEc/mIFWRcHheORkDOfah73QlfZjrbSUJa2M0rsg88RKBtGOMDJA5zUEmmRQRXEscrpiMp5iAeZggHjpg85HP+NaF3Y2d1EsFw804hbIZmyRnqCe46cVRs71Y7S5QG2STzmEURYBgg4AxnrwefbrSUpPqF/xIhNaLZveNbiVYflll2KWwSo5zgnkjjmtCC7CaJcXch2WiSMwGOcZGeO30qpZXVtD5hQQsxJc+SqqTnjnOPm/Ws1o757SSzuIWktpUDKqEF2IyeQTjIwucDGKpx7hK7ZIL61Sd1mSJJnlFsVJLtG3O3YdoAOd2DnAq4InKxvayTOYy3mFpdpbn+Lg7sdB7AVWlaxCGV7U5VA0kkKAhzkDZ7nJzz0znNQW2paZb3MarY+ZtO+UFc7N3PduDjsO9O3VINELFc+ZNEF8oNKz4hCFlfDbjkHaM4U4+prT1PWIrGCKSWxcq7HcrSKGRR1YYBBPtkVmWsjT3t3LayuVjbzYrdXwyrycMv09e+Oat2dwkspup7eNiYs+a5RgpDN8pO7GcAHHXBonFXE3db2Zct7pLhJJLUQNKRliUI4479fTPHc1TmVpbd47mUSB+T5SlAuCOxJ9anmummsI54zbW8k2GCzuBgE8DgnnGPX3rHA8m5UTwx29uxJd5CeMDj5skZJOMH0oiluUmrlp7aayWzmMUQjdFw7IDI4PGSQetZNzc2eprPLayzuiKUxKuCrE9ep/yK07x5Y3kNldItuVJCqQ21geTnBGMDHB6mrV1bQLZSm0gLOq4aSddxZj1Iz16Zp32uTKMmZejqwTZIBvjKv9V7foK0rBbOeea4Rt42s0m8fMvB+XoeDjHU1SsPMWV2meKSOFUZpAAPLHO5eg6Yq8bmGJTLGZi6szbQwYsASDnnkZIxj2ptPYpK2wyMRXLNcWcCjKOm18KpCNg8gHv047mmXFxtitoY3BSZdoEYIYDg53HHt2/CpZrizuFt3v7ieGOXIEcETmXORwcqVC9e+cmqFzJL5bNYm4VWICvcPn5R1PynC5GeeO1Jauw46b6lSMTRLLuvZ7cjktbOd8gOOp49B19PpRqFxFc6UsjKhtC2cYxIW3HknBB/z+NiydbG6Cb/PifmLpvxj5s5wDz2rQuvPgslW1wiZGWdGdifXgH29qpPXUqcY2uizqEUN1dCy0+RytttE9wuHBVgG44x1HXJ6VkDZa3lxEPtDRI5Y7V8sOcANkspyMKpO0j73GK35Suob5p4pjPHAYp4lKkESqNnzE8dFGcHG7oRmuXm8y5M6L5sC2avlhLlowuFClsDI/dnoO3HasKe1n/X/D/qcDb26mvNOj2Vxm6YWt4yxtC7ou0Lkd1DA57H19q5OS5n0eQGW1jRlBBt/NDLz0yQSe5PUfoasLDHcOIor+8meI/wCvBwu3qSMncwIGRkKeORk4C6Om6ZlRH/s9SRIxIBJIBAx35A/StUkkO90rFm+mhXw9YpYxSyPCzbpEfOwDzAQflIOPUdajiYQKzaelzG0rkSoF3AsOSy5XODxjk8A9eSMkomV8u5njhZiCHkLovyknGACGHUfKRkZzzgXdCtpWDjSEk1CXcZWdtsWzcMHhm5PA5z0JpWUb3Ii22dB9nihs1szf2r2Ubq6sIyd4ZgwfcHwDn+H/AGQMc1l2moG+sJLW2iLJGDBH9ocOZI98QABQIBn5Tnnofwrpd3SB7mG4ljacF/sszlw7KNwZduAOCDzzkVpSzpY3aTXkEdpf3BFyrKBJCgGWI2jDAnB6E8KOvFSk15jtoU4ZLoXtpFcWG6BZxCzh8+WvyhioHJ2gLycjscmrcErm2nVnWBHDjyLtCc5yCEcFN5OTgDJ7cnmoiVur6O7tLi4S7uH/AHShBHEzE/eyGLFWYcghTx1PWluoopN9rIsoisrlTcyxqqvJljhSdx3ZG45/2exIFG/X+v8AhxX00ZNY28NnA0q6f9uXzGt5Yp5TH5SFUZmJGCcAjGPU9e0FwrQWSzNbrI1rJgfMRIcE/vFOdpAzkHaV471oPHHZXFzaxLtliUidzGMiMqpJbB+bqMYJ4HQ1n2riJfLknlt5bgmIvOSXJZ92BsyOvTLcfhy1rqXfsWdHtLa9vcXc88quN4eLBIUgg4wpDYKIDgfxfm+8t/sF9LaadNPFbIjLEPL85i3zcnAyMHHB/wAat6bFHcXMss1pLPDLhWkljjGzaCdrDexPqMZ69qL6OOC7nRZo40dvPjTLKw5zjcFIx8voOc9M0ou7sWk9x6LczXJtbSfyomZ5yS8e0McZUZGeigAZyd3tUd1pM8kcNrhUTc8kmGXMpJB3AE9iOQP0qxcahaJawy5jlSMhg5hJUMOQMHBJ4Jzx0qaPWomge5gjhdQo8yTyzGVPcMuTuHPGGo99fCixbfck80hTZb3SoZQn7xv3eArcZPPXbjv7GmW5t7jUp1t4rguYyj3M527lJB2iLapA5PzZ7e9S6frO7w42lrEzWkUZZp5JMSBVb5ywAIOCT061LZ3Ec6RizaF7dAqhnVgS2AQDx0wR+fas7PXT+u//AABRu9/+HKz28Om6flZEZI3VIkzgsnHOcnvn8vxrQ1+O602yhnhvrTaxOVwAMdPvFiOtZmuWa6nrEt8bqNfJQr5aRNtAUHnk++cVBpOkWtpexnUrtp4pYy/nTx74wMlR8vLZyG/L6ZqyspSfyt+H9blc1rNuw/7b9sspoLhlCCANLIDuAJI+UY78jv0OarZg1ZzLe3LQi1AUJjADHIxnHOOatWd1PAjpcWrIlpneVKg7gmOSCdwJI6AcnPblLuyt7+MKtvGBIC0MUTBDICVO8kqQDgD161adtlYfNfYivPCmoW11ZTSWzS225pHuGdflBwcEKQOenTPNW5ggs5JQ+JArKsuMnuMAdMjA456VdvtekNiNILgTzKE2Rg8McEAMTjuKy0Eca221Y5JJIjCsrr99goyzL3+7/eqYOcl7/wDSCHNZ33H26Xs1vbvEG81lKF3AztBGHxxzyeP0qBpIobQqkkcd6jL5iNIuQS2SuTx2P5VPYapPY6kcXUiw+ZEpjRSELKOVVd3AbOc/zrHv9Z02+1XUr2OJfMwAxIztLDAJG0Z6etXFScrW0/rQrmadpDVttPlhMJhKTFw7w3G9M4GAdx29m6f4VYs9duGma3lsFjWWTEr4cjdnGPbgCptJgmsFZIfLnikUZRWKg5J5ORz6dO5p2pakz6gYZVWCV49jwgZ4OeQRxnpVS1dnqC913W5Hd28FppV3DHF58rSBio3Ann9eh6elLpct1Dpt0ZIWZbcnZGq9SeTg89M+/Sq66zJJA6RRReZu8tDIDhccnGO3ArW0pEhhvLK5ZJCjYYbSVkDDPQ/XvS5ny6/1sCld3Kl+0lvZm8g2FtzPuYYA3YHTOc4LcfSqdnb2upyQ3NyJUViRIyA4d1Ge4PfA4q5e3Vi0FxaeVDsTEkgVcYGcZ+71pohtjHDNAks8RVFBiYKIwvbDAHuc4qldLsJrUqWlwun+JVFiHVJlMczMOFVgPmII4x/n0qe+u3s/MCMkpZ1UfKdjgg5IwcrjABJJH0onvfIkm8yABJlK/PhjKCpI2/3c9Tn2q7Cxe0Mz2cdqNrDqCUHfAX6Z61Mt7scY9bmGdPMi5E6xyODDNDIQrR+pwSCf/r1eis2u4YoGLm3DNIgZCp34AJJ44x0HHI71ZcfYbS0t3WOVH2qJpOZMEEg9Pb9aivYZrmWIwiLykJyrZHbrj64/P2p8zerKURg060MCxSSstyGCMYx6ndtGcjoa0JgsF9KZ723dlJUAMuI0B+bkHBwAfrjjk1nLZ3cTQYuldlO0koeevJ+bk89ahuDNPePkQGVfllMTMmxATkkleT16egpO76lctrPYle6kWa4itHjnt5nDwyFgN/TcV9gQeuelWYT9qtozcBRlhwrgZIPTP1FRQGK1WNnm8wSlvKcgnbxjnuefp68dBMZY9Otx5EkZlfJ3yIcAdScDvyO9DvskNKNt7kE013BclWWOODaWXPzdD0yD1xg/j3oWAyxybp41llUMyvCxBGM4GGGPXr271YtFmmC3FrGswcky+XhSx4y3zEf160ybVLlROs9uIUR1Q7mB5JwAACf8Ker0W4uboWRFALhZIfnZl2b1bsOeB+PfPSqrXbQajIbwFLULsiXcASeOc4PoeMVfvl8+RZvMVTkZ2g44BH1/i/QVn6ldSwIbpxIlrIwijZWG08bg2M5yQD2qY6g5dxLLVpLjQbFXFv59vFKzh0yXUHbgk5yChPJ9V5AzWJqtyt8UMwMSAKyohWNEUZAICnBPX1J4zmnAm3WOASRq3kmKRxt3c7Sy7ecHgj8CaoeVBczmOe5EADBFONysvQZ9D17j8KIwUdUcco8pEYooXWS/e4kZWVZYxKUMan+6HKnpjGfbNaYs9MvjFHYRaz/Fg3ilkxxkZTJzkZ/KsaIFxPLqA826BXYs77fNwcHJJx0x16Vrpsiu2JvjbwyKGRVuGURkZB4DgjP9Pejle9zGMbskfTnBeaNbqaVlKHejCIljnC8AAAHJAwfvY7VWMlyYRdXkcE+FC+UVB2ocEMcYAORjg568Yp1rcxG+WC81C8FkF3CSCeT5T0BIy38PHQdaS7Nwn7qMxTSAJC8e5Y1YLvJzzjIIX5u+cU1vYLpLUs3MNnDpqvHPNJvX91bygDk4BVyoGwjjcNwyc9c8yWVi1yUcwXlruQtiVpERZNuFKYPTcwxnsDjmr0s0MU1tEkNtJpt1dOZbiSMDj5Bkbvu8gjjr15rXu3MskVrAJZctkeZ8nkhFdlG0BdwyP/HRjpU3aRcYq+pgTWlw0lnFqO+NBIBI6OI96jA3A8EnGeW+YnPantZ2E0kSzfaZHTMc0bOS0RCkArg46KQRyTnoT0vTQ3GopuE1tJcRyGEQnrsAGWCl85B4ycnn0Iqveae1vsuEhnmvLm4XKi58sO3JwD05x9T2PXLVh8trsttZ/Z7sQwWski20e6Ke4I3qCck4yAeem5ex7UfZJ3gNpNcQmB3WVo1dvMkOAMtkYwcAnHUn1JrfNsNWIMpu7PDYWVIGBlAx+7OV5Uk9Pb61HFa2knlSwu28YV5CRyo7AMOR0OR+dYKemu/9f16ladjlpo3kknnkudNjA2+ZIk0qpnoPucdCB9RWro6RT2l5dX1wzqFVN9vKxSRcfeHbPPXjkeoo1yKwsrPy7RUeXI3wtGuJB2yNvsSP932NO02OW60OW2kEelWUhKG3t7bfIVDdQ53MMjBAGP1rSUrx02/r+v8AIbXYrXk9lcWtm9tcRNdwS+dc20jKgTAHQPjqcggntjgnlfNk1G8NwyWVthUjiFuyAnOVLMASCff270XenaejRtBbGRjtWVST5rvuGVyfvY6nCkH2pl5JNYJbJaaOys6O/mEb/LKyOQpGO67T7bsDGOGrWVvxGpWZebTJVdDpdslzGiPLMGYyFfTbk4DEk0WJ81ZrOO3YXRVnlikckhSSCG+YgD7vBOAGH4WrG3aAXn2Se+WKeNS0Yc7ovl3Fd2M/e47YrPur67srgSaXaEzhAkkjorGXIBKszLkj5QCc445qFzS0X9epSvrYmsoSbMab9vt5LgoTIInjdzhcEBmBOMDOAfrzmqjW1wkKwLZROlwF2YjETcFywwu3ABAPA/i79qlnJMtyJvsCwL5BLXkWSRL0IHUFepzjHvWhe6jqMsUMvkQwXEeVVE+cLnr8wODx2HTjNacrT0EtbE8N7apNIkJigmSLA37QzdMMP4iCcYPeqq3M93FHcR7Gk8x/KYlhmMhcHr97k5B/Ic1WjiaC4uYJ7cXTRgRRT4CsUV1CsGwTjA6En0Oai1QGyOdPSeWFCPLWFiwjLZ3bgM9lQDOMZNUki4t9S3bWdzM0l3fTMixuW8uVsbUyfvADB4FJZrEtrCZppDOhWR455CA/pnnkZIxk+lTwSXF9bB5swrLCvmRmMsZMgjOQRj6AVDapZ3dwXkuVZjGUaLGCo42nB5H3Ril3uataFaedvtU1wbqDCYYRxAkqvOSQB90YAz+pomEMIkS3eeSO5HlS+WseSx/Drnd16e2OBNLsZZpSt1LFIZGhwHzuB7Njquc/Kas6cJWe4eeKFV3vs2hRv+8ucdVPOc9c96rRbE+817xFPbxQjaXuljlOVDyNkAcEkDhefpVKSb7T5wvHeQohWMMo3H06DOcE1tJZLe20ZE5dgCp/eBgQT6g/Tv3qleWENrfG4D7kXDcsGHXaR7nrRdbdRqCbSRlW9l9sje2hFwCVVsOAVX2PB59q27G3lsLRLeSWF7mWTeS7chfl6Dg9j2qjFJLaSGRWk/fjJkC5C9xwBVyRUR7e6u50e4ibbs3r83OCCB9T0ot06A6diG/ltUniHlxhijNIwRQpyp5yeedp/Coo/s1w6ReYVKoGWOOQpwck4weRgetFnPd3N2PtVlGVCHDGBSHUgjGMdeT06bqbcfZLa783OyVAAQoAMY/ubcEDg45HemuxTi7dBr6gjW+xlRogzqRGCfl5C7fc8Dn1qpbiRLSKG3tfKLM3MkYLIvGQ2M8Z57itCa3RpJ7eOBLTZ80GQPnyQcc9QOP06VKE+ywzxKJHlYbhJI3zMMEHjsBgfnQ32QkrtXZlWKwy2mJ3uIWTnZnYqknONv48d+lXvsUr2u1pvtB3kqscztngckk5OOe/cVn38KMqywzN5kzZ2Mw2J8pOc8Z6Z61t6KGW2muJgAWfCCM7lK4AJBBIHPGPY1Lb3LfJF2sTRSwJGg2xpMrMJFXDFFAJ5xnHQHHoR0rN0+e4SZXOnzLHIBz5Y+X8jyOR1z3960b2KBpmS0Rma8XEhRSrIGHL5xkcADqOOKigv0kdla4RRCrIVRcfQ+2MHnp61KIi3K+pNLaWlzp9/cSWup/a0TCruKxnqAQMj61WWdpbCW1e0HnDEonaLcRJncMbckjkgjBHAqSyvZSZU+0u9qC2X3iUYxnJI4AGcY4Hy1RuJ7hrSK4gvYbefLZiXaQcNwSSeRtBOKag9mRp1JtDup7PVGn82LzcKHCkKgIbrsOCDxzx2NbE7s19dXnmvJLdMpKlmZEAHOB/Dx+tZGnR2t0xF1JCZ3j3M8PDMc8nAJ9atwGSGztkHG8KkhLZK5HTJPJzxRJK9+pUYJtO2osJDTSM13H5DrvAkzlsELhOMD1Ofwp80spVPsm1gW+83K4wf/rdqq6K3nx/ZpLcr5efmBEigHnrgtn2DY9quxpDa20cDTKv8IkkOCSPy7CpvZjTOMuNQiu5LhHleRIpQ0RfLB8tu2gH7qnA9e3A7Lcuby3ggj8pNrs5gXISPhRuUYxuIwSc9SaWV7KWSIXsV55LyZuJdpTAY/LhnwByQPm4xUTNBb3N5bQPH9leIiIyyJIxB4GShI6d+1UmuY4W79SvHaSzum6RcjdL8pOeOrD6Z6cZ7VJK9nJLaR300MJIbdO6M6FeccAFjzx061NBPbxWErXDyNcM6FE3FsxMxJIU99u08epontkmMr2wmfDbx56KhdcKoPzAKcEMM/T2q79NhP4XruXtXupINLksluIpolBQwzwsrhNxIAIZl2A4IHUEA7eKZokkFvqKQwu9mZkOGUfMGHJKbenHHJHBP0qS0MNvY2H2pbuF5HjQyWaKqyRbuocDO/cCcZwcdCTzq2UlmbS3itIrz7SIkE0ktqAiYHVdq52kkjLDPQHBNY6JNWEknqyK/FtYxQWkVxfTrex+cu9VKFMfNk7gTkAkDb19c8dHdQG0nQxzSw20NqV2ocjyzwGK8DgA4wTjJ45qG1NpY2yrHqU8E8u0pAFXbKMAbTlM+vQgfNxUuizave3lxFqNvbNuG+DywclM8bucf16+hxnJu13su5abXxEWlTwTiZbaSMRwuG3GMjzmYZJZe/Cr1PPtUkNw7yXCDUZrgxYkmWV3CwocnKDB7Hp+tT39xYW+RNcJ9qUtHHbW7lnD8ffC5KgHA5IA3c1LCwUqghMcbNldofPGSWYjgZ6596i6etik+xi2OgtI0stmzW1u4yGiYIzqODkgeueMds0anPdQhJY5LO2CoFEhDs6qpx94AZ5HTArb1HRbPUJXeS0MpCgeXMGKIOecDpnv9Kl0vS9GtY0EzXNqEBCpbMFhI9SO56+1N1k9Xr5CTtuclpWh6bNHvOpGeFhlpJomkkPOBjIGOnvW3py29lFbQQPuto8RoSmC4wACw6f5PSrWr2Vm84g0q4m+2IPM8qV1xsPG4lRkHOR1FLbWqw6WqX2ZpVwSQCQeQc4x1+gpupzq93r0KTTKyaL9untFbDxJMDv4DFgynDA5yMDPXtVXxBMsOtx6XPGrxzHyQ5QZWPgOUGTztJ646DrV/TbmO6MUxVvIVSzMCCF4BHc8/Sq8li2pa0N81olvIGVUnkAlmGD/AKsd+MZ6H8MU4tqXvPRIJPld29DM0zT57Nrm4jeOETycGUFwSWJ5C4yOoHsR70SxEXNzHO6T3GfPEpQnb8oACEnKqMD1xxjPbXu0ij2rdNd/ZASWaJ0V9mMtjcQD6fTntkZUNxZefJNbqjWsL7bYSAPOB1YseR1wcqccjv00UnJ3Klq7E/8AZl1bahPfsS65bDHGWQpwMZ4bOB1xx1qvPZy6n9rNpbSmJPLbdPMvlgjIIwASPvDkA546YqJdakvrCOaeeCRSxWSGQpsjTkcehJI6n+KrNhpVikF095aW8sZChFhiaRevuCW5zzzj2oUpWUnv/XoN8zIFgl1GNrO92yRThZgbc4ZUYBgwL/wgHG3Gavfu1tbCSD7a6oocZZV2qVwO/I56cdKhspEvPEi2tm4hiuIlT93GFYkMGbJxkDapBHt61a1C0bSropfLBbWLZNmlpD8xXPVgVxnbtpt6qP4Bza26lCSeWws4Hgt4vJlTzUd+THnkhgOo54x27ccxXVppz28wIeFpOCY0AIOePy7c1Zje3iklfUZYMlmYENh0IJwFHXhuuPcZ44nutSsFigkme48iVtqzFT5LHOOD35/Kq5mnoi011MW1tfsmJI4txm/dLJMRvcYAU8djt6E/lWq/k/YIgBwXMTAcZPzZGcckbSc9OD6iodQttK3fOtuRIqyBY0UueDhxgZP60ycs9wEuEBAkUK/k7Q5II4YgDJ7EYqvi1LT0sPhu7u3u7qBYreKIqCBFkHpyew//AFVQ0ayV7lLaJ4jblXRztIaI7iDgYwefT1qxrb2s8kSXMTCF/lVLgFcuemPXj0yKt3N5emwigtg0mJcypHEoVlwcHAA3fw+owPap1SuupXM7Xj/wTMv7G4uWW0cPI7k/M2MADnpk46Huf61FJa3dqhVQII1ZhIT14+h/xq1e276fZz3DzSsxdczEF1QHPcjC5NPS4jurC3juWmid15HIZcYPy54Ax07Zz70+Z28i/aKO+pX1eR0t4LpQ9wyqCm9vl2ZByQec8DH1qOyvYZdQikjiEdz5asRHwzkg5BOOeOnPegWa3cZ+3mV44lBCnLFjkbdueTnB98UsdzFBcRpCW2NtiCRoSVYdA3HByRx19adtLC0b1Zakt5LnTWuL2FmNpFJK0e1QpB4Kg7m6gk9O2O9aPhLVYo7xDC04gEbNLCp+Q4cYG3gZPz/Nk+mPXOkYWuitHK1y99KwXcA4UjdkgE4JHTg9h7VEGsBqkUNjE9wbgBXuIQZAgJxneM4A5yR0rKcVOLi9jnkoyTTfYvW2iK0sszxRRL5vyR7QVEYwAVA+6cfrk1ekurTT0z5Qz2iRRgdOewrnIb2QAabdT5hDlyYcqNuTwOgGBzjA6fm+6tmFhFcWiMFnlZVcZyoVRuznpyy8j1qnFt+8zaKiknIu6x+9L3EMkKJGu6QlCHHqcjr1HHr3rPgRDp13bwoiTzgS7c9RnLbjjnp75p2ny31uyw3cjNaLuHALNI5yV6dc5AP41p3k1oIhK6fZ7liCGdNm44ORz169D61Xw6EP8DEsre6jgfEUZgdSsjRHhQMjocZyKZbQ3DeUiQo1uxZoYyctja3B/hxz0yK0/tE0jxNp5tmQg78vkg8g7RnAP4Vovby2+ye7gu47FVIaecqjcjgAKQcnkYx/WiU7PXqN2te5k2Mf2RZprx0tpAufKIJCoM4Py5H4DPerpaC7gijQhZom+USR5BIyuQoPpnuP6UXtu9xAZbS0+0qiF4fP3tjvkgHOen51d3J9ltZ2hIumVfN25ByQAdwB5Az3zUtoHd6Mr6bp8Nq5tLB4lij+Z12EOSenIwP07Vctg80MjloDF5rBGG4txxyCB6GqGpatZaVeOkiukSqPM/vhj90lQeeM84Jx7ZodyrCKKSRLPGUeKF3YH0bCkdPXnOKjlctyIvp2OVkmUwrNfsJ0J4t9wVWUHndjh8ADgAY69AaeLO2Mq3cNoCm0Hy1G5VUhWGSBwPrVmZDqdotw8CK7I3zrJ9/JCjAK8YGRyeM9xVe3sMXttFdSKGLRpCNu/IJICt0wSQenHB6cZ2SS8jC3WWo/7LaNdwNNJvDKgHybVVQUGAwAHTj2qe9to/Nj817zT4ijBpJYnmSLlcRjAGSeWySRyBgEZKC2trHVrWS8y1w4kVktxiLgYI2kfnz156VFc31ndbpdQtZ4NOicBVglVJXJXpnawGCCenT3qZa7f1+hEmrMmhMqWumWk8UsUKyK8juC5UhiAFXHH8JAH860/DU9pGUjvbiUZyhYzAMSAPbJU8nByBtyOcmobiCDRJVTUWlikUjzYTgwomdwGFz8/C5wCMFsHpU9nc2mmi4tp5GeRpCDHKpdVPbb6AbGwPelZSi7dQjqbGnaXBqtvHdTOcrIwDp1i+bAAI4BBHQAD0Aq7aaag+WLULrIUK3kzkFMdixy3twVxz61zlnFqGptp8sMdnbJBJ5jBQQGJCtkAHpxznkkmuphjg0+CKC1g8tZGCRhVX5m45PQfdBP4fQHnqXWl/l2Kbl1K82n6fZSxyywt580uxZirSNJ03Ekc9QuWJPbNLY3M1zqLQyac0cCKyRT/av9YcgY8sYJz+n41es7YQSyLLI000hMjbhlUDMwVR/3yfXp9Kp61MyjypElS282NnlaQKm3cPlAAZjuJA6AHvgcjO/M+Xd/1sQ5ClriC3k+ym4YklWY3HmAcA85yWHP3AR+tZVnfamlzFFcaet5aupzdQKyiM5PVCX4H4de1bV3cW2m/Zc29mqXMnlKscZUljjnOOvsQO3NR2usW8/nR2fkSXSRiUwxoygqSoyMgDPzDv1PI601zWvy6CUkMtpoGu/PcwRNt8ppj8pI6heTkjmpJ2CvMEDmXj5WkO08dAp+73/niucu/wC1NFvER7XT5buGJpbuCEnyirMqoUBx83XOSenarlxqF0l9pdjODbpfKjQsRgtuxtHysduTwRz35xzWnKpO6LUr67F7TbWWztHONkcmCY3KFVPdQQBj0/LGO8sEMUsi3Fzb7WtnJt5ElGVGByCO2cjHt3zVieOQ3CrblRcM5wkgyrEAkoSMds4PYgHnpVa5me1uEdjCY5l2S2/zAllJB2HGAckgkjkKo460ruT03ZTZQvmXUDdLDdANAo3RvgImR/ebAAPOeemazZ7B7WCIRQiV2UupjwFAbqxYEhwCBhc4we/Wuj8iKYLMFUhgGDMOHUqeCMZ6Gq4jjhkkFnHHEWGDsXaqv24HXPJz/KtIztojRGdZ2Fna6RMpt4FYyf6iZUDsQwGdrDOMrnGDyK0r2xmljzZXT2tuzbY5olU7CBkqUOQc57gdc9s1Bp1taHxBq6X6x7HtnfZs3YVSpDA+o29MVX8KzXF1p91cTMkSskYAIJX7784B9hT6X9Px/wAhOSLmhva2XiK385AJJJ2RMxgMoZWAOQuevHPrzVjx3cJJq+lxLsnWONg0RcIQcHv7Y6e/0rGuZLm4sJ5J1it51UHfCxDqoII+bB574+nNWvEB8nSbOe9jmVnC7XDL5hcjJO7nqAaPZ/vIze+39feKUbSUipPpljeao7zzTLDG3loEQhWI+YksQQMluvv3NSxabBBYQ2txe/brK0IeK3MK55OWJIBLYJ6VrDR7q9hu5IZfLIJLjd8rZG0AjuPl6Z/iPNcvceUbS+ku0RpUXFzsQKNrZA25J6jHrVRfPpfaxSau/IfeyW8Eol3RLEZFQGSIh4o8ZCjPUjkjjj0qS4uLi3mjtAbe5lSRI1tX5liwQNxO7lsc9Aeaq7xBpdmLZbWGBFMyy3ERZtpxjlecrg9u/FalvoV7p9/JrF0iSrcM5VDg7S4OMnPIGcDjuOnNVJqPxfLzHzdFoVLm4bVEia3tI7h48hzkMEz0K9lbr79KSe+1CFYhFYpCCqr5hlUfN3X8emaltLye11g2It2gEqrsQMNqnOCeD05H5VJeeaLwriFlCo8jkENhSCzd+flp6J2toW5aWEtZDb2d9D4guo5re4l2x2jwhVIBDBtw54wQBke+axLqWGWJrvz1lG8xxKjlQqgjBBBwQc9CDj8a2Wu7a1KTzTobWVWlT923T5e3PTcOffoKy7mOPylvrUma2kBkVWQDbjlicnngjjjhcUQjZ37ii1EZDIPN8pbppPuGNsk8Ddtyc46454zuFWSFiSeZohCy4Mb5H7yY8Z29Tzs57561X1LFvd28gSJGlJePbnLYIxzjj738qmd2miUz3Ajt2A3YLFgxYqQOPUU3qjZu3wuxVjudTkvrZLi3laLJbaSHy2OnA+Xk47fzrXubW0tlItm+xqkRRGjYoG3EnGeM8j6is27MMDIZlaCAHyxjHOSOQB0K4/wqVpxpmmxadI0M8eGkLXG5jtBOTgA/3vXpScbpJGd7X6+oul2Mq3wa6jEinOGePDdPTp7cir9/9skBt4rdWtol3RwIwjJZiN3zdugP4YrJn1mCe3jFmlyZYeSuQqcA5B55H/1qvWk0X2IXAhLNKCpE+CAFbvjr1ptNO7CVpoY4K+VKsMihWIIln4i4IGemTnbg+4+tV49RfULgQXxtHe3LkrGFcn5SCCQTtJOBnrVi48lro2kMEBlkw0shTb8vByDyc52+tLJbQvYagssUPnxjbHMsY2hifmZv4i2B1Hr3qU7a2KmtFqXLS2jWFLmOIQxorsIUVTuPJyWx796ga4uLuWO1muJrsiVXNtIxxF/vH+LGe/pSaNcRzWiWSpJKBHtZjgqcZ5wSO4P5CqRcvZxwxSW7TlQwxExJ9NoOAMEjq3p+A4tvUNN7eh0DNLbyoRIYoBGVPlqxDHPTCnjGCKyL27inQJYXEzXe8faIgwYQIDywAUHHHcnGe/WruhaPqwlt1gZvOljd/MkYKfmZeAAx56c5/wDrVtd/s9ktGWO1hTezSSCIl59oyxZgOeh6jvWSs5Wjr6fMybd7lY2uqeKBJfadpFpNM2FdVdJMbeACxO3PJPTPFa0F+9pqKwahdabZReWd0Mnlny3zjkgjOQM47Z9qrrILS0+2w6fHaQNlYgIUdJDkbiUDryOmSfwouY59VjW4tdlvdFyGCR4XYMjj5uOccexovfdK35fPVEKMtkRSNBdWEe3yHEfl4VbjzGVd6g5A+Yk+44yay76xW9Mu0x21vCQxFym9eNwKqzDI3Y7dNp4HenpKSpNDJCZVijIW5Qx5MYJ4LEAE5IzntS3r3LSXMwuM2aMxRZIywdlJ4xkZzzz0rZLl0RN+ZWGRiOC2uIDNHfXG1IY3ic7bZmUgMrHHVtuenPU1s+GdFtpUkbWbi3+yg70SVVhEgOFDbsjoQwxzXOLaTR30txKslnbXJO2EYHOcjg/dI+8MjtXo1voMUmm2dhdzm4t1Dym9CiPHzYEW05OMnPXr9azqT5Vva5hJ30Ev4Li/BuLVBDneVmllyS21gpC88H5SGHGPc4qCCKR7eO1u7FcxthS8gkL4XG7Pbp65qzqVnf6dp4vV3NFwPL8wLGq9cgEk8D5QufwqHRmlhtpru+kZkyHXzB/q938P4cVnFrlunc3jZq6L1tDPaadEivFHiNikatnzZDkenGDtJ7c4GcVb0LTriF2e5uWuZ5sEk54yQcegH3vTrWfaOb//AEm3mJt4Cqqp/jBPLHPI4wRjGfftpSp/ZTXF39puHRS7De5KYLKBhRj5fQD1PNZTb+FbvyMZaIdNczpfXCQQ/u4w0YLHaokGDkkj5gN3Qbs5bjjmwj3ENpGzStdMIxlnAjGAPmbLHA/ve2KzJI2vGtTcX7QtdTrKqRoyrKox+7HOVLB1yxOTx/d4S+1OFJLyA3kDxog+0QZA8mMoflDdctkDg56ntxnyX0RCV9txbeG5tZRC13eXM8z7y8GYkAwo5IYDA6kd89Dg0kVtI0eoz37TCV2K+W6+cyIQv3QCSVOcYwMFiMZFc7bazrl5Kw0m2YoMBtqiVlT+L3B6HJz1HbFaWl62l2tvuZleWRo5neXeYWyzclcZUYUAdBkDOQK2lSnHU0cGi9NOdHmMLK1xBGgLMAJEMmT0xuwdrAdvu+9WbQQxW13DZKt1aLKoNtuG6IggsNp5ORyMcenIrKuriW0067WEnU1hCSRTxosrT7m2sTsUodvyjbt3DGela0UYgWOa33yG6/et+78lgMDGTgAk89v8KhrTz/Pr8v6RMXcoWpnV386YXzXDJJbhsq8RIckDgnkAAbtvIxwSac90lvOn2iB4Yxvd5Wl+RWUZIdc43cAYPU885qa/tpFtWli2tNHKu0xfumCA7gevUFe/uMcnMVxbpeWcDiUSgP5kqNhvOIILIcYBOVKng++atWZab6EqSRm6aCONoy4Vl5kdZOhJwV2ryegPU89KsTAqUVsZK4BJAwQenvnjj2qGeFJLi1xLIDCxGYmC8FTwwwcjgH8Ac0w3JkmkiaPe0b7Vy3K8DD5/Hp69+DStfYtOy1KU8VjeMtzLbF7tRuLMrKXAB+Xd6Z+veqmjTQ3TrFDFG2nsoMkGzKOuXx1GMhwDx6e9aMsY+zyMJJCpkEq4XAA4yF44GNzYOep45qnPaR6YsjWt0ljbeUEWR03LC28HJVjkk5Yc+tbRas116b/19xfTUI3ubnUHiWBUsQu1pN2Q+O+Mf16ChraImYmUpF5hDEEllPYAA59fyNVbC4ksy9q10khjyXV1O6TPPy88cEdM9D+Fq81NNKhluhDBKGZZPIkiOWLbucn+WOPxrSzTtErmfQ1bfWjbh3h33Ft5Q3oFOZTtIUjg55rk4YLi5ubyQ3qQxTRhI9mG2OFwzAjuMN096txJd30NxcRymO5s2aBYoEEaMOqgp0yNx7c8Uy7S2jt44o9QijiQPuaG33biWALgjJXqeCTjd7cKEVBtR3f9f1/wCFFdiPT530luQdV3r5SbwI9zZJZg3JPVRtOBkE9c1ZMUdrcmBbHBlfcgmAjTAYEYLcHGRj6dqbpVkZ4pHjDkxoy28jMCH5yGC9mJ79e1OdV1eIwTXUkN1aumJHZv3hGdyoCRnlcHaT1H0Le7f3/oFuRFWC7slmkJtph5TBTKZTgMwyCwz0AX3+lRTMbC6t7m9sXM5AkIyFV8oc4I4DHluQPStnQtDuF0u7byUvJIctLHKFTflcglmPGACOcj5ulZNxbR3s0UVzqMlzaKuRcJIFJPI29+inkjA4zgVSlFyaTGpXfL2NHfaLfW8S27SiVAYgeQRhjtzz2GfwrnNKuLxdY8rzlliuBI8lqD8qHawCk4wOg5HUY+lbEdzcRW8NxLa28XkTGNC+4bF2YB+8CepHX+tJAbe3WW5msobO93fMgY/L2J5PQEtz7deKI6XW478zXYq3mlIJALPyku2OWbGBgHk46ZyRzj8aVrdPsghM8KzxYLO4wrtvJwfxz16ZzTorhpriTEJNxGvk7zLsVicjvwCSB3649KrxWl59vcSxF4nbDxSMCD8vGG7c9xzkZzVK/VmstNEiS8tZG06OKOISzlA8mxskqEwSp6MRu6A81BEv2nTXt5mmlnijOGZCG3EsR/Tj2q/wCU8CyvLJIUCAKkcgBj6cAjn29+9W7aFykygIk23cpaMB++CQeuD0pXsg9TATTbi7utsvmeV5gLb1+TGB8pPUdfSrml6f5VxKPJQWEqAiEOXBYHBODyDwO341ozQbR5ckxTcRvcSFN5xzwDx07UwRG1maKyxISu8h5CxXkDgk8DqaTlcdrsgguLOZg1qhSfGwyFc+WoGMMD+A5HpWh5MTXOxilySrHGQQvbcQT8uRkY9/asaxWeJrmaW2jimWVlWMDd5qAA7ioPUkE/l+OrbWSWwkmnmkEkpByu5QCc/KRknHJ4yKUmujJTukMlVrQlN0otmBY+WgKoOeM5yB2HY/nTbRXkvTqDylLAKGjQw7XjAHLFsbvmxnBPetBBBLbSDzUkiIMbkk7R7E57Ek8ms0uEdtOWGVLTBAmN2HYqeQMEHPXAqbt6f1/w4Nt7f1/XmXLuafUljbTL026JlfnLbZAe/I68Hj3qpeFdPurY2phgiRmVoIv3juuMAbsZGM54Jx3xTUtT9qhSC8aCEJt2zOqBiD1UHblue2e3FUprbU2jj3vD9piPzPHEGY5B3Z+Yr+IFCS+FEr7y5h9RjEi3Ec12XLK33ii4ACnjPUMfxFVWuXvULJM32cDaFki2/N1LdOOp4pNHuJLGdfNi8qSbIEWzLqADzhQCR17D9DUem6Ve+ZJ9guVnjHBhmx1wCThmyOtaKyeuxfwtdipcQzyWEV1FZRxTRwsgCFQUIwu5myNxOCRgDBPPvRN050aBHt4JZBIRLIwzIJCW2gk+wPIzitrVTHBPeGCxuYXdSI5Uzkqo6E5BHQe5/Oo47fStUggtrjUI/P8AIEryN5haJujKfUjjvg4qOZJJnHKSiyloenPHq9pe3X2pLeMRSxDzVYTmOPdk+i/Lk5GT7Gu2vtPvNXU6Q13MlzJILgzBi6KoUjauSD2B5AHPes17Gw0aSK+sTNHCuVMsYaUOcFUdgzdz0C7h83XABN7TdWuLWd2v47qeOEBDIIRGJCcn5VHTGQM+3vWUm5e/Df8AX+vMmEOqQanFeb9MtrOW2tRDbxL9lJcMTuJ3uVG07s5yOeRx1qSXTopri3hm3Oqn7QVRhtkk2lSuCPugEnJ5yB74F8xJBILWS2curu6xbnycM3GOoBK+uR0A5EB1OcX+kzXiy2htZHDrOvMgMTAEbQeM/wCelJc3L7vn/X9altpRsjTgjebTb63eQh7q4wxHXbEwY/muf1q7qe9YbFIWGRGlpBECU858HA3c7RxnJHG0dc8ZUn7m1vrGOcwXH22cqzDjKvv79mBAz71pys1nFFMI5FZWHyhiPIQjaMgdSC56A9DWEtPeX9f1sZyWt+o+01KS3e1tHsWa5WVo3clZEjk+TrkgsBnsBnB6cVzHiuwaGHVb+6EJeYgsqpwQrqhIOenI4PIyOuDWvJd6bPrVnOkiPJFhbmYRHCqzD52ZgCAuxvoS3Qk5h1VJLpbu1kiYwxwlzcu67SzbcbPmzhixHYDI9BVUvcknt3+8UHaVzT+GgsJ4bq8sJJzIVEciOAFXk4K/XH6fSuG8VW1xovja7vlcEQyi4KpwGUkNg8/3SAfpWv4P1yPw1NNZ6tDOk8hQY37sDJOfmPP3u3NeiXtrYavpxcxw3KlN0cg4Oeoww5HWlOo6NaUpK8ZDnN06rlLVM4HwzrEEMl1exK7wbBJ5X+s5yEyhO3HuCPxq+LS4TT3Wa6WeK3PlyLKG8xFRy4dW5GSrDPHIUDA7cz4d1BYL6WGCHzMjz44gQmTjYy+nYN/wGtq3aISWd9IkFpfQRtb+XPKHkQlfly7fMNvmcggHAxg8CtasOWbt/Vtv+HKqR5JF+KKSxuNPsr2ZvLjlVra4xkzb45FCPzn+Ac8ct0qS5s2nVoxI67ZZNpjODndnH55HXpWTFo8RtGgZrtjGxkl84O2fLwARliQAzBux4PHUUyxS+0yVMSyT2iym6IRAd65zsGeVIC55xkt9TUqOvNF6jgnY35bWK8jmKSYeVGQEDBjLcce/oaguLWT7OtqJGE0EQZXzyxRcDcfQk81YRkmgU284ZfM+cx9Rtf5lIHToQfxqb7RDADEWCJuAAb+8xLbfXJ3cewqFJrYe2pWYEwSgsQw+XA6KcA8VBodhLr891I7tagkSRbDuKcBSAeODjPbk/nMbqMwYYKuxvNeQHIK4wR+fOfaobW3EalJQroDuXDEcdMH8c/nVJtRdtGU3eLtoZVu0xzJZwxS28amKMzH94xU4yx6c4I+p64q1Hbq1g0FxKLu4LZ3SLkIwxlee3XvUjWklvby2csOyMh2RSAhOWJyMe+cf4U3Rmt5g++GKa3njXzMfJvIORkAdec5+lbOWl0XfS6MSzjij0i0sxeSreyLKIFySWbJP3scYG3+nSpIbg3mlyWcQdc/PHKXyTubLY4425wPX2q1bSRW6X1mDHJv+a1WOUI8gYc7SDktxnJOenNWIRA00Ba5NxI5ETouTICcZZh0XGM5z9K0lJX1Xn/X9f8BLQz4knt4onE0s8FnIs0rKf3gVclwxJGQc9B/dHXtsanps9zD5ltbW7mXcRLHiKRAVJVixznHAxx3qHUI7ZLgpZxbZwGWE3CHDSYUbwSD0IHP49+Wm3+16VNNC0iXRCPcQSuxZWUHGEPyAlgDgYz3qHK7Ulp/X9fkJt6NGj4Fc6RBd2UkjzskQlMmfdsdfx/Kuavp2eznt4IYpopn3B2iBdWHGBlhz8vXvk9M1V08SZdvtB3earSK0rEy8YUZXdnG1uGwPmNX5r57DW4ZFs1nthLuVyFUOwJZk5HU4YZP1qvZ8s3Ldv9B8sdZLr+hUOp+V5stxaolp5YklcoOSWAyFBPJJXJPYVpxzw/2dbxGxDXl4Nz5ZfLQABju4yxILfjioPFOqzat5c5VoZ51WMEyKrBRubZkEZAyeR61T1G6S10uCwaK5+0fc83BZgu4Ak4JPIB46800uZK6s/UaukuYp3Utrd6VYi3kmVYH8uTco3K6+WfXB6Hn6+2bOm3EflXW3E4VwjmXIyCAADweM5q29yNL3W8NtK6KzkzRjcsZ2kAnPXBAJzjtms23uLG6uY2kvIhIHYNu+baSSSdp+XLEnhcnpntWl7x/r1Hez3LC20h82a1eGeG6DQhoIzGQD027jxjGMn04BrUENysSCGFEk58wl+EB78denSseG9uVFzHch4YmdkUE7TgbjtC8Y4HUcnrVyKO2vY4w0bQ+aARGWbzcAsCzMucjkfxEc84xUSurXKUrLfUo38FvHYiC+kzHKRKkyrmUgndj6Y3Dr+FOj1i2kWO1Mfk4Bc/JuPU9CCMULBLd6ipuLJW2ygyT43FguMr8oLdunTipbiHy4i4ujEByk5iJdCTggpznOOpPFXZbMd3e5X0y0tBbRXcmoztbRSqclSCuMAIevy+w9a19VkE3leWwKgouNuN5JIXJ9s5/Dt1rGEd1DcyXdsHudyYkMLtDnod2ABg8DoP61YW6sEije2igjvJ0B3mRtyOcEg7wB/wB8k+1KSvJPcSfLoS61FI8sE7rHI0MSqu5chSAB3PTgdKpaRNLfXzPaxW5tHibqm0HjAyM885P4VNqd0YVihuJypmVP3qxK6r0yckjPOScVZDLHFLOq5WJSDKwx5g7n/wAd70rPlsXda+RWvHurSzJurSMwBynnQSBWCHPygEcdD+lOtIysrtaPFGWyojYEhQDg8jGSPoKgt7g3V1HIkvk20MbTCH7wdd2WwR3J7dRVFFwzfZ5o8/MoVk2GINz87EZ7Y79afL0HGo1uaOn208nmB41e3LAv83TjgqD05BB+tOgMrXhdJirIvlsrLyDjP97k4Iq5ey2/2aOe5ieSZQQFEeQuT3BwORj8qqOIppw128UloF8uOJlCAYPYryeh/Wkm27/1/X3F8/Np1H6ha32ZUWB7xXKgsjtu2ggZxk4yOuMZ5qDSLCzWeae4tJILu1yfs+GIdc5BbjkEg8HJOcdsVpXGnNd6pNumcpLGSCi54wMgtng+nB6H0qhNdRaYzo8c8c7N5URnw6NtAUYPy4zwSBn681mndWOS0b2Z2NzotvPokVyk1xcmaIGKJI8RAjBUBAMg5AHJ6547Vn6heLBaGQW8bur4EMkgQEkdMnjOOfy/HXtfET2ml2f2qzeJ41VCtvwnI25APVRkHHHauOfTDdtHbXd1HbbkMirCMAEEg/uye4xzntWNFS1dTZP+tjKmp6qRTt7/AF2GaRZDcRxMweJpXVvM3YPDsD2LY5PT8K1byziTT7aS9Ny5u1VWWSaR2gYKWID5z6jjA496qvYahHItsupTJZjEYjgZhGhC8bRnG3IAI9Salh1TdpkUiROXgCROl184faCM54xgsex61tq2rfgUou1zegitNSDTgs052PIru2WJA+ZRxycYYc/dzgZNdNPaW+owO8UuWYrIQnP8QbH046e9cNFL9jvtlnbFrWRlb5Bt2kIvGACCOAOoxg9a6d0cyKLS7jSSaNmiSWT5w/YYHXkqDj1HtXFVi1Z3suhlUi9NSGXR1Z7hZY7eLz0kjP7gjMZwMYRlJJOTyeCW4+aof3MjNC8M0tg0Aia6DE/OGRVTCgYy2ckfdKZ4qU398+nSNc2ZuL+xd1liRGPmBRndGDk7iAo571Hd6hf2+hpFDb3FwXTe0kgbciZGfXEilwQc87Cfl7Jc39P8TPUxvEGlQvDb3ka/ai6uFuWYMRjHp1IIOPpiul+H9/BeaGLUSr9oid0eMNlgOO3tnHHHFVYv7LSxePdaabLctsELBYldmBUAL/ESFHFZV3pdw2vTzafLPFPGxfCkmESbcckYIYg9MZ5znnFau1WDpydrGjaqR5GzmtPsSuroxnEJMRJkZTtj5x1BHXPTNdZdaRBcwebLLNLfS4cIsRZbnCqThgOGxkZByfl6nrm+GreYam13qdq0MMMRR4zEUU5IwMNxnv8ASuit9Pks4QYlM6RMrQeUpLoVVflHqzEYOMelbYip7+j/AK/r/gamlSV5aEyTLcK4kOGnjkVJY0x5kRAy4yCM85/LikkjjsbNk3xyEwKsUUq/OxBJJJ4zkFT0Hp9MPT5J7eybUI2uJGlwx08yFzEWG5XC4G1Dhl6cBOp6BI9Mm8QNdPI86zyNEY1KktaA4Rth6rkoTwBxg+wx9mk9XZELXU14bO0sLu3t7SaVJlmeWVSWZWVtzHIPBI3dMnB6jjh9zFHNcyO6+aBICvGOQMBuPTpiqlzbW8y6Je2KSI+6bzRgfvMKY8sR15PU+vvWorgQSRz7dhRYwQf4mBO0Z/Hik7rW+v8AwdRp6XKX2dJJT5S5iOUKbcg9yD6VBLai5tfKnmkiLZAMUu1yAQSQRz1wKNPs/wCzb+EQTXL220xlJDhS24ksQOM470/7RFFLPFdPHDHFg+Y8oOAQME5Axk8fhV2d/dZa1WpVuEa71WIvf3KmErG0LRsQ6gfe3njqRwPSn2MUMDssWBsQBY+i4J6/htx+NPsyEd7Ha2YIdwkY5BwQq84GScg9u9OvNIjs7OGPSpbWCe4jSW5kjGNr87ipXByT68kZp8yT5WylK3uozI7HRpRZobiZL0r5qOMhrc5J2jjB4HQ9iOBnJp2lnLF4stopZzsvH/d3Ue1VZQNzEAfLzwPbJpdKtDd6gJGuJ4zK5kMcowQ2SoUnPOCvBwOCvArWNoNV0CGITLaSWjs0UlucldxbPpxjPTFbOXLdX338r3/ULNK5W1meK21gx/aN0CTxhJWYOS+MMox0HyrkDHNZdzfSxlm08LcefIq3MsV1t2gn5Ww5YAnrjHr35E9ralkmtsswtd0kTyLvaWXPLleNuTjBBJIqWCV9PuryCygs97IU2iT5nONyjYFHTBxyaastFrYq3u2IdLuYWeYXjabF8wSJYXjUuwAOepP8QGPy61JL5VykVtibzImz5e0hickbvmUkDnOfwzzWLq1vb3UM8V5/aL7PmSJ5Q7M204AJXofp6Vsapiy0hSLe4ntZEEbwEbsDbjJTGCeAMcVVrP1HrG6Ygs1vlg866EVyqcxCFGCM2CegxuG0jA7ZqOW3ge5G67U3kSjy0aRf355JyGJK49z/ACqrdRwa9LbeRI9vO6BmVHCDLAkkYySOMZ46j14pvBcT6u24ob15FJjjYqU2tjGcE9Fz0ppMI3ZOYLhbO7hgead2O0gzY3AZyctnr3wfSqc8cNrbSxixDzo0Lh4lBJchCy7sHlTxweTn6VrGyjhl8u8urWRok80JCArMVIJLAk88dfb2qprd05kghtNo+0AO7o2XjQBducd+Djp1q4u7CSW5cZLSSOwmmmeSKYb2Z3A8raME8jcSSdpOcjcar6fcytZSfZlS5nhOyEs4V5IyCx6YzhzjgenpU3hewZ1dZHkjmidWO4Y253FlHp6Gr1zAmmtE8cVxeO7gM5XOwepPt/jWbaUuXdiSTd7lbTpzbFJbmfan3ZNh3OWzgsFXJzj5sY5p11dRR2pyUuc/34jAGGRyQ3Trjnrjiq06wavpW24UWrTy/J8wyXC8NkjvjHQ+lXbDTo7ZkjDfaYZEIYuQ8YIYkcY9zznsKHvdlre6ZSut81nGYGkjYzqHiicDA75KgYXHY+1RR+TJK6ta20yIxEbcIQCQODnrjkfTiruqPDbPCoVXiEwnltoAN75zkkf3ScAkionupL9pgJNgmuDLsgYtw2SQemBwAetOLL1aK+oLYzCOOW9jZYekHylkPGV3enA6g96s2kEgjuGdg8UgKmHiRVXB5A56+3rWjJYizEZd0kldBJ5O7eFj2LgsuBgcMcdML164yre+R7mRzJHHZzMFkUrjYOgI5xj29xRzXWgQ5ZXsMsDaQs8UxggUuUyw2gKcdieg9KtyeHrO1kuxHrKXTu6qUjiDnBz8zEE9OOOAc+lDxWFqiy200kqNIXLxqrdDznB4A4HU4AqssNnbWS34SLy3IWNlKyOxOQrScDjpzk9altyd0yXbR30H68ssUG0xvKY8NuKsFOTjnZjOPc96sPblFUvFC9wrEiJ9kQPXPB4HU8Vn3t2Lpoy0zLHGxAhjj3Lkjksu4fhRqoudUvPtchSKSaMFg5O1iDjj8s96ai9EF5dDW0b+1bkXqSRm6Vc+W1uAzLliBkAA/nzgE44NJdyiOxMOoxq5WUpNEy7js56gj5Tg9f1rrPAtrDaWTlJS17KA0xJIJGWwducDg9QO/vVrxD4eh1S3laBvs12Qx3xxofNJHRwRz254PvXA8TGNVxktDh9uozcZbHFJqU0V4tskMtvZk7bcpuBXjIA4BPpwa08yiS3a9lLBSzOJId27IwPWuM+33q3YS9uAt1BIoMbrgRneueScKT6n6Driuj8JJqWuS3FrPcrA8CB98sXml8nnjcAMZX8/rXTUioLmdrHTJqOr2K1/HE91KdPQyhcPMoZh5ibcFVB6t0PYnBqvd/btPSHbFJFB5a4txiGSYcgYxzxwSQSTj05rpb7w3fadMt0Jobq3AzOIoTCyDBJcHeeAR0wevtWU92bqaN/NN1BDlfOlgJ8k9NuSPfp3z7UQqRnbl1X9f1+Q4uNRe4zMmsGFzaXlhJF9lXy2Nw0zLuXC8YYdQdwOcda27L7TcWU9vqtnHYXIUPbSzyhomU4zzjAB2jr6D3xbsUjnszH5dqI8cYiBRsfxbei8j9Paqq3V4kKpq9pb31o2EDNKFYr/AHV2t+PA4pOTlp2+/wDRepLTb0L9h5twIreeEXDwIGdIPm2oCQksZUfMAAeBzyv4R6JJeT309wL6Z7CQrGltKyhS0nACtuLKQcgZCkngVd0+YwbptLhKlYR5Ue751UdYyzfeAIHbv3qvuDWthcaalobe5dJpItjKV2/MCrBlAIOecHBx75wlrdNb/wBP08vz6nM1La2pJq819Iqx2FtFeIdjQSyAbdoLhlYbWKnceDg5BPIxguMltPfC6vrS3S1eVQhYq0q3Iwuw/wC0FDcZOQOhzTbiaDTdQa0WYwWlwFWCZ7sAsTkOiBuQR8pA65Y471MyyiyDz6Qrhrlp1AnU/MGIWYEDGSADwAecZ65labL9H+fkRfsFtcRXliZLG7QxngSqS6gg84DAfTGAO9ULnTI31Wxnt5otPuppAZRgTNceWQTjsrL82McnIJwemoYoraKaGx0+IxggRQRZjD5wWb2xjGPbNTlLOJ0upFWMQbpV8z5tpPVsnkdASO/ShVOXWP8AX9en4lXdijbSLc3l5KYooJGcQLOrb3OC3VQPl5cEKemT05qtr26301zYmRb4uJQ65/eNEVLZHOchenOM+uavWUSTYmtWRLeUtJ5oAbzWYrtce+M49SwJztArD8Vf2oZbSPRYTcTxyvJN865ijyoBbPHzlJCcj1HYVcLOfZf5dxppOxvxW7mysF5mKJnZxggrkc55xwfwrM1YXKzg21whEqhTA23AIyC2TnlTxgf3var/AJ0kMs1swCbYkS1UsVdsKFY9c4BI9OD171mIgE/2Z1O6DzJZJzJkqzMHKDdnP3unOAo455Ke93/XX8y43NONxLdqsDsLZXICE9skZ/EcZ96qTon22RntdqSKqtIeQ2MnB+nH5ipE/wBHhlklPlbJtkZX5htLAKO5zkjqaS2uY51iimlVpGVnBwRGwBAJDfdJ5A69qErarYu5U1NAsMm6VxEyojKgJCjeGyAOmMdsED6Umkz6a6MlgIi8p82Qp6nu2ehqe+j8uwkuYZEmwjNskYBSSDgEntkgVBptpZh5obK4jEpwzrDEgYrzx0zjP8vrWt04f1+JSta5mLdTG+UKZpBFKDv2cKowCSfqrflVu0uiLi7ksZcrEMhAh3LkHABUHdn8f6U2/tprDU/It0+SQndIx3AEsxIPOO/GfWpYks7WZ7qC4+zoxBlEqbFx2642kDOPz7Vo3FrRbmj2uEcbRwC4eKNZ5CzSGRihYklskYzxnGCPXitmLR7vyHvZostF5jIrAmTqei9jgduTn3rMVoNS1K1i+0r5byqqyb8hwxX7vIBPI9f1rrde1aK0tbiOFjJOMI6xhmaIEfeIUZzXPWnNNRitWYVJyVox1bOGmlitRbi88y5DsFiBXeYyT97JOR/9aqFzFawXUYMca3aKrbsbpDHnGNvUAjj6/ia0L/Tri7DMsnleUx+zsEGC21SFYE+ufTA+uTWntkuWE92vlTPKLeOTPzMpGcg9cHJx2z7iuqMl3N+plx3jWdmItmbmJU4T5sLgjcGxyMjGenIqfS0uY3t55ZElXyUYD5WZUwW+Un5mOwqcfh71bWPS5l320buFxbqxLjzFHO3LduAc/rUKrLucWsSRyw7YraNj0QKFOSTycAgHjoOve73vpYpNtkOi2MkN0tzesrFELI20klSPvMSBg89Oep/FlrDHeal5jlJ0+1M04fggKQY1A74AB49eas6pHeIVtbSQtAyKqsAHZ+cYJHIBGDnjp1rOWa5tr5Le3tlCou6Q5wzMAdxyeeSpXPPC5FVrLW+ojXnd7yaUWsczOIiUY5UQsVGOGwMk+nejSreWPSgmqxTtJExcojO+QMkHjg9celMs5b0XMENxEbe3dSjSh1YycfKwIGR69T1q9ZmS3gl+1JLG8uY0jMrSMRj1ycDOayk2lZA7GVJcRxy3OoXU0htHYRxoY1McTbV6nPB+90B4brTGWaK03+cY5wPlRFMgXJAzwPZh07+1VLaW1ubZtP1BXhfzFfYshKh9qgbsgjPbng8VqxxS2+rFAjXEcg+WRmGMY5+UYAwQB26n1q/hepV2ttiF21G8ng8gs9vJtYSI2CR1yR1HHasvR7KW3lunmm8h1UO0kmIfLYkqN24gE7iOPUVrzfaLHUjHYhvJZPuDc3lkcZBzwMKBj3pL1zLZNPrFiLedlWMrKCqyvnKkjgN89JeRTlLlLVnPcCaB3eSaYIY3lUBvNXB27dpI7n6571nT2zzy3EdlEhmwrpI23dJuGTnqwHOeh6D2qC81DUrCO2EUMcCzpiCXCgNjrsB4OCccelXIr6W1nPnxRRrBHl7kDa0hwBgegBPYHoBTSe6t/X9WEmo6ozobu5h3xXN2DJDJse3SNn6AdGC8YBx/+qiSe7vpIrdwZQOAG2su7aQdv90j5umCTVozQec98nl+XOjb2bYAGB5bOOTg8/hUmm221I2tbdpmBJMqzEc5Occ8E8n1GMd6bSWrQfHqyOwmzaSzTyySBkGSoPA3YC4XPORnp0/CobBJbqYXMJSSBd0SLChYqQx5GF9P506xAE8sXmRwSttZoUdWCjB4xyD0zmrUwnsSiaRE8GnkhvMSJmYHb0IHfoOg6Zpt2bt1ITlpctWa3NprzvfXEInZtkcUDEeUex2nleABwe9deNUntY8lZblhtymSSTjp7Z/HrXEz2CymCa0iiK7szTtImHX1BBO3HrxWjpd2tpaSC5d2iaZvLZQ0uFGB1APHB5zXHUpqdnuZSpxktTpba40bxQjIVEN8o3OmUW4XB5x1IHA7dCK5zxHor6bPIz3d60E6qIpLYYnQqfmGc453du1W2uvNSO4sjE+8Flm3gFwRx0yP1qudStbu0hjvZWuPKcsEZSCDjGR+B7etZ06coO8duxEKMls7rsbNhr1/5cf2mG0msygCyKWDtwOWzkeua4BnWG7hazXaXZxLb2snzKMZ4AAwuQByO1aLsHnuWllKxmQuioxyAMYGOM8CobaGYzoq3UggyzZZFUjIGBgMc/U4+ldFOnGnd9zaOHUNUi3bWQntGnAljWLYHhZdudxwrAc4ye/qtTadeT207QTpHeoHYFlcl1wOoYg7SOM8Hr2rGe3MV5JGt1MkEqBSGi3qD82CSTx1H5VvwS6daWqxXCfZt7B2n8krlsfM4bjrgcA96c1prrcqWis0TyTXXkSttiERYtC6xlynHSQ5Gce2K0L2Miys5JvKVN4eO7s+inByXbsOTk57Gubur57eXFtdTC2uCVjuIg0wTtuI6d88ntjmtTSLhktFUT6fc3OAsjgrDIp5PzBVxnAPBOOOtYzg0lJGU4JOyOmZj5aNKq89GkXcB+PGP/11DPDC96Ckyx3cahyltcBXkXp8w25ZecfgPSsyWaVdnlS/ZWQkyOMMrr6blyK0LK4tJSLlFgk9SjDI/EfMMcdq5nDlVzCVNrUil1NrWPF4ZrmdTjyF+Xd3ztJJIwR+VVZoYI72I3FyqxH5pUu7oLGuRhSEK888kkitC+V5An2O5WJ9+5yHM+8YI2qOe5B7dKiuNJtrkme6gidiMcRKT0xyCR+vb6VUXFK+1/69AjZFe38T2LpELaUXRDCNXjdWGcfdGD1AySM8A1dt4xOzXS2sjOSfvRZZOvA9M/rkenMJMdkAyw2yoqnD4AfPHGMYA98+2DUUUst3GyLMXJJ5WEMqAkkfoQOPSnyq146DUHuR6hdFr+4sYI5UljgkL3SdHZgANrDuu4/Qis27DWOmw7ob+5Y/u/Mh6pnczOxwedxJq9Y6NBYXkk7W8kZALysqufMP3goBwPX06VfkaGWBpWiuFVl8vZJIVDKc8bN2O3p07jir51FJLVFqKW2pl2k95MY4YLO+eLy+ZWyq5DYKkgHDZzx9KyTqQi1WcNDqNrHDt4tRhGLL17YPbPPGK3rS5nk+0GcqLVi2IzLhd6tgsRjbjcp5/SoTJCk8TpH5O5yHEX7wP8vAOPTrkj0Fawlq7orV3RUiuRHZ3KXSIVtrlgzMOAgbcuc9Ox/WtazhcTb9xXuMHaWHYA/n+GapW96v2q4t5YnjeHeGmK8OuNwx+BUY9c0kVpDIrC4hNzBJ8zeeS455GFbOBwfTr9KU/MrdaE00Fy2mMLiRvOjXMhXIJIOe/fisyG1n8Q6Pp0SszSKxuNoctGSxPJGOgDEZ7ZrVEP2c+XEoW3jGAEAA+gH+eta3gtYwb4KiIU2LtCgY+9np64zUSqckHNdNf0JnLkg5HJiyOnQXNrJbspj37XA5VmHJ6DHIGPYCsueWFrr7OtyrksYEAnDFSOpdMdCV9e9dH458u51meB5Wijjt1klkDsAByCpA4PAzye3Ssq5tre5kKw21oZ5mRYmSIF1dhlWb5eOATknj1FdFKTcVJ9dS4zvBS7j9VaHUr2J7LdIYQ8bLEgYjfsIJweF+U81Vm0+2v7gXEQiiltwsMIUgKuACB065Y4A9qsxWsf22CZUhiS3G1oVKjgsG5IPfB5qW6capdTW/kNbTtKjrKEHlg5UfK3AzjjPHenflslshrQytK1CWCyuWu0mQRybm81j5mTgDAOMr97nNaLLDMXeZoZHFysMakBmPzLuK/wCyQ3BFU74XF3p080Cxadi5EUskhUgjDEc+5B6elVIN9tcZuNt5DEzK08Q+SUqSA4Uc5JwAMZ+UfQW1zarRh1suhpCzuZI5G8y3d2yFkbO5VJGV+mCeM9cenMejqsk9xEmWntpPkLjA5GDt6kj5TzxzVZzcQxz3UnmCUSZVt7crkEINuTjg8kd+lTzaiHUPmQGSJd0EbFiuV255wcdXJwO/pQ72sUtWR6Qxh81I7u2uAi4ba+cNnGcZODkn8avbZLdYnu/sxuw2JZokJVEznGSQVHQ8kjjNRt9m1CWa1ntljjsimHJZlYgcnJAHBHqf0qFNN099Qee2Wy2xqqLbuVBL5zlT1J6Zx/eXntUt31Ytki4Vj1CMJMmJNu5ZIh93jjaexwf1rP0m0jijj3TxwWluzHMzYBLAfeHA68DnvU9lBEtvmKQSwF12so8kZGFIBU7s4B4xjt2q4fLl1KSM25eXyw5kJO084ww6Z5789PShu10i9jMuwl485LXaiJyhlLcDvn2HP5VSnuppIiskSTxW7CRoypZtuGBYD9AeOan1lgbmSO3DxxqRErMxAAC42qORyRnjnk9ecwXUpmtY7lbdbWaIFPmPmeb8uBgYIHLDg+9aRT0Hf3bWLdrdi4s3mlDx287IkMEnUbMLnHTsvTpj2qC8sJZLePfMiy5KhQpZAW4xjI6dj+lMtSt1YrJc2Cs0R2jEfXONxGB8vr2qWFkCSzWqPDajYxIjO4jr2Ge2OvGapLl2FpbUS2huI/IsfNASL958hIdufmz6AkgfhVkqQQ8JIMuYxGzYEK9jtx8o4GOfSmrMt3EZGhkiilSSOC5EuGQrgbmQH5lBOeeuCMVB55aeSRYmaFgBBOi8crlmAYAdvu98+2KlasXMtkX57ays0aC/heCNzmMKFVGOBkgkde3T1pqwXdxDDFb3DQwxgRmUud7YGR04IPBB4zxxSGOG3WSTcZDHGD5ijAO5sdu/B4GevvVzRkaGwnDlJSX3oisuQG2nkA5HXv7eorNuyuR111Nw6K/kxwwwpHb7sONo+ZDnPQjFQGxELPb+SBbRgjZjOV/vZHPr0qGGS+0+zmlnvLi8tUQkWghTOB2BABJxx159qdZXYuZbW6soLi2VwAySAKEOQfmJzj6fWuT3km27oyjzJ2ZmzTRWztYWj20UUSMUJA2oq4yDz79SeOta/gyzs7u6u47qyQPABgSyB2IbvgAEdD1znsRjFV9ZuUj8+aREuTEQzLC+c8ggcevb6VS1GaON1k0/zkvwPKC22JHA+8flbPGD1q2nOFlo31KneUOVOx3U2h6cWUSW9qsROMLFhif97Oah/wCEd0qKXzRakgZ+UyPgZ/GqNpqWpG1RLyO3niVdkxw0c545O3lc+3H4VmXsMuq3MDpbqiR7iiyzFOvvtPIA6e5rljCps5WX9ehzKFbrKyNW88M2Mt1G4ZoIUz5kRJIkHbknIxz0NJd3nhqe2NvK1jdJEdhRu2OoB6np29vUVWl8PWtqzyvGsqcMG805UHruAAx3PXp9KzLy6tdI1XTRZwyJvcN54+ZdysoKnJwNwY4Oe3SrgvaWSk3bbp/n/mUoqXxTbHw3uiXjTWFtaC3iicLG6BmAyOoBXnnPHPT3qpCLWGa4Ito4ZvNdXZgV83YWUEA8dM56jB5q14kkuIbaG5kDTre3LLH5ce4x7jnc+MYUfqPSuY1B0F5FmTy9RspYllbAKyEgAvyflUDJzjoc4rqpx5lp+d/61NouK6nUxagrRKr26QKx4Mq71PUHsB6flTreeGON7ePyxM2SJ4LdkTP1OU9ueD6VSsbhmv7q1sFRprYIXZiWRtwzgY53dKl0e1kM32iG7WUShWYLFgRnaowTk84A4x361EklcuXL0N6EPJISBHFjtAnAPtjJ/WnfaYWjL/ahsBZdzKVBK8HIPOR6VHMsUl+8s8gAwMHeFKnGOOMHPuKYIoNQVpt7eWHZcOm3DDjK4bnOB19K5kk9WY2XXYr+H5LG51S6E9zLqG8sqhkZI4cEEoExyefvEk4GPWti61Kx0o+XDaRKrZIYjYDjk5JHb3NYV5ZO4MWRFIVJ3SghAARkZ/vYPA9qiitYbOEzu8P7gAqEcl5CSc/KTg89hjA9a0cISd236DdGD1u7GqmsLq1kzNmCQH/VRgnd82AfMxt5H6NVeKSQSMk0Jy7YhVzvJ6DIIwDyOOOOfWie/db27VIRHFagMZ8na/T7ueCBzmqloba/l+2iMMpWWLcWI5LjLDBI6r/+rpQoJJu1l/Wn9ahGCS0Wg+SMPBdIkhVpN4QgLsBPoCO5yeuOabaCYXbRXMMYZgHDJjDNgggDJIIAB68jtwat2yfZngtonztwExyfb61W1OSZbkWdtcPG5jEiFVU7AGIPBByTnv2q4u75UU99BdKtUk1pbe6mDeYnmPkgZbIGB7HHSrGpQw6df21hp/mTyzQkSNLIXWPYfvH0JzjGQOOlZbTPHazWaKI9Sd1t2ul+YCJmX+E8A5Iz17/QJ4UeNo5ZnRmkgZoGA/5aH5cnHYcA/hVSi379/l+v9fMmzbu3ouhHDqlwJnSa3ItzPIJJHlUiBAAV6AZ3A8dxnvT7TX5dOmke2j+0pcEHlTGdu4Ybpk4DHjvV+5s1dHkDDP8ArNp7t3yPw/SuRiurVpdXuIFMt+hBhiHOG3hc4By2ASe3TnNaRUKien9f1+Rp7trbm7rM0t5aXFwkCM8rBXD4+dNpPOeQBnbz6Vmy3Ytrq6eWBrSMlYRc72OWI2gqB0xyMj1qbR2uGmFxcQKs06KgOGzuBOCV7cknqetaWm2Q8TRW63LNHBFiUlBgkrwAfTn/AD2qrqC12X9foXNKMfIydS8zFmLPK3MsyLcRxMp/d5Yckg8e4weR6VFpGqx3d19neIxpKnmRyiZi2RIEHB6HIzwB9PWbxBptidckt9MvpCqRec0ylGEjDH7tX5APP90np9D2iaJ4bW2uVjltpTcIVZVu856ZAwfVf51M68IxV09TKVRR97WzOIkja2sRFqFyn2d9jzRyLvw+GCsdpzzlhj1/WrdG6injS2hAtFaPMilFiOWDFhuBznd6mteNxNe2kcLw288ZJcGTcPukY5Gaqo195qtdXENw8MnmO+4IueCNuFOeRjHHPHNaqTv/AF/X4mmqdupSmuZoXnt3Zd4VzEsq84yABz1+pqKKO7NwssMUElw/lqUK5zkAEfe44J9vbrWzqVst1rzXhNpOrgFo5XYMjKXk3AKRzx3yPas3VAbhyAtvOjkqw80nYpwoIKgYx3Bz9080RnfSxa95bWZp3FvM1l5hCW7Kwa5QFSJl5ym7PGT3HPPeowbS2xHcwwQSOdsDsQHLHuM85yBz7VNftus9OiuLcLE8kbryx+dVyMnjAB69aqxXzte7US3YbWLKXIUsdgAzyc4Xp75qY3aFdu9xHiUW0f8AZ8/m20TAiJANx+f5nB6nGT+VNtpJ7y1WWCQ287EsUQhmIHG0k9eoP5CnqTbXFhG8lxLESNsUca+WhJbBZvvcDg8066s0ul8qKOKPzfkO6Q5wvzdOfUfnV7bhzORm3SbtXijSVn8ogyq8Z2lgDlyeMHHocVRnuY7yJINPMsgZ8FQDxjvkjj88Vq2DRCS7lURK8MnWSQnLBVXB6YH4VNNG+wTzOkt3BHlI4xtGAR25PU4zVqSi9St1oVNOE9ssrtkWKr+9dmDFWVcNj15HoalsiFVrW3kaWGRdvzxFQB2AJ+vQkn9aSS9uWtriZ5RDGyokkRAJTOFyOB655qBpvsdxeQmF3iVfODg4BYDcQOOTkkAZ9qV+a45R5d2Nlg+xywySzSPbyObdYfNCJES3zEMOOcZ2+59DSAXTpPawIyyRFVAXDYznhU6LnpnrVfyYJNLl1KWCaZJWLmI/Ky43dh/PPftWperNrdmBJNa20JKyOHk2MxHPz5B2gEdvxobtuZxdk9LkUW6KCS38yPzSy7X2NIjkbiVPzEZAIPX04zzWjbrOuozxSwGOB41YXKjy+AFATaee3UnPHpVa+mW+gjvNRu7mZ0JVCnliVc9fkCgY/wDrUmmyxLdxxqLrzroNIZXRdiDJ4OOh+X36/lGrTk9xKy0lobdpeFAI5JTJMpG5BknB9iPpVtHt3ld0UbtuH+UZz1A478+1UJPLt4ZbxkQSsq/PgkZ4GMdepFb/AIV0u2W0+2uzTy3f7wh8lVPT5R26VwTkorm/q5nWnGC5mYlzbWd9YOYlt4UlIbzyN+HBwC0bAKTnI6mtKxtkBW3mkhltFHCbNi5yT1UE9xxjHGe9dE9rZ+T5X2K2EWc7VjAGc57D1rA1xIrKW2nhaRYmcrJEG4bKnBBxkdKhVvae6r/15nPGtGehm2OmXNnqTXEmpzzEbgLd2OAnQL94gYI9qvTahKitHDbeTI3K3CIwBx1BwuOeDkmor4sIfOiVpZVY4QMELjnq2OnOcetJBNfJa3Dw26XEzY2Qsw2Dkf3s8gZ5BA6cVtfnXNK35GrV1tcfAiXoW8+yiQxsQkzKMj1Kk84PtVXSLCfV47YajDdW1xDKzJ9pkLMylMAZDEgA1oadc3LWcS3NolmSxDRIwKrhuOF49Pzpmi3rX1xbywyyOjyZZM4KZHTcRnAz06VLc7O3T+vQiUmUfKl0rV2t5llltncyOzn90oG0cZJGeW9P8HXFrDcRBQJo7wlXYQLNIByCRvA27emecdj3xteI7NZIGhw7pM3luwfa6Ag5YN6jPp6Vi3GZZY7aG5mtJixCmNjlwOSDjjt345pwlzpSuOk+ZXQ+xtFtx5iKHkJ27+VJHf39OvoPQVLcPNHOoSF9rEljGgPljBOeOp9hzk1fjjSILEjksASdw5/E9+3+RTIJfs0TG5kEpUEySBducDJwO3T3qea7uU5dRI7ZZpMvnkZG8AZ9+uadIY3kazKGRHB3FrbdH0PBYjHbpT5riKOTa04eMkhZTHggYB6ADuafDKkkKyxyb4mOFcDG4euDzU8z3J5nJaiQWkEMnnGzimlxhXLbWUf3Rx09ulVNRlkNxBGghtiSTgKGZgME4OOOPenz38kF/BAFLxuCWkyBtPYYx3NQ3tmNXglcXUkMsDlAsK7W5xyW/wAMdx3qo6NSlt94+Vx96RTD6tvjkRo4fLkBIQrJ5o6YyRx26e9WbI+deXEtwQZgCpL8+UGxwB2OVJBHvinnR3jhNvHcXixodwczAnnJxk/NwT69hRYaZFZCeIzztJcDLM7l2PXGCc46mrcoNO2/kiueLWhXsmji89IWUFlaVHjJZtu3acY+9znnNSSvtCR7WCAHMuSDyRxtbB7dapwQ+Vrazwp5VjFbeUHLs2SD9wLnA/3ip7+vEusiZ7eJRmMzNtMmclAMnPvzgfjVacyKjduxHaZlu7iK3jZJXJmmmK8BQRlz64UD64AqbRoVtVfdiG5n2zK6JjYpB+8MAljyMYOMHmrNon2PRbWIYk1G+VTK5GG8pjggHoBhf1NZMEpE09/I0quhEYRpC6FecDb0GMmnfnTS2/r8Bp8+i2Ls07wxiSeBfMO4uquG2kduOvPH9O1Yl3pFzHZXTyu11HI6GKB+sZBOVBJOcnHXHSujwwacSxxOxnKxttwPvcZGevNMvWeSwlVEUtt3KM45HfOaITaeg0+hylxBIkiP55jKwxfuHBCqwB44yPy/wpssF5JqF7G6zrbTGNEMaYDjGG6cgE9TU6r5zXB1TciWsXn/ACNjeOcgkZPAA5/2vatZIppDpciX+66dC01sYAEhVipGCMbsKfU10Obg/wCvX9Cm0tGYAs4YY44LbyZkhYsJBllYHkk4BwQeM9gBzzirV19is43a1WHeMxJGJihyOuF6A5U88epIp9ndabb2lxHoe67hWMtvnzkE54OQCRxWWtxayfaS8aSvN5iwhwdxZiV3qwxtyNxA7Zp6yetyYyfKpdxb6A3TW66heC9ALpJ5Azs4BGdh9R9ea7SSzlvtG+1W0u0wkfO2cNyN2fUkZ5561gTW0VmsbROkVs8e+SYQqWVsrgHIO7OTk4zT28QNEkOko5YXMfmbU+TYuPvdOfuE4yOlZz5p2cOn9MJaJW3ujP09Z4dQ2TmHynjwnmYXyyAe4BOcEj8+nGdGxkt4JJVt5Y5vNfHlglmZujAk8gZzjtjpWXaD7Xp8jRyubpLg2vmt82Uyv7zB4zyePetW3SLR5rSaOBL65zh2cBBuwACVxg4znjHT3q59fyNYtydkjLnkvvLL6h5z7wywhJEXyQPlLqNwI4IHA6kdeKlJTUpXujNLPH9oVQTnaG2jk7ypPT0z6DB5j1qQ7ALudTPKJAsccZRQ+RhVPJAz155IB9qaIJNNZLByXVpfPVgcbyAo5HPTdjqB7HrVJ3s1uZx35WaE10tihgciKBZWYAdREQSTgdMEnjPQZ74qSS0ddNdbG8drg4U3G53IG7P3eee2fSsvUWuYr61Uxx3Fq2XZmAyTl8qcknbxjH61NcyXFuyW1ojlHGPNWUoSOT0znORjPoaOXazGlfQZO6zhUkZ2l3hQFUBivmcN1Hy9Pl6+1RXUn269Z1ViELxqQx+THU9uxxiptQuoI7tSY/LQw/65MAoQ5wcYz2B/GkvbZrSyt7iG5EiXWJ1YRBDg4bn1yMdgaObY1gryRtnSba30gRyXpEl1EskaCFicjlvnGcEjA5IrlrqVmvC8cYtI1bc7yoDt+UhiVPU7j7/hmtm58Qyf2daJ/o0kkcbKcRFWA7YOcA49j0qgEa4GZXHkld6lkVi6rhnJ4z1H/wCus4cy1l/X4Fwozs3U3ILKedLiJrdmuVMoZiIvLWRAfmCqAcE8dh+tPWHzxAiRl1DMySMQeAdy5ye4AAGT1PpWlZW6tBNPFIqCJS8TKmAowD90Y68fl71zdjeznUDEiN5UTKUkV8AqOMlDkY5Axjv9a0T5r26GdT3dGatwkcrGVJjaSqMlY7h0Z+3zgYwQCMdcj0pkNvNdv532kS3yRqDG0pXgKo8xiudxPToeoOcjg1nyHtzNbBZF2Hcw3JuYMvvuzhx3xx+UlhaXAurcRRK3nW2VukYoxiDEKCu7GflHOAanpcyvd20P/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power view of a liver biopsy in primary sclerosing cholangitis showing mononuclear cell infiltration and charactertistic concentric fibrosis around a small bile duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Edward L Krawitt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_61_35796=[""].join("\n");
var outline_f34_61_35796=null;
var title_f34_61_35797="The epidemiology, pathogenesis, and clinical manifestations of smallpox";
var content_f34_61_35797=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The epidemiology, pathogenesis, and clinical manifestations of smallpox",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/61/35797/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35797/contributors\">",
"     Harvey M Friedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35797/contributors\">",
"     Stuart N Isaacs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/61/35797/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35797/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/61/35797/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35797/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/61/35797/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variola virus is the causative agent of smallpox, a highly infectious disease characterized by fever, rash, and a high mortality rate that was eradicated globally by 1979 through a program that included widespread immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/1\">",
"     1",
"    </a>",
"    ]. In the past, smallpox accounted for 10 percent of all deaths in the world.",
"   </p>",
"   <p>",
"    The virology, pathogenesis, epidemiology, clinical manifestations, and treatment of smallpox will be reviewed here. Issues related to bioterrorism and vaccinia virus vaccination for the prevention of smallpox are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40057?source=see_link\">",
"     \"Vaccinia virus as the smallpox vaccine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3856688\">",
"    <span class=\"h1\">",
"     GLOBAL ERADICATION OF SMALLPOX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The global eradication of smallpox was announced in 1979, marking one of the greatest achievements of modern medicine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/1\">",
"     1",
"    </a>",
"    ]. An unusual combination of factors facilitated eradication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Human beings were the only known reservoir for the virus",
"     </li>",
"     <li>",
"      No asymptomatic carrier state existed",
"     </li>",
"     <li>",
"      An effective vaccine was available",
"     </li>",
"     <li>",
"      Vaccination of contacts resulted in prevention or modification of disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there have been no reported cases since, continued interest in this virus remains because of the concern regarding smallpox as a potential agent of bioterrorism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The use of variola virus as a bioterrorism agent and the use of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22247?source=see_link\">",
"     \"Identifying and managing casualties of biological terrorism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3856772\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smallpox occurred in two forms: variola major, which was a serious illness with a mortality rate of 30 to 50 percent in the unvaccinated individual, and variola minor, which was a milder infection with a mortality rate of less than 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/2\">",
"     2",
"    </a>",
"    ]. The two forms are caused by different strains of variola virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3104273\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, smallpox was endemic. The illness was described in Asia during the first century AD, in Europe and Africa around 700 AD, and in Central, South, and North America during the sixteenth and seventeenth centuries.",
"   </p>",
"   <p>",
"    Endemic variola major was eradicated from the United States in 1926 and variola minor during the 1940s. Eradication was slower in Asia, Africa, and parts of the Americas. The last naturally occurring smallpox infection occurred in Somalia in October 1977 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/2\">",
"     2",
"    </a>",
"    ]. The last known case in the world, in September 1978, resulted from a laboratory accident in Birmingham, England.",
"   </p>",
"   <p>",
"    In temperate climates, endemic smallpox occurred in winter and spring and was mainly a disease of children and young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/5\">",
"     5",
"    </a>",
"    ]. There was less seasonal variability in tropical climates, where there were fewer fluctuations in temperature and humidity. However, in regions that had distinct hot (high humidity) and cool (low humidity) seasons, the incidence of smallpox was always much higher in the cool, dry season [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2770716\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory viral shedding and infectivity was highest at the beginning of the rash [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/6\">",
"     6",
"    </a>",
"    ]. However, transmission was not widespread and was usually confined to unimmunized persons sharing living quarters. Among unvaccinated family members, approximately 58 percent contracted smallpox compared with 4 percent in vaccinees. The severity of the illness, which usually confined the patient to bed and restricted contact, may have contributed to the relatively low attack rate. Because of long incubation times, transmission intervals were two to three weeks apart; thus, new cases of smallpox would appear in a community over many months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3104395\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variola virus is an orthopoxvirus within the Poxviridae family. Other poxviruses that infect humans include molluscum contagiosum, vaccinia (the virus used in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    ), and monkeypox [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16439?source=see_link\">",
"     \"Monkeypox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/43/6842?source=see_link\">",
"     \"Molluscum contagiosum\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Variola virus is a large (200 to 400 nm) DNA virus that lacks icosahedral symmetry, unlike most other DNA viruses. The virus has a complex structure with an outer membrane, two lateral bodies, and a dumbbell-shaped core that contains a single molecule of double-stranded DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/7\">",
"     7",
"    </a>",
"    ]. The entire 186,000 base pair genome has been sequenced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The majority of the genes are closely related to the genes of vaccinia virus, the virus used to vaccinate against smallpox [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 1800s a milder form of smallpox was recognized in the Americas, which was later identified as variola minor. Sequencing of the virus clearly indicated it was a different strain of variola virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/11\">",
"     11",
"    </a>",
"    ]. While variola minor strains have high sequence similarity to variola major strains, it is believed that changes in differential gene expression may explain the differences in virulence. However, because of their high sequence similarity, it is difficult to distinguish variola minor from variola major in the laboratory. Newer diagnostic tests under development may differentiate the two strains of virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expectoration of upper airway secretions, including secretions from the oropharynx, led to person-to-person transmission of smallpox virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. Inhaled secretions containing variola virus entered the respiratory tract where viruses multiplied locally and then spread to regional lymph nodes via circulating macrophages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/6\">",
"     6",
"    </a>",
"    ]. Multiplication within lymph nodes then led to a primary viremia with dissemination of virus to lymphoid organs, such as the spleen. Viral amplification within lymphoid organs led to a secondary viremia, which was associated with the onset of symptoms and the characteristic smallpox rash. Virus could be isolated from the oropharynx, skin lesions, bone marrow, spleen, liver, and kidneys.",
"   </p>",
"   <p>",
"    Virus that localized within small dermal blood vessels produced endothelial swelling and infection of epidermal cells, resulting in characteristic vesicles in skin and mucous membranes. When stained with hematoxylin and eosin, the cytoplasm of infected cells contained characteristic inclusions, called Guarnieri bodies, which were faintly basophilic or acidophilic (",
"    <a class=\"graphic graphic_picture graphicRef59400 \" href=\"mobipreview.htm?42/52/43844\">",
"     picture 1",
"    </a>",
"    ). Extension of infection into the corium and sebaceous glands produced the &ldquo;pockmarks&rdquo; or scars which, upon healing, were hallmarks of prior smallpox infection.",
"   </p>",
"   <p>",
"    Variola virus infection stimulated specific cytotoxic T cell responses, neutralizing antibodies, and the production of interferons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/2\">",
"     2",
"    </a>",
"    ]. These immune responses restricted viral replication and induced prolonged immunity in the patients who recovered. In one study, survivors had evidence of variola virus-specific CD4+ memory T-cell lymphoproliferative responses and neutralizing antibodies greater than 40 years after infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, smallpox occurred in two forms: variola major, which was a serious illness with a mortality rate of 30 to 50 percent in unvaccinated persons, and variola minor, which was a milder infection with a mortality rate of less than 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/2\">",
"     2",
"    </a>",
"    ]. In general, smallpox was most severe in infants, the elderly, and in the impaired host, particularly those with T cell deficits. Milder forms of infection were observed in patients with a history of smallpox immunization.",
"   </p>",
"   <p>",
"    Variola major is classified into five clinical categories, each associated with a different level of severity of disease:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ordinary type",
"     </li>",
"     <li>",
"      Modified type",
"     </li>",
"     <li>",
"      Flat type",
"     </li>",
"     <li>",
"      Hemorrhagic type",
"     </li>",
"     <li>",
"      Variola sine eruptione",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these forms have a characteristic rash except for variola sine eruptione. The following descriptions refer to observations in the past before smallpox was eradicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ordinary type",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a typical case of ordinary type smallpox, the incubation period was 10 to 14 days (range 7 to 19 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/6\">",
"     6",
"    </a>",
"    ]. A pre-eruptive phase, lasting two to four days, was characterized by the sudden onset of high fever, severe headache, backache, and malaise. Vomiting occurred in 50 percent and diarrhea in 10 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than 70 percent of smallpox cases were of the &ldquo;ordinary type&rdquo;, which was further subdivided into three categories according to the type of rash (",
"    <a class=\"graphic graphic_picture graphicRef61772 \" href=\"mobipreview.htm?30/5/30803\">",
"     picture 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Confluent rash present on face and forearms",
"     </li>",
"     <li>",
"      Semi-confluent rash present on the face with discrete rash elsewhere",
"     </li>",
"     <li>",
"      Discrete rash on all involved areas with normal skin between pustules",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical outcome for ordinary type smallpox was closely linked to the type of accompanying rash. For example, in unvaccinated patients, mortality was 62 percent for confluent infection, 37 percent for semi-confluent, and 9 percent for discrete rash [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/2\">",
"     2",
"    </a>",
"    ]. Death from smallpox was secondary to coagulopathy, hypotension and multiorgan failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The eruptive phase was characterized by lesions on the mucous membranes (enanthem) followed approximately 24 hours later by the cutaneous rash (exanthem). Intraoral lesions first appeared as papules followed by vesicles on the tongue and palate. The spread of the exanthem was centrifugal, involving initially the face, followed by proximal extremities, the trunk, and the distal extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/17\">",
"     17",
"    </a>",
"    ]. The exanthem began as small macules (&ldquo;herald spots&rdquo;) on the face. Macules evolved to papules by day two of the rash, vesicles by days four to five, and pustules by day seven. Fever occasionally recurred during the pustular phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of lesions ranged from few to thousands. Classic lesions were described as deep-seated, firm, round, and well-circumscribed vesicles or nodules. Crusts developed by day 14 and healed with residual depigmentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Modified type",
"    </span>",
"    &nbsp;&mdash;&nbsp;The modified form of smallpox was similar to ordinary disease except that the phases of the rash developed more rapidly and pustular lesions were smaller. Modified smallpox was common in vaccinated patients who became infected despite immunization and in those intentionally infected by variolation, a procedure that had been widely used as a method of vaccination prior to vaccinia virus vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2771052\">",
"    <span class=\"h2\">",
"     Flat type",
"    </span>",
"    &nbsp;&mdash;&nbsp;This type of smallpox infection was characterized by pustules which remained flat and were usually confluent or semiconfluent. Flat type smallpox occurred mainly in children and was often fatal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2771028\">",
"    <span class=\"h2\">",
"     Hemorrhagic type",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this rare form of smallpox, skin lesions and mucous membranes became hemorrhagic. Profound prostration, heart failure, diffuse bleeding, and bone marrow suppression commonly resulted in a fatal outcome within three to four days, earning the name \"sledgehammer smallpox.\"",
"   </p>",
"   <p>",
"    Hemorrhagic smallpox was difficult to recognize unless the patient had a known exposure to a patient with smallpox [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/6\">",
"     6",
"    </a>",
"    ]. Pregnant women were predisposed to this type of smallpox.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2771573\">",
"    <span class=\"h2\">",
"     Variola sine eruptione",
"    </span>",
"    &nbsp;&mdash;&nbsp;After exposure to variola virus, variola sine eruptione occurred among vaccinated individuals or in partially immune patients who had been previously infected. These patients had fever but no rash. A rise in anti-variola antibody titers at a time after the fever would indicate that such patients had been infected with variola virus, but did not develop a rash [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3857051\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific laboratory findings included granulocytopenia, thrombocytopenia, and lymphocytosis, which were common during the prodromal and early rash phase. Leukocytosis often occurred when vesicles became pustular. Disseminated intravascular coagulation was often seen in patients with hemorrhagic smallpox [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3104607\">",
"    <span class=\"h1\">",
"     COMPLICATIONS AND SEQUELAE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional complications of smallpox included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35797/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Secondary bacterial infections of the skin",
"     </li>",
"     <li>",
"      Keratitis and corneal ulcerations leading to blindness",
"     </li>",
"     <li>",
"      Viral arthritis and osteomyelitis",
"     </li>",
"     <li>",
"      Bacterial pneumonia",
"     </li>",
"     <li>",
"      Orchitis",
"     </li>",
"     <li>",
"      Encephalitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Residual pockmarks appeared hypopigmented in dark-skinned individuals and hyperpigmented in light-skinned patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27725591\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Smallpox (variola major) was a contagious disease characterized by fever, a vesicular and pustular eruption, and a high mortality rate in nonimmune patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The global eradication of smallpox was officially announced in 1979, marking one of the greatest achievements of modern medicine. (See",
"      <a class=\"local\" href=\"#H3856688\">",
"       'Global eradication of smallpox'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Smallpox occurred in two forms: variola major, which was a serious illness with a mortality rate of 30 to 50 percent in the unvaccinated individual, and variola minor, which was a milder infection with a mortality rate of less than 1 percent. (See",
"      <a class=\"local\" href=\"#H3856772\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the past, smallpox was endemic worldwide. The last known case in the world, in September 1978, resulted from a laboratory accident in England. (See",
"      <a class=\"local\" href=\"#H3104273\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inhaled variola virus entered the respiratory tract where viruses multiplied locally and then spread to regional lymph nodes via circulating macrophages. Multiplication within lymph nodes then led to a primary viremia with dissemination of virus to lymphoid organs. Viral amplification within lymphoid organs led to a secondary viremia, which was associated with the onset of symptoms and the characteristic smallpox rash. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis and pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Smallpox was most commonly characterized by the sudden onset of high fever, severe headache, backache, and malaise. These constitutional symptoms were then followed by the onset of lesions on the mucous membranes (enanthem) followed by the onset of rash (exanthem) involving the face, proximal extremities, trunk, and distal extremities. The risk of mortality was closely linked to the severity of the rash. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of smallpox infection included secondary bacterial infections of the skin, keratitis of corneal ulcerations, and encephalitis. (See",
"      <a class=\"local\" href=\"#H3104607\">",
"       'Complications and sequelae'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     WHO. The global eradication of smallpox: Final report of the global commission for the certification of smallpox eradication. History of International Public Health, No. 4. Geneva: World Health Organization, 1980.",
"    </li>",
"    <li>",
"     Fenner F, Henderson DA, Arita I, et al. Smallpox and its eradication, World Health Organization, Geneva 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35797/abstract/3\">",
"      Henderson DA. The looming threat of bioterrorism. Science 1999; 283:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35797/abstract/4\">",
"      Henderson DA, Inglesby TV, Bartlett JG, et al. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 1999; 281:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35797/abstract/5\">",
"      Breman JG, Henderson DA. Diagnosis and management of smallpox. N Engl J Med 2002; 346:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35797/abstract/6\">",
"      Moore ZS, Seward JF, Lane JM. Smallpox. Lancet 2006; 367:425.",
"     </a>",
"    </li>",
"    <li>",
"     Moss B. Poxviridae and their replication. In: Field's Virology, Fifth Edition, Knipe DM, Howley PM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35797/abstract/8\">",
"      Massung RF, Liu LI, Qi J, et al. Analysis of the complete genome of smallpox variola major virus strain Bangladesh-1975. Virology 1994; 201:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35797/abstract/9\">",
"      Massung RF, Loparev VN, Knight JC, et al. Terminal region sequence variations in variola virus DNA. Virology 1996; 221:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35797/abstract/10\">",
"      Shchelkunov SN, Resenchuk SM, Totmenin AV, et al. Comparison of the genetic maps of variola and vaccinia viruses. FEBS Lett 1993; 327:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35797/abstract/11\">",
"      Shchelkunov SN, Totmenin AV, Loparev VN, et al. Alastrim smallpox variola minor virus genome DNA sequences. Virology 2000; 266:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35797/abstract/12\">",
"      Loveless BM, Mucker EM, Hartmann C, et al. Differentiation of Variola major and Variola minor variants by MGB-Eclipse probe melt curves and genotyping analysis. Mol Cell Probes 2009; 23:166.",
"     </a>",
"    </li>",
"    <li>",
"     Christie AB. Smallpox. In: Infectious Diseases, Epidemiology and Clinical Practices, Second Edition, Edinburgh.  (Ed), Churchill Livingstone, New York 1974.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35797/abstract/14\">",
"      Sivapalasingam S, Kennedy JS, Borkowsky W, et al. Immunological memory after exposure to variola virus, monkeypox virus, and vaccinia virus. J Infect Dis 2007; 195:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35797/abstract/15\">",
"      Hammarlund E, Lewis MW, Hanifin JM, et al. Antiviral immunity following smallpox virus infection: a case-control study. J Virol 2010; 84:12754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35797/abstract/16\">",
"      Koplan JP, Foster SO. Smallpox: clinical types, causes of death, and treatment. J Infect Dis 1979; 140:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35797/abstract/17\">",
"      Albert MR, Ostheimer KG, Liewehr DJ, et al. Smallpox manifestations and survival during the Boston epidemic of 1901 to 1903. Ann Intern Med 2002; 137:993.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8341 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_61_35797=[""].join("\n");
var outline_f34_61_35797=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27725591\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3856688\">",
"      GLOBAL ERADICATION OF SMALLPOX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3856772\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3104273\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2770716\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3104395\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS AND PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ordinary type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Modified type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2771052\">",
"      Flat type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2771028\">",
"      Hemorrhagic type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2771573\">",
"      Variola sine eruptione",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3857051\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3104607\">",
"      COMPLICATIONS AND SEQUELAE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27725591\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8341\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8341|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/52/43844\" title=\"picture 1\">",
"      Histology of a variola maculopapular lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/5/30803\" title=\"picture 2\">",
"      Smallpox rash",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22247?source=related_link\">",
"      Identifying and managing casualties of biological terrorism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/43/6842?source=related_link\">",
"      Molluscum contagiosum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16439?source=related_link\">",
"      Monkeypox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40057?source=related_link\">",
"      Vaccinia virus as the smallpox vaccine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_61_35798="Androgen production and metabolism in normal pregnancy";
var content_f34_61_35798=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Androgen production and metabolism in normal pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/61/35798/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35798/contributors\">",
"     Howard D McClamrock, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/61/35798/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35798/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/61/35798/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35798/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/61/35798/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The production, transport and metabolism of androgens in normal pregnant women will be reviewed here. This information will serve as a background for the discussion of hyperandrogenism during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18470?source=see_link\">",
"     \"Causes of gestational hyperandrogenism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31236?source=see_link\">",
"     \"Diagnosis and management of gestational hyperandrogenism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MATERNAL COMPARTMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum concentrations of some, but not all, androgens increase during normal pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Total testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum",
"    <strong>",
"     total",
"    </strong>",
"    &nbsp;testosterone concentration increases progressively throughout pregnancy (",
"    <a class=\"graphic graphic_figure graphicRef61213 \" href=\"mobipreview.htm?12/16/12558\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ], an effect that is due primarily to a progressive estrogen-induced increase in serum sex hormone-binding globulin (SHBG) concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. The increase in testosterone concentration in normal pregnancies occurs as early as 15 days after the LH surge, implying luteal phase ovarian production rather than adrenal production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few studies of androgen production and clearance in normal pregnant women. One study of five pregnant women found that the production rates of testosterone and dihydrotestosterone were similar to those of nonpregnant women, but that testosterone conversion to dihydrotestosterone and the metabolic clearance rates of the two androgens were lower in pregnancy, as would be expected since serum SHBG concentrations are increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/5\">",
"     5",
"    </a>",
"    ]. Another study including 1343 women with singleton pregnancies observed that maternal age over 30 years and multiparity were associated with lower androgen levels in pregnancy while smoking was associated with higher androgen levels in the first half of pregnancy compared with younger women, nulliparous women, and nonsmokers, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maternal serum testosterone concentrations are three to four times higher than umbilical cord serum concentrations; maternal values are 100 to 140",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (3.5 to 4.8",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    and cord values average 33.5",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (1.2",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Free testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum",
"    <strong>",
"     free",
"    </strong>",
"    &nbsp;testosterone concentration changes minimally until the third trimester, at which time it increases about twofold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/1\">",
"     1",
"    </a>",
"    ]. The late increase in serum free testosterone concentration cannot be explained by the change in serum SHBG concentration, and must be caused by a rise in testosterone production. The source of the increased testosterone is not known. One possibility is that human chorionic gonadotropin (hCG) may stimulate the theca-interstitial cells of the ovary to synthesize testosterone; however, serum hCG concentrations are highest at the end of the first trimester and decline as serum free testosterone concentrations are increasing. Another possible source is the corpus luteum, as documented in sub-human primates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/13\">",
"     13",
"    </a>",
"    ]. Finally, the testosterone might come from the maternal adrenal cortex, in parallel with the increase in maternal cortisol secretion late in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Androstenedione",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maternal serum androstenedione concentration increases during the latter part of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dehydroepiandrosterone sulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal serum dehydroepiandrosterone sulfate (DHEAS) concentrations fall across gestation, despite an increase in production that appears to be of fetal origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/12\">",
"     12",
"    </a>",
"    ]. The decrease is greatest early in the second trimester, when the metabolic clearance rate of DHEAS increases sharply [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. In pregnant women, DHEAS is cleared by conversion to 16-alpha-hydroxy-DHEAS by the liver and by conversion to estrogen in the placenta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/12,14,15\">",
"     12,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     3-alpha-17-beta-androstanediol glucuronide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal serum 3-alpha-17-beta-androstanediol glucuronide (3a-diol-G), a product of dihydrotestosterone in hair follicles of the skin, is elevated in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Whether the increase is due to increased activity of 5-alpha-reductase and other androgen-metabolizing enzymes or to increased substrate availability is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     AMNIOTIC FLUID COMPARTMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amniotic fluid testosterone and androstenedione concentrations are, on average, about two to three-times higher when the fetus is male [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/12,18\">",
"     12,18",
"    </a>",
"    ]. The median interquartile range in males is 17.3 to 33.7",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (0.60 to 1.17",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    and in females 5.05 to 12.98",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (0.175 to 0.45",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/19\">",
"     19",
"    </a>",
"    ]. This difference between male and female fetuses indicates that at least some of the testosterone and androstenedione in amniotic fluid is derived from the fetal testes.",
"   </p>",
"   <p>",
"    In contrast, amniotic fluid DHEA concentrations are similar for male and female fetuses, probably because this steroid is mostly of fetal adrenal origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FETAL COMPARTMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum testosterone concentrations are higher in male than in female fetuses, whereas serum dihydrotestosterone concentrations are similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Male fetuses",
"    </span>",
"    &nbsp;&mdash;&nbsp;In male fetuses, serum testosterone concentrations rise to a peak of about 150",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (5.2",
"    <span class=\"nowrap\">",
"     nmol/L;",
"    </span>",
"    one-half the lower limit of normal in adult men) at the end of the first trimester and then gradually decline by about 60 to 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little is known about the regulation of fetal testosterone production, but it appears to be more dependent on hCG of maternal origin than on fetal pituitary luteinizing hormone (LH). Maternal and fetal serum hCG concentrations reach a peak at 9 to 12 weeks of gestation and then decline (the maternal hCG concentration in fetal serum is much lower than in maternal serum: fetal levels range from barely detectable to 2.5",
"    <span class=\"nowrap\">",
"     mIU/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/24\">",
"     24",
"    </a>",
"    ]. The appearance of maternal hCG in fetal serum coincides with the appearance of Leydig cells (the source of testicular testosterone production) at about 8 weeks of gestation, suggesting that maternal hCG plays a role in fetal Leydig cell development and testosterone production. Leydig cell development peaks at 14 to 18 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gonadotropins have been detected in the fetal pituitary gland at approximately 10 weeks of gestation and in fetal serum about one week later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/24\">",
"     24",
"    </a>",
"    ]. The late timing of gonadotropin production and studies in male transgenic mice lend support to the idea that Leydig cell development and testosterone production is initiated mostly by maternal hCG. Furthermore, fetal Leydig cell function appears normal in fetal mice lacking LH or its receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Female fetuses",
"    </span>",
"    &nbsp;&mdash;&nbsp;In female fetuses, serum testosterone concentrations are low (about 50",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [1.7",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    throughout most of gestation, and decline near term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/21,22,24\">",
"     21,22,24",
"    </a>",
"    ]. The source is probably ovarian [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/28,29\">",
"     28,29",
"    </a>",
"    ] as gonadotropins can stimulate the fetal ovary to produce androgens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/30\">",
"     30",
"    </a>",
"    ], which are converted, in part, to estrogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NEONATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborn males have only slightly higher umbilical artery serum testosterone concentrations than females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/32\">",
"     32",
"    </a>",
"    ]. However, the serum testosterone (and androstenedione) values increase during the first day of life, particularly in male infants, and then decline over the next six days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increase in androgens on the first day of life may be a response to uninhibited hCG. During pregnancy, other steroids produced by the placenta may partially inhibit the action of hCG on fetal cells. The decline in serum androgen concentrations during the first week of life parallels the decline in serum hCG concentrations that occurs at the same time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3934970\">",
"    <span class=\"h1\">",
"     PLACENTAL COMPARTMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies suggest that the placenta may be capable of de novo synthesis of androgens, most of which are converted to estrogens by placental CYP17. The significance of placental androgen synthesis is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PROTECTIVE MECHANISMS AGAINST MATERNAL AND FETAL VIRILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the increases in serum total and free androgen concentrations in pregnant women, most women and their infants are not virilized. Mechanisms postulated to account for this lack of virilization are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High serum SHBG concentrations &mdash; Most of the elevation in serum androgen concentrations is SHBG-bound androgen. As noted above, serum free androgen concentrations increase relatively little and only late in pregnancy; therefore, much of the androgen in serum is not available for action at the target tissues.",
"     </li>",
"     <li>",
"      Progesterone competition for androgen-receptor binding &mdash; Progesterone production increases 10-fold during pregnancy, and may approach 250",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      at term. While the affinity of androgen-receptors for progesterone is low, the increase in progesterone production is so great that androgen binding to its receptors on target tissues might be inhibited.",
"     </li>",
"     <li>",
"      Progesterone competition for androgen activation in target tissues &mdash; Testosterone is converted to the biologically more active dihydrotestosterone by 5-alpha-reductase in target tissues. Progesterone has weak affinity for 5-alpha-reductase; thus, the additional progesterone produced during pregnancy might inhibit conversion of testosterone to dihydrotestosterone in androgen target tissues.",
"     </li>",
"     <li>",
"      Placental androgen aromatization &mdash; The placenta has a massive capability to convert androgens to estrogens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/37\">",
"       37",
"      </a>",
"      ]. It is therefore highly likely that most of the androgen produced by the mother or fetus is metabolized by the placenta. This mechanism may afford protection from virilization to both mothers and female fetuses. Androstenedione and testosterone are substrates for the high affinity placental aromatase enzyme system and are converted to estrone and estradiol, respectively. Dihydrotestosterone is not a substrate for aromatization; it is metabolized by placental hydroxysteroid dehydrogenase enzymes to less active metabolites, such as 5-alpha-androstane-3beta,17 beta diol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Support for this theory can be derived from a case report of a pregnant woman who had a serum testosterone concentration of 15,000",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (520",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    but the cord serum concentration was only 252",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (8.7",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    or 1.7 percent of the maternal value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/39\">",
"     39",
"    </a>",
"    ]. This suggests a high barrier against passage of testosterone from mother to fetus. In addition, even though the mother's serum estradiol concentration was normal, the cord serum concentration was high, suggesting conversion of testosterone to estradiol in the placenta or in the fetus. The increased fetal estrogen concentration may have inhibited the effects of the androgen since the cord serum testosterone concentration was still supranormal (see above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/3,4,40\">",
"     3,4,40",
"    </a>",
"    ], but the fetus was not virilized (by comparison, an adult woman who had a serum testosterone concentration of 252",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [8.7",
"    <span class=\"nowrap\">",
"     nmol/L]",
"    </span>",
"    would be virilized).",
"   </p>",
"   <p>",
"    These findings suggest that fetal androgen exposure may be diminished by placental aromatization of androgen and production of estrogen. Also consistent with this hypothesis is the observation that female infants of gestations in which there is placental aromatase deficiency are virilized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In one such infant, cord serum testosterone, dihydrotestosterone, and androstenedione concentrations were 26, 26, and 207 times those of normal infants and serum estrone, estradiol and estriol concentrations were 0.6, 0.9, and 0.2 percent of normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, aromatization is generally insufficient to completely protect against the transfer of testosterone, and does not fully explain the lack of fetal virilization. There have been reports of pregnant women with luteomas of the ovary who had high serum dihydrotestosterone concentrations, but delivered normal female infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35798/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Since dihydrotestosterone cannot be aromatized to an estrogen, female fetuses in normal pregnancies must be protected against virilization by decreased androgen action. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18470?source=see_link\">",
"     \"Causes of gestational hyperandrogenism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Maternal androgen levels",
"    </span>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Maternal compartment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Total&nbsp;testosterone concentration increases progressively throughout pregnancy (",
"      <a class=\"graphic graphic_figure graphicRef61213 \" href=\"mobipreview.htm?12/16/12558\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Free&nbsp;testosterone concentration changes minimally until the third trimester, at which time it increases about twofold.",
"     </li>",
"     <li>",
"      Androstenedione concentration increases during the latter part of pregnancy.",
"     </li>",
"     <li>",
"      Dehydroepiandrosterone sulfate (DHEAS) concentration falls.",
"     </li>",
"     <li>",
"      Estrogen induces an increase in serum sex hormone-binding globulin (SHBG) concentration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Amniotic fluid and fetal androgen levels",
"    </span>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Fetal compartment'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Amniotic fluid compartment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testosterone and androstenedione concentrations are higher when the fetus is male.",
"     </li>",
"     <li>",
"      DHEA concentrations are similar for both male and female fetuses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Avoidance of virilization",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite increases in total and free androgen concentrations in pregnant women, most women and their female infants are not virilized. Four factors that may protect against virilization include: high serum SHBG concentrations, progesterone competition for androgen-receptor binding, progesterone competition for androgen activation in target tissues, and placental androgen aromatization. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Protective mechanisms against maternal and fetal virilization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/1\">",
"      Bammann BL, Coulam CB, Jiang NS. Total and free testosterone during pregnancy. Am J Obstet Gynecol 1980; 137:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/2\">",
"      Berger NG, Repke JT, Woodruff JD. Markedly elevated serum testosterone in pregnancy without fetal virilization. Obstet Gynecol 1984; 63:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/3\">",
"      Mizuno M, Lobotsky J, Lloyd CW, et al. Plasma androstenedione and testerone during pregnancy and in the newborn. J Clin Endocrinol Metab 1968; 28:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/4\">",
"      Rivarola MA, Forest MG, Migeon CJ. Testosterone, androstenedione and dehydroepiandrosterone in plasma during pregnancy and at delivery: concentration and protein binding. J Clin Endocrinol Metab 1968; 28:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/5\">",
"      Saez JM, Forest MG, Morera AM, Bertrand J. Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. J Clin Invest 1972; 51:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/6\">",
"      Pearlman WH, Cr&eacute;py O, Murphy M. Testosterone-binding levels in the serum of women during the normal menstrual cycle, pregnancy, and the post-partum period. J Clin Endocrinol Metab 1967; 27:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/7\">",
"      Anderson DC, Lasley BL, Risher RA, et al. Transplacental gradients of sex-hormone-binding globulin in human and simian pregnancy. Clin Endocrinol (Oxf) 1976; 5:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/8\">",
"      Forest MG, Ances IG, Tapper AJ, Migeon CJ. Percentage binding of testosterone, androstendione and dihydroisoandrosterone in plasma at the time of delivery. J Clin Endocrinol Metab 1971; 32:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/9\">",
"      Vermeulen, A, Verdonck, L, Van Der Straeten, M, Orie, N. Capacity of the testosterone-binding globulin in human plasma and influence of specific binding of testosterone on its metabolic clearance rates. J Clin Endocrinol Metab 1969; 29:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/10\">",
"      Castracane VD, Stewart DR, Gimpel T, et al. Maternal serum androgens in human pregnancy: early increases within the cycle of conception. Hum Reprod 1998; 13:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/11\">",
"      Toriola AT, V&auml;&auml;r&auml;sm&auml;ki M, Lehtinen M, et al. Determinants of maternal sex steroids during the first half of pregnancy. Obstet Gynecol 2011; 118:1029.",
"     </a>",
"    </li>",
"    <li>",
"     Tulchinsky, D, Ryan, KJ. Maternal-Fetal Endocrinology. Saunders, Philadelphia, 1980.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/13\">",
"      Treloar OL, Wolf RC, Meyer RK. The corpus luteum of the rhesus monkey during late pregnancy. Endocrinology 1972; 91:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/14\">",
"      Milewich L, Gomez-Sanchez C, Madden JD, et al. Dehydroisoandrosterone sulfate in peripheral blood of premenopausal, pregnant and postmenopausal women and men. J Steroid Biochem 1978; 9:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/15\">",
"      Gant NF, Hutchinson HT, Siiteri PK, MacDonald PC. Study of the metabolic clearance rate of dehydroisoandrosterone sulfate in pregnancy. Am J Obstet Gynecol 1971; 111:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/16\">",
"      Braunstein GD, Horton R. Increased maternal serum 3 alpha, 17 beta-androstanediol glucuronide concentrations during pregnancy. Fertil Steril 1985; 44:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/17\">",
"      Mathur RS, Katikaneni LD, Garza D, Moody LO. 3 alpha-Androstanediol and 3 alpha-androstanediol glucuronide. Maternal and umbilical cord plasma concentrations in normal pregnancy. J Reprod Med 1992; 37:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/18\">",
"      Saez, JM, Bertrand, J. Androgen studies in the foeto-placental unit. In: International Congress Series, Pecite, E, Linze, C (Eds), Excerpta Medica, Amsterdam 1969; 183:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/19\">",
"      Sarkar P, Bergman K, Fisk NM, et al. Amniotic fluid testosterone: relationship with cortisol and gestational age. Clin Endocrinol (Oxf) 2007; 67:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/20\">",
"      Robinson JD, Judd HL, Young PE, et al. Amniotic fluid androgens and estrogens in midgestation. J Clin Endocrinol Metab 1977; 45:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/21\">",
"      Rodeck CH, Gill D, Rosenberg DA, Collins WP. Testosterone levels in midtrimester maternal and fetal plasma and amniotic fluid. Prenat Diagn 1985; 5:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/22\">",
"      Diez d'Aux RC, Pearson Murphy BE. Androgens in the human fetus. J Steroid Biochem 1974; 5:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/23\">",
"      Fowler PA, Bhattacharya S, Gromoll J, et al. Maternal smoking and developmental changes in luteinizing hormone (LH) and the LH receptor in the fetal testis. J Clin Endocrinol Metab 2009; 94:4688.",
"     </a>",
"    </li>",
"    <li>",
"     Burger, H, deKrester, D. The Testis. Raven, New York, 1981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/25\">",
"      O'Shaughnessy PJ, Morris ID, Huhtaniemi I, et al. Role of androgen and gonadotrophins in the development and function of the Sertoli cells and Leydig cells: data from mutant and genetically modified mice. Mol Cell Endocrinol 2009; 306:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/26\">",
"      O'Shaughnessy PJ, Baker PJ, Johnston H. The foetal Leydig cell-- differentiation, function and regulation. Int J Androl 2006; 29:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/27\">",
"      Ahtiainen P, Rulli SB, Shariatmadari R, et al. Fetal but not adult Leydig cells are susceptible to adenoma formation in response to persistently high hCG level: a study on hCG overexpressing transgenic mice. Oncogene 2005; 24:7301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/28\">",
"      Payne AH, Jaffe RB. Androgen formation from pregnenolone sulfate by the human fetal ovary. J Clin Endocrinol Metab 1974; 39:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/29\">",
"      Weniger JP, Chouraqui J, Zeis A. Steroid conversions by the 19-day old foetal rat ovary in organ culture. Biol Chem Hoppe Seyler 1985; 366:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/30\">",
"      Raeside JI. Gonadotrophic stimulation of androgen secretion by the early fetal pig ovary in organ culture. Biol Reprod 1983; 28:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/31\">",
"      George FW, Wilson JD. Conversion of androgen to estrogen by the human fetal ovary. J Clin Endocrinol Metab 1978; 47:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/32\">",
"      Forest MG, Cathiard AM. Pattern of plasma testosterone and delta4-androstenedione in normal newborns: Evidence for testicular activity at birth. J Clin Endocrinol Metab 1975; 41:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/33\">",
"      Tapanainen J, Huhtaniemi I, Koivisto M, et al. Hormonal changes during the perinatal period: FSH, prolactin and some steroid hormones in the cord blood and peripheral serum of preterm and fullterm female infants. J Steroid Biochem 1984; 20:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/34\">",
"      Tapanainen J. Hormonal changes during the perinatal period: serum testosterone, some of its precursors, and FSH and prolactin in preterm and fullterm male infant cord blood and during the first week of life. J Steroid Biochem 1983; 18:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/35\">",
"      Escobar JC, Patel SS, Beshay VE, et al. The human placenta expresses CYP17 and generates androgens de novo. J Clin Endocrinol Metab 2011; 96:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/36\">",
"      Escobar JC, Carr BR. The protein kinase a pathway regulates CYP17 expression and androgen production in the human placenta. J Clin Endocrinol Metab 2011; 96:2869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/37\">",
"      Edman CD, Toofanian A, MacDonald PC, Gant NF. Placental clearance rate of maternal plasma androstenedione through placental estradiol formation: an indirect method of assessing uteroplacental blood flow. Am J Obstet Gynecol 1981; 141:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/38\">",
"      Liu H, Robert A, Luu-The V. Cloning and characterization of human form 2 type 7 17beta-hydroxysteroid dehydrogenase, a primarily 3beta-keto reductase and estrogen activating and androgen inactivating enzyme. J Steroid Biochem Mol Biol 2005; 94:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/39\">",
"      Hensleigh PA, Carter RP, Grotjan HE Jr. Fetal protection against masculinization with hyperreactio luteinalis and virilization. J Clin Endocrinol Metab 1975; 40:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/40\">",
"      Bilowus M, Abbassi V, Gibbons MD. Female pseudohermaphroditism in a neonate born to a mother with polycystic ovarian disease. J Urol 1986; 136:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/41\">",
"      Shozu M, Akasofu K, Harada T, Kubota Y. A new cause of female pseudohermaphroditism: placental aromatase deficiency. J Clin Endocrinol Metab 1991; 72:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/42\">",
"      Conte FA, Grumbach MM, Ito Y, et al. A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). J Clin Endocrinol Metab 1994; 78:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/43\">",
"      Nagamani M, Gomez LG, Garza J. In vivo steroid studies in luteoma of pregnancy. Obstet Gynecol 1982; 59:105S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/44\">",
"      Verkauf BS, Reiter EO, Hernandez L, Burns SA. Virilization of mother and fetus associated with luteoma of pregnancy: a case report with endocrinologic studies. Am J Obstet Gynecol 1977; 129:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35798/abstract/45\">",
"      Jewelewicz R, Perkins RP, Dyrenfurth I, Vande Wiele RL. Luteomas of pregnancy: a cause for maternal virilization. Am J Obstet Gynecol 1971; 109:24.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7445 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-9318902EC1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_61_35798=[""].join("\n");
var outline_f34_61_35798=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MATERNAL COMPARTMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Total testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Free testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Androstenedione",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dehydroepiandrosterone sulfate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      3-alpha-17-beta-androstanediol glucuronide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      AMNIOTIC FLUID COMPARTMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FETAL COMPARTMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Testosterone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Male fetuses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Female fetuses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NEONATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3934970\">",
"      PLACENTAL COMPARTMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PROTECTIVE MECHANISMS AGAINST MATERNAL AND FETAL VIRILIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Maternal androgen levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Amniotic fluid and fetal androgen levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Avoidance of virilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/7445\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7445|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/16/12558\" title=\"figure 1\">",
"      Serum testosterone level across gestation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18470?source=related_link\">",
"      Causes of gestational hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31236?source=related_link\">",
"      Diagnosis and management of gestational hyperandrogenism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_61_35799="MR normal fetal chest";
var content_f34_61_35799=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74495%7EOBGYN%2F63320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74495%7EOBGYN%2F63320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Fetal MRI T2w of a normal chest at 32 weeks of gestation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial (A), coronal (B) and sagittal (C) images demonstrate homogeneous high signal lung parenchyma with normal pulmonary vessels coursing through them. The heart is black due to flowing blood.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dorothy I Bulas, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound image of a normal fetal chest at 28 weeks of gestation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal (A) and axial (B) images of the chest demonstrate homogeneous echogenic lung parenchyma, slightly echogenic compared to the liver.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dorothy I Bulas, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_61_35799=[""].join("\n");
var outline_f34_61_35799=null;
var title_f34_61_35800="Hematopoietic cell transplantation in chronic lymphocytic leukemia";
var content_f34_61_35800=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hematopoietic cell transplantation in chronic lymphocytic leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/61/35800/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35800/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35800/contributors\">",
"     Kanti R Rai, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/61/35800/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35800/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/61/35800/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35800/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/61/35800/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders (lymphoid neoplasms). It is characterized by a progressive accumulation of functionally incompetent lymphocytes, which are monoclonal in origin.",
"   </p>",
"   <p>",
"    CLL is considered to be identical (ie, one disease at different stages) to the mature (peripheral) B-cell neoplasm small lymphocytic lymphoma (SLL), one of the indolent non-Hodgkin lymphomas. The term CLL is used when the disease manifests primarily in the bone marrow and blood, while the term SLL is used when involvement is primarily nodal. While there are some differences in the treatment of early stage CLL and SLL, the treatment of advanced stage disease is the same. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35431?source=see_link\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The natural history of CLL is extremely variable. While many cases follow an indolent course that is well controlled with standard therapy, others progress rapidly and die within two to three years after diagnosis from complications or causes directly related to CLL. The initial treatment of symptomatic CLL primarily consists of an immunotherapy-based chemotherapy regimen (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    plus chemotherapy). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29352?source=see_link\">",
"     \"Overview of the treatment of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/6/15466?source=see_link\">",
"     \"Staging and prognosis of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35017?source=see_link\">",
"     \"Overview of the complications of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of either autologous or allogeneic hematopoietic cell transplantation (HCT) in CLL is an emerging therapy for selected patients and is the subject of ongoing clinical trials. Autologous HCT is not curative, but may result in prolonged remissions and has a low treatment-related mortality rate. In comparison, allogeneic HCT may cure a percentage of patients with CLL, but is associated with higher treatment-related mortality. The term \"hematopoietic cell transplantation\" (HCT) will be used throughout this review as a general term to cover transplantation of progenitor cells from any source (eg, bone marrow, peripheral blood, cord blood). Otherwise, the source of such cells will be specified (eg, autologous peripheral blood progenitor cell transplantation). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of HCT in CLL is reviewed below. Other treatment options are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30442?source=see_link\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351650637\">",
"    <span class=\"h1\">",
"     DETERMINING TRANSPLANT ELIGIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CLL are generally elderly and, due to the relatively benign course of the disease in the majority of patients, only a selected subset is considered for aggressive treatments such as HCT. The determination of transplant eligibility should be made based on a risk-benefit assessment, and the needs and wishes of the patient. Eligibility for HCT varies across countries and institutions and depends upon the type of transplantation (ie, allogeneic versus autologous) and the conditioning regimen (eg, myeloablative versus nonmyeloablative).",
"   </p>",
"   <p>",
"    In most centers in the United States, patients are considered eligible for nonmyeloablative allogeneic HCT if they are less than 75 years of age, with normal cardiac, liver, and renal function, and have a good performance status (ECOG performance status 0 or 1) (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 1",
"    </a>",
"    ). For myeloablative allogeneic transplantation, eligibility is more restrictive in that patients should typically be less than 55 years of age.",
"   </p>",
"   <p>",
"    In general, age is not considered to be a strict inclusion or exclusion criterion for autologous HCT. In most centers in the United States, patients with one or more of the following factors are NOT considered eligible for autologous HCT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct bilirubin &gt;2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (34.2",
"      <span class=\"nowrap\">",
"       &micro;mol/liter)",
"      </span>",
"     </li>",
"     <li>",
"      Serum creatinine &gt;2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (221",
"      <span class=\"nowrap\">",
"       &micro;mol/liter)",
"      </span>",
"     </li>",
"     <li>",
"      Eastern Cooperative Oncology Group (ECOG) performance status 3 or 4 unless due to bone pain (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      New York Heart Association functional status Class III or IV (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351650834\">",
"    <span class=\"h1\">",
"     TIMING OF TRANSPLANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal timing of HCT in CLL depends upon a number of factors, and transplants should be carried out in the context of a clinical trial whenever possible. Such trials may be appropriate for young patients with clinically aggressive relapsed or refractory CLL. HCT may also be considered for patients with histologic transformation to a more aggressive histology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3609?source=see_link&amp;anchor=H16#H16\">",
"     \"Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma\", section on 'Hematopoietic cell transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following sections describe the use of HCT for the treatment of previously untreated CLL, relapsed or refractory CLL, and transformed disease. Interpretation of the trials that have investigated the relative value of HCT versus combination chemotherapy alone for patients with CLL is complicated by subsequent changes in the standard care of CLL. Since these trials were performed, the routine incorporation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    into the standard treatment of CLL has improved survival rates among patients who do not undergo HCT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6362?source=see_link&amp;anchor=H5622415#H5622415\">",
"     \"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia\", section on 'Initial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1138003\">",
"    <span class=\"h2\">",
"     Previously untreated disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with newly diagnosed symptomatic CLL are treated with immunotherapy (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) plus combination chemotherapy. This approach is well tolerated and produces prolonged responses in the majority of patients. Allogeneic HCT is not recommended in this setting due to its higher morbidity and mortality rates. In contrast, several retrospective analyses and a single multicenter prospective randomized trial have examined the use of high dose chemotherapy followed by autologous HCT in the treatment of newly diagnosed CLL. While some studies have demonstrated improvements in progression-free survival, none has shown an overall survival benefit. As such, immunotherapy plus chemotherapy remains the standard therapy for most patients with previously untreated CLL. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Autologous HCT'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6362?source=see_link&amp;anchor=H5622415#H5622415\">",
"     \"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia\", section on 'Initial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351650955\">",
"    <span class=\"h2\">",
"     Relapsed or refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of patients treated for CLL will have an initial response to therapy, but virtually all of these patients will ultimately develop progressive disease requiring subsequent treatment. While relapsed disease is typically sensitive to additional therapy, the duration of remission becomes shorter with each subsequent regimen. While progression is not always accompanied by a change in histology, a subset of patients will transform to a more aggressive histology. The use of either autologous or allogeneic HCT in relapsed CLL is an emerging option for some patients and the subject of numerous ongoing clinical trials. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Allogeneic HCT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Autologous HCT, myeloablative HCT, and nonmyeloablative HCT have not been directly compared for the treatment of relapsed CLL in a randomized fashion. As such, judgement of these treatment modalities must keep in mind selection biases that inevitably hinder comparisons of retrospective analyses and uncontrolled prospective case series. The use of each of these modalities is described in more detail in the following sections.",
"   </p>",
"   <p>",
"    For patients with disease that has relapsed more than six months after an initial response, we suggest retreatment with the same therapy that provided the initial response rather than treatment with another agent or upfront HCT. Chemotherapy is also the main treatment modality used for early relapsed CLL or refractory CLL, either alone or in combination with HCT. Young patients with a good performance status and few comorbidities may be considered for HCT performed as part of a clinical trial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30442?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\", section on 'Treatment of relapsed disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30442?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\", section on 'Treatment of refractory disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351650981\">",
"    <span class=\"h2\">",
"     Following histologic transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of patients with CLL develop transformation to a more aggressive histology. Histologic transformation from an indolent to an aggressive histology has been associated with a poor prognosis. The use of allogeneic HCT for patients with chemotherapy-sensitive transformed CLL is supported by small retrospective analyses. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3609?source=see_link&amp;anchor=H16#H16\">",
"     \"Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma\", section on 'Hematopoietic cell transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351651079\">",
"    <span class=\"h1\">",
"     TYPE OF TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clear consensus among experts as to whether HCT should be performed in patients with CLL and regarding the ideal type of HCT for patients with CLL. Patients with early relapse or refractory CLL who respond to second line chemotherapy may be candidates for HCT, administered within the context of a clinical trial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myeloablative allogeneic HCT has a treatment-related mortality rate that approaches 50 percent, but may be curative in a highly select cohort of patients. Side effects include graft-versus-host disease, secondary malignancies, chronic immunosuppression, and cardiac and pulmonary toxicity. &nbsp;",
"     </li>",
"     <li>",
"      Reduced-intensity and nonmyeloablative allogeneic HCT appear to have a lower treatment-related mortality (approximately 5 to 25 percent), but an as yet unknown possibility of cure. Side effects are similar to those of myeloablative regimens.",
"     </li>",
"     <li>",
"      Autologous HCT has a low treatment-related mortality rate and may prolong progression-free survival, but not overall survival, in a subset of patients who are in complete remission or have minimal disease at the time of HCT. Patients who undergo autologous HCT appear to have an increased risk of developing myelodysplastic syndrome, perhaps as a result of chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation therapy administered before or during preparative regimen. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Autologous HCT'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Myeloablative HCT has not been directly compared with nonmyeloablative or autologous HCT or with combination chemotherapy in a prospective manner.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study compared results in 14 patients with CLL and unmutated Vh genes treated with myeloablative allogeneic HCT with results in 20 patients with CLL and unmutated Vh genes who had undergone myeloablative autologous HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/1\">",
"       1",
"      </a>",
"      ]. The five-year risk of disease relapse was significantly less for those undergoing allogeneic HCT than autologous HCT (17 versus 66 percent, respectively). There was no difference in overall survival.",
"     </li>",
"     <li>",
"      A retrospective analysis of 162 patients with high-risk CLL who underwent myeloablative allogeneic (25 patients) or autologous (137 patients) HCT at a single institution reported no difference in overall survival between these two groups at a median follow-up of 6.5 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional nonrandomized studies of each of these treatment modalities are presented in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Allogeneic HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic HCT is the only treatment option for patients with CLL with the potential for cure. This appears to be largely due to the graft versus leukemia (GVL) effect, the presence of which is supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Donor lymphocyte infusions (DLI) are sometimes effective in the treatment of relapsed disease after allogeneic HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/2-4\">",
"       2-4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduction in the dosage of immunosuppressive agents following HCT may decrease tumor burden [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Non-myeloablative allogeneic HCT, which relies primarily on a GVL effect, has resulted in long-term remissions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of myeloablative conditioning regimens in CLL is largely limited by an unacceptably high rate of treatment-related mortality. Nonmyeloablative approaches have been studied in an attempt to decrease this complication. A major difficulty with both myeloablative and nonmyeloablative allogeneic HCT is the induction of graft versus host disease (GVHD). Intensive research is underway in an attempt to dissociate GVL from GVHD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16298?source=see_link\">",
"     \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of uncontrolled studies have evaluated the efficacy of both myeloablative and nonmyeloablative allogeneic HCT in CLL. They are all limited by small size, absence of long-term follow-up, and treatment-related mortality. Evaluation of the results is also limited by issues related to patient selection, since variable criteria have been used to determine appropriate candidates for HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Myeloablative HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (HCT) takes advantage of the graft-versus-leukemia effect to eradicate remaining disease and may cure a subset of patients with untransformed CLL. Several nonrandomized prospective trials and retrospective analyses have demonstrated the potential efficacy of myeloablative allogeneic HCT in CLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/2,6-11\">",
"     2,6-11",
"    </a>",
"    ]. This approach has been associated with treatment-related mortality rates as high as 50 percent. However, of those who survive the transplant procedure, many obtain complete remissions with long-term disease control. Rates of five-year overall survival are approximately 40 percent. There has been specific interest in this approach for patients with high risk disease such as those with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -refractory CLL or certain high risk markers (eg, unmutated Vh genes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following is a survey of some of the largest studies that have evaluated the use of myeloablative HCT in the treatment of CLL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review from 30 centers worldwide published in 1996 consisted of 54 patients with CLL (mean age 41 years) who received a transplant from an HLA-identical sibling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/13\">",
"       13",
"      </a>",
"      ]. Most were treated with total body irradiation plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      <span class=\"nowrap\">",
"       (TBI/CY)",
"      </span>",
"      as the conditioning regimen followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      for graft-versus-host disease (GVHD) prophylaxis. The three-year survival rate was 46 percent overall but varied with the Rai stage, ranging from 68 percent in 10 patients with stage 1 CLL to 34 percent in 22 patients with stage 4 CLL. Five patients (9 percent) died of progressive leukemia, while 46 percent died of treatment-related complications, mostly GVHD.",
"     </li>",
"     <li>",
"      The Center for International Blood and Marrow Transplant Research described matched unrelated donor HCT in 38 patients with advanced CLL; 55 percent were refractory to chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/14\">",
"       14",
"      </a>",
"      ]. Conditioning included a variety of regimens but was TBI-based in 92 percent of the patients. Twenty-one patients (58 percent) achieved a complete remission (CR) and six (17 percent) achieved a partial remission (PR). Five-year overall survival, progression-free survival, and treatment-related mortality rates were 33, 30, and 38 percent, respectively.",
"     </li>",
"     <li>",
"      A retrospective analysis of 30 patients with CLL who underwent myeloablative allogeneic HCT using related (20 patients) or unrelated (10 patients) donors in Canada reported rates of five-year overall and event-free survival of 39 percent each [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/15\">",
"       15",
"      </a>",
"      ]. Cumulative incidence rates of non-relapse mortality and relapse were 47 and 19 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the high rate of treatment-related morbidity and mortality, myeloablative HCT cannot be recommended outside of a clinical trial for the treatment of CLL. Nonmyeloablative HCT or autologous HCT may be considered, as part of a clinical trial, for high risk patients who have failed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -based chemotherapy. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Nonmyeloablative HCT'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H5\">",
"     'Autologous HCT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Nonmyeloablative HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced intensity conditioning or nonmyeloablative conditioning followed by matched-related or matched-unrelated allogeneic HCT offers the potential benefit of decreased treatment-related mortality when compared with myeloablative HCT, while still maintaining a graft versus leukemia (GVL) effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/4,16\">",
"     4,16",
"    </a>",
"    ]. The reported rates of overall survival after nonmyeloablative allogeneic HCT vary, but are approximately 50 to 60 percent at five years. Specific regimens used for reduced intensity and nonmyeloablative allogeneic HCT are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link&amp;anchor=H13#H13\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Nonmyeloablative and reduced intensity preparative regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have",
"    <strong>",
"     suggested",
"    </strong>",
"    a potential benefit to reduced intensity or nonmyeloablative HCT in CLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest prospective trial of nonmyeloablative HCT with the longest follow-up evaluated a regimen combining low dose total body irradiation (200 cGy) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      used to treat 82 patients with advanced, fludarabine-refractory CLL with related (n = 52) or unrelated (n = 30) donors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. Patients had the following outcomes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Overall and complete response rates were 70 and 55 percent, respectively; all patients achieving a morphologic complete remission (CR) achieved a molecular remission.",
"     </li>",
"     <li>",
"      Patients who received grafts from unrelated donors had a significantly higher rate of CR at five years (67 versus 48 percent), perhaps due to a more effective GVL effect.",
"     </li>",
"     <li>",
"      Cumulative rates of five-year overall survival, progression-free survival, and non-relapse mortality were 48, 38, and 25 percent, respectively.",
"     </li>",
"     <li>",
"      Chronic extensive GVHD developed in approximately 50 percent of patients requiring a median duration of treatment for GVHD of 25 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another prospective trial evaluated",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"        fludarabine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"        cyclophosphamide",
"       </a>",
"       -based",
"      </span>",
"      conditioning followed by allogeneic HCT in 90 patients with poor risk CLL as defined by primary refractory disease, initial relapse within 12 months, relapse after autologous HCT, or progressive disease in the presence of unfavorable genetic features [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/19\">",
"       19",
"      </a>",
"      ]. After a median follow-up of 46 months, the rates of nonrelapse mortality, event-free survival, and overall survival at four years were 23, 42, and 65 percent, respectively. Event-free survival at four years was 89 percent among the 27 patients who attained minimal residual disease negativity after HCT. On multivariate analysis, outcomes were worse for patients with uncontrolled disease at the time of HCT.",
"     </li>",
"     <li>",
"      A retrospective case-control study from two institutions (data from 1999 to 2007) compared outcomes in 37 patients with CLL who underwent nonmyeloablative HCT with 43 patients (controls) from the same institutions who were candidates for HCT but did not have a suitable donor or refused the procedure, and were treated with conventional therapy only [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/20\">",
"       20",
"      </a>",
"      ]. Median overall survival for the HCT and control subjects was 113 versus 85 months, respectively, when calculated from the time of diagnosis, and 103 versus 67 months, respectively, when calculated from the time of first treatment. It is not clear that the patients were cured by the reduced-intensity conditioning regimen despite the longer survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following is a survey of other studies of reduced intensity or nonmyeloablative HCT in CLL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 30 patients with advanced CLL who received reduced-intensity conditioning with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      , and antithymocyte globulin followed by allogeneic HCT, acute and chronic GVHD were noted in 56 and 75 percent, respectively, with two-year overall and non-relapse survival rates of 72 and 15 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, nine patients with CLL and unmutated Vh genes were treated with nonmyeloablative allo-HCT and results compared with a group of 26 patients with CLL and unmutated Vh genes who had undergone autologous-HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/23\">",
"       23",
"      </a>",
"      ]. Minimal residual disease became undetectable in seven of the nine patients undergoing nonmyeloablative allo-HCT from day +100 onward, subsequent to the development of chronic GVHD or donor lymphocyte infusion. At a median follow-up of 25 months, these seven patients remained in continuous clinical and molecular remission, suggesting that a graft-versus-leukemia effect might provide sustained disease control in CLL patients even with this poor prognosis variant.",
"     </li>",
"     <li>",
"      The ability of nonmyeloablative HCT, with or without donor lymphocyte infusion, to overcome the adverse prognostic significance of ZAP-70 positivity was evaluated in 39 sequential patients with heavily pretreated advanced CLL undergoing nonmyeloablative HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/24\">",
"       24",
"      </a>",
"      ]. At a median follow-up of 27 months, progression-free and overall survival were similar in the 25 patients who were ZAP-70 positive and the 14 who were not.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       Alemtuzumab",
"      </a>",
"      was combined with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      followed by allogeneic HCT from related (n = 24) or unrelated (n = 17) donors in 41 patients with CLL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/25\">",
"       25",
"      </a>",
"      ]. The two-year overall survival and transplant-related mortality (TRM) were 51 and 26 percent, respectively. The relatively high TRM was largely due to viral and fungal infections, a significant problem when alemtuzumab has been included in allogeneic HCT protocols.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reduced intensity and nonmyeloablative allogeneic HCT are promising treatment options for patients with relapsed or high risk disease who are willing to undergo the risks of aggressive therapies. Aggressive treatment of the patient prior to the planned HCT is generally considered an important component of therapy. Reduced intensity and nonmyeloablative allogeneic HCT are considered investigational and should be considered as part of a clinical trial for such patients. Patient-related features such as short duration of first remission, unmutated immunoglobulin heavy chain genes, and certain genetic risk factors including 11q22 and 17p13 abnormalities predict for poor outcome with standard therapies and should be considered for reduced intensity or nonmyeloablative allogeneic HCT.",
"   </p>",
"   <p>",
"    In the US, a multi-institutional, large prospective study has been initiated in which patients with relapsed CLL who have adverse prognostic markers and good performance status are offered nonmyeloablative conditioning-based allogeneic HCT from a matched related or unrelated donor. The study has been initiated by Cancer and Leukemia Group B (CALGB), Chronic Lymphocytic Leukemia Research Consortium (CRC), and other large cooperative groups. CLL patients who meet the eligibility criteria should be encouraged to consider joining this trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Autologous HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous HCT may prolong progression-free survival, but not overall survival, in a subset of patients who are in complete remission or have minimal disease at the time of HCT. Initial retrospective studies suggested benefit from autologous HCT, especially in patients with high risk disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/2,26-28\">",
"     2,26-28",
"    </a>",
"    ]. However, this approach uses more intensive chemotherapy regimens and the impact on quality of life is not known. The best data regarding the use of autologous HCT come from two randomized trials performed prior to the incorporation of immunotherapy (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) into the initial treatment of CLL. High dose chemotherapy followed by autologous HCT can produce a complete remission (CR), but is not curative. The lack of a survival benefit seen with autologous HCT suggests that patients relapsing after standard chemotherapy could be successfully treated with second or third line therapies. In addition, autologous HCT may be technically difficult in patients with CLL since exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    may impair stem cell collection.",
"   </p>",
"   <p>",
"    The following describes the two randomized trials of autologous HCT in patients with CLL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter phase III trial randomly assigned treatment with autologous HCT versus observation in 223 patients with CLL who attained a CR (59 percent), very good partial remission, or nodular partial remission after first (83 percent) or second (17 percent) line chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/29\">",
"       29",
"      </a>",
"      ]. Peripheral blood progenitor cells (PBPC) were collected in both treatment groups for use immediately (HCT group) or for possible future use (observation group). Of the 112 patients assigned to HCT, only 80 proceeded with HCT. There were 22 PBPC collection failures in the HCT group.",
"      <br/>",
"      <br/>",
"      At a median follow-up of 44 months, patients assigned to HCT demonstrated the following significantly better outcomes when compared with those assigned to observation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Longer median event-free survival (51 versus 24 months)",
"     </li>",
"     <li>",
"      Higher rate of event-free survival at five years (42 versus 24 percent)",
"     </li>",
"     <li>",
"      Lower rate of relapse at five years (54 versus 76 percent)",
"      <br/>",
"      <br/>",
"      The estimated rates of overall survival at five years were similar (84 versus 86 percent). In addition, myelodysplastic syndrome occurred in three patients undergoing HCT and in one patient in the observation arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the second multicenter phase III trial, 241 patients &lt;66 years old with Binet stage B or C CLL (",
"      <a class=\"graphic graphic_table graphicRef80421 \" href=\"mobipreview.htm?0/50/811\">",
"       table 3",
"      </a>",
"      ) were initially treated with three courses of a reduced dose CHOP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) regimen followed by three courses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35800/abstract/30\">",
"       30",
"      </a>",
"      ]. The 105 patients who achieved a CR were randomly assigned to further therapy with autologous HCT versus observation. The 94 patients who did not achieve a CR were treated with one to two cycles of DHAP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ) and then randomly assigned to autologous HCT or three courses of fludarabine plus cyclophosphamide.",
"      <br/>",
"      <br/>",
"      At a median follow-up of 50 months, the following outcomes were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who achieved a CR after mini-CHOP plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      , autologous HCT was associated with a significantly higher rate of event-free survival (80 versus 36 percent), but a similar rate of overall survival (96 versus 98 percent) at three years.",
"     </li>",
"     <li>",
"      For patients who did not achieve a CR after mini-CHOP plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      , autologous HCT was associated with similar rates of event-free survival (49 versus 44 percent) and overall survival (82 versus 87 percent) at three years. In addition, there was no benefit for autologous HCT when the analysis was limited to high risk populations such as those with 17p deletion or unmutated immunoglobulin variable heavy chains.",
"     </li>",
"     <li>",
"      Of the first 50 patients in CR after mini-CHOP plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      , 20 (40 percent) failed to mobilize an adequate number of PBPCs. This lead to a protocol adjustment to mobilize PBPCs following the first three courses of mini-CHOP and before fludarabine exposure, after which only three (8 percent) of 36 patients failed mobilization. Of the 59 patients in whom mobilization was attempted after DHAP, 15 percent failed to mobilize an adequate number of PBPCs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these two randomized trials demonstrate that autologous HCT prolongs event-free survival, but not overall survival. The effects on quality of life have not been reported. Immunotherapy plus chemotherapy remains the standard therapy for most patients with previously untreated CLL. Chemotherapy is also the main treatment modality used for relapsed or refractory CLL, either alone or in combination with allogeneic HCT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30442?source=see_link\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6362?source=see_link&amp;anchor=H5622415#H5622415\">",
"     \"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia\", section on 'Initial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     INFORMATION FOR PATIENTS",
"    </strong>",
"    &mdash; UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/39/12914?source=see_link\">",
"       \"Patient information: Chronic lymphocytic leukemia (CLL) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/10/6309?source=see_link\">",
"       \"Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with chronic lymphocytic leukemia (CLL) are generally elderly and, due to the relatively benign course of the disease in the majority of patients, only selected patients are considered for aggressive treatments such as hematopoietic cell transplantation (HCT). The determination of transplant eligibility should be made based on a risk-benefit assessment, and the needs and wishes of the patient. (See",
"      <a class=\"local\" href=\"#H351650637\">",
"       'Determining transplant eligibility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ideal timing of HCT in CLL is unknown and transplants should be carried out in the context of a clinical trial whenever possible. Such trials may be appropriate for young patients with clinically aggressive relapsed or refractory CLL or those with high risk genetic factors including 11q22 and 17p13 abnormalities. HCT may also be considered for patients with histologic transformation to a more aggressive histology. (See",
"      <a class=\"local\" href=\"#H351650834\">",
"       'Timing of transplant'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no clear consensus among experts regarding the ideal type of HCT for patients with CLL, although with the development and wider use of non-myeloablative or reduced intensity allogeneic HCT, this approach has emerged as the preferred choice by many centers. Transplantation based treatments have not been directly compared with combination chemotherapy in a prospective manner. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nonmyeloablative HCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with newly diagnosed symptomatic CLL, we recommend treatment with combination chemotherapy plus immunotherapy (ie,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ) rather than autologous HCT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) or allogeneic HCT (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). An exception could be patients with p53 mutations who have very high risk disease and could be considered for non-myeloablative allogeneic HCT at first complete or partial remission. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Autologous HCT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6362?source=see_link&amp;anchor=H5622415#H5622415\">",
"       \"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia\", section on 'Initial therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with disease that has relapsed more than six months after an initial response, we suggest retreatment with the same therapy that provided that initial response rather than treatment with another agent or upfront HCT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Following response, non-myeloablative allogeneic HCT is a reasonable option depending upon other factors such as age, comorbid medical conditions, risk factors and patient preference. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30442?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of relapsed or refractory chronic lymphocytic leukemia\", section on 'Treatment of relapsed disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with early relapsed CLL or refractory CLL should be treated with second-line chemotherapy regimens in an attempt to attain a second response. Young patients with a good performance status and few comorbidities may be considered for HCT performed as part of a clinical trial. (See",
"      <a class=\"local\" href=\"#H351650955\">",
"       'Relapsed or refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/1\">",
"      Moreno C, Villamor N, Colomer D, et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005; 23:3433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/2\">",
"      Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005; 106:4389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/3\">",
"      Rond&oacute;n G, Giralt S, Huh Y, et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996; 18:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/4\">",
"      Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100:3108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/5\">",
"      Mehta J, Powles R, Singhal S, et al. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Bone Marrow Transplant 1996; 17:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/6\">",
"      Michallet M, Corront B, Hollard D, et al. Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: 17 cases. Report from the EBMTG. Bone Marrow Transplant 1991; 7:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/7\">",
"      Rabinowe SN, Soiffer RJ, Gribben JG, et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993; 82:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/8\">",
"      Khouri IF, Keating MJ, Vriesendorp HM, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994; 12:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/9\">",
"      Malhotra P, Hogan WJ, Litzow MR, et al. Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years. Leuk Lymphoma 2008; 49:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/10\">",
"      Khouri IF, Przepiorka D, van Besien K, et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol 1997; 97:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/11\">",
"      Khouri IF, Keating MJ, Saliba RM, Champlin RE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 2002; 4:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/12\">",
"      Schetelig J, van Biezen A, Brand R, et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 2008; 26:5094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/13\">",
"      Michallet M, Archimbaud E, Bandini G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med 1996; 124:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/14\">",
"      Pavletic SZ, Khouri IF, Haagenson M, et al. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. J Clin Oncol 2005; 23:5788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/15\">",
"      Toze CL, Galal A, Barnett MJ, et al. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant 2005; 36:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/16\">",
"      Sorror ML, Storer BE, Maloney DG, et al. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/17\">",
"      Sorror ML, Maris MB, Sandmaier BM, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23:3819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/18\">",
"      Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008; 26:4912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/19\">",
"      Dreger P, D&ouml;hner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010; 116:2438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/20\">",
"      Delgado J, Pillai S, Phillips N, et al. Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case-control retrospective analysis. Ann Oncol 2009; 20:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/21\">",
"      Khouri IF, Bassett R, Poindexter N, et al. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer 2011; 117:4679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/22\">",
"      Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 21:2747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/23\">",
"      Ritgen M, Stilgenbauer S, von Neuhoff N, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104:2600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/24\">",
"      Khouri IF, Saliba RM, Admirand J, et al. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 2007; 137:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/25\">",
"      Delgado J, Thomson K, Russell N, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 2006; 107:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/26\">",
"      Milligan DW, Fernandes S, Dasgupta R, et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 2005; 105:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/27\">",
"      Dreger P, Stilgenbauer S, Benner A, et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood 2004; 103:2850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/28\">",
"      Dreger P, D&ouml;hner H, McClanahan F, et al. Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial. Blood 2012; 119:4851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/29\">",
"      Michallet M, Dreger P, Sutton L, et al. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood 2011; 117:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35800/abstract/30\">",
"      Sutton L, Chevret S, Tournilhac O, et al. Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. Blood 2011; 117:6109.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4541 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_61_35800=[""].join("\n");
var outline_f34_61_35800=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H351650637\">",
"      DETERMINING TRANSPLANT ELIGIBILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H351650834\">",
"      TIMING OF TRANSPLANT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1138003\">",
"      Previously untreated disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H351650955\">",
"      Relapsed or refractory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H351650981\">",
"      Following histologic transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H351651079\">",
"      TYPE OF TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Myeloablative HCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Nonmyeloablative HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Autologous HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4541\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4541|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/50/811\" title=\"table 3\">",
"      Binet staging system CLL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16298?source=related_link\">",
"      Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35017?source=related_link\">",
"      Overview of the complications of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29352?source=related_link\">",
"      Overview of the treatment of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3609?source=related_link\">",
"      Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/39/12914?source=related_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/10/6309?source=related_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6362?source=related_link\">",
"      Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/6/15466?source=related_link\">",
"      Staging and prognosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30442?source=related_link\">",
"      Treatment of relapsed or refractory chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_61_35801="Scleroderma renal crisis";
var content_f34_61_35801=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Scleroderma renal crisis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/61/35801/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35801/contributors\">",
"     John Varga, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35801/contributors\">",
"     Andrew Fenves, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/61/35801/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35801/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35801/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/61/35801/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35801/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/61/35801/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathological hallmarks of systemic sclerosis (scleroderma) are uncontrolled accumulation of collagen and widespread vascular lesions characterized by thickening of the vascular wall and narrowing of the vascular lumen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/63/19450?source=see_link\">",
"     \"Pathogenesis of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal involvement is common in systemic sclerosis, with most patients manifesting only mild renal dysfunction. By comparison, an acute, severe and life-threatening form of renal disease, called scleroderma renal crisis, develops in approximately 10 to 20 percent of patients with the diffuse cutaneous systemic sclerosis and much less frequently in limited cutaneous systemic sclerosis. Despite the widespread use of angiotensin converting enzyme inhibitors for the treatment of scleroderma renal crisis, morbidity and mortality remain high.",
"   </p>",
"   <p>",
"    Scleroderma renal crisis is characterized by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abrupt onset of moderate to severe hypertension",
"     </li>",
"     <li>",
"      Urine sediment that is normal or reveals only mild proteinuria with few cells or casts",
"     </li>",
"     <li>",
"      Progressive renal failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with systemic sclerosis without overt evidence of renal disease frequently have compromised renal function. Using sensitive measures to assess renal function in such patients may show decreased renal plasma flow, elevated renal vascular resistance, and elevated plasma renin levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of systemic sclerosis (SSc)-associated renal disease will be presented here. Extrarenal manifestations of systemic sclerosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29224?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autopsy studies reveal histological evidence of renal involvement in 60 to 80 percent of patients with systemic sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In addition, as many as 50 percent of systemic sclerosis patients show clinical evidence of renal involvement, such as mild proteinuria, elevated serum creatinine concentration, or hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The course of renal involvement in most of these patients appears to be benign without progression of dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/5\">",
"     5",
"    </a>",
"    ]. It is likely that, in at least some cases, proteinuria and hypertension are coincidental and not a reflection of systemic sclerosis.",
"   </p>",
"   <p>",
"    Scleroderma renal crisis develops in up to 20 percent of patients with diffuse cutaneous systemic sclerosis, although its incidence appears to be declining [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/2,5-10\">",
"     2,5-10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Scleroderma renal crisis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL RENAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, approximately one-half of systemic sclerosis patients show some evidence of renal involvement, such as proteinuria, a mild elevation in the creatinine concentration,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. In one study, the most common cause of proteinuria was D-penicillamine use, with proteinuria developing a mean of 1.2 years after drug initiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/5\">",
"     5",
"    </a>",
"    ]. Proteinuria generally resolved following discontinuation of the agent.",
"   </p>",
"   <p>",
"    Renal abnormalities in systemic sclerosis may also reflect prerenal disease associated with heart failure, pulmonary hypertension, nonsteroidal antiinflammatory drug or diuretic use, hypovolemia due to gastrointestinal involvement,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    malabsorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/5\">",
"     5",
"    </a>",
"    ]. Additional causes of renal dysfunction include direct drug toxicity (D-penicillamine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ), effects of chronic hypertension, and, rarely, glomerulonephritis. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Diagnosis and differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SCLERODERMA RENAL CRISIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scleroderma renal crisis develops in 10 to 20 percent of patients with diffuse cutaneous systemic sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/2,5-10\">",
"     2,5-10",
"    </a>",
"    ]. It is observed less frequently in the limited cutaneous form.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scleroderma renal crisis (SRC) is an early complication of systemic sclerosis that almost invariably occurs within the first five years of the onset of the disease. In one series, renal crisis occurred at a median duration of 7.5 months from the onset of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/9\">",
"     9",
"    </a>",
"    ]. In some cases, SRC is the initial manifestation of systemic sclerosis.",
"   </p>",
"   <p>",
"    As described below, early-stage disease or rapidly advancing skin induration may be associated with an increased risk of SRC. However, SRC can occur in the absence of warning signs. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    SRC is characterized by the following findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/2,6,8\">",
"     2,6,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute renal failure, usually in the absence of previous evidence of significant kidney disease.",
"     </li>",
"     <li>",
"      Abrupt onset of moderate to marked hypertension, often accompanied by manifestations of malignant hypertension, such as hypertensive retinopathy (hemorrhages and exudates) and hypertensive encephalopathy. In a review of 145 patients, 85 percent had new diastolic hypertension with a mean peak blood pressure of",
"      <span class=\"nowrap\">",
"       178/102",
"      </span>",
"      mmHg [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21859?source=see_link\">",
"       \"Ocular effects of hypertension\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In approximately 10 percent of patients, SRC occurs in the presence of normal blood pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. However, some of these patients have blood pressures that are still higher than the patient's baseline (eg,",
"      <span class=\"nowrap\">",
"       130/85",
"      </span>",
"      mmHg in a young thin woman whose baseline value is",
"      <span class=\"nowrap\">",
"       100/70",
"      </span>",
"      mmHg). These patients have a worse renal outcome and higher mortality than patients with SRC who are hypertensive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/12,14\">",
"       12,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The urine sediment is usually normal or reveals only mild proteinuria with few cells or casts. Nephrotic range proteinuria is uncommon.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other findings associated with SRC reflect both the underlying vasculopathy and the marked hypertension. Microangiopathic hemolytic anemia can be seen, although thrombocytopenia is generally not as profound as that observed in patients with thrombotic thrombocytopenic purpura (TTP) or the hemolytic-uremic syndrome (HUS) (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"mobipreview.htm?37/50/38694\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Additional findings may include heart failure and pulmonary edema, headache, blurred vision with hypertensive retinopathy, and hypertensive encephalopathy, often complicated by generalized seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of risk factors for SRC have been identified. These include diffuse skin involvement and advancing skin involvement, glucocorticoid use, and presence or absence of certain autoantibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Diffuse skin involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important risk factor for SRC is diffuse skin involvement, particularly if rapidly progressive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/6,8-10,15\">",
"     6,8-10,15",
"    </a>",
"    ]. In a series of 110 patients with systemic sclerosis who developed scleroderma renal crisis, 78 percent had the diffuse cutaneous form of systemic sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/9\">",
"     9",
"    </a>",
"    ]. A retrospective study of 826 patients with systemic sclerosis found that rapid progression of skin thickness was an independent predictor of early SRC (odds ratio 2.05, 95% CI 1.10-3.85) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Glucocorticoid use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of glucocorticoids, particularly in high doses, increases the risk of scleroderma renal crisis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/9,10,12,13,15,17\">",
"     9,10,12,13,15,17",
"    </a>",
"    ]. This was shown in a retrospective case-control study of 110 patients with SRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/17\">",
"     17",
"    </a>",
"    ]. Moderate to high dose glucocorticoid use (&ge;15 mg per day",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or equivalent) in the preceding six months markedly increased the risk (odds ratio 4.37, 95% CI 2.03-9.43).",
"   </p>",
"   <p>",
"    Other studies have found similar results, with approximately 60 percent of patients with SRC having had prior recent exposure to glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/9,10,14\">",
"     9,10,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence or absence of certain serum autoantibodies appears to predict the risk for SRC. Several studies have demonstrated an increased risk among patients with systemic sclerosis who had autoantibodies directed against RNA polymerase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/18\">",
"     18",
"    </a>",
"    ]. In a retrospective series of patients with SRC, the presence of anti-RNA polymerase antibodies markedly increased the risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/9\">",
"     9",
"    </a>",
"    ]. The anti-RNA polymerase autoantibody could be detected in the serum of 12 percent of 735 systemic sclerosis patients who did not have SRC, compared with 59 percent of 96 systemic sclerosis patients who developed SRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/9\">",
"     9",
"    </a>",
"    ]. In another retrospective analysis of 1029 patients with systemic sclerosis, the anti-RNA polymerase III autoantibody was detected in 52 percent of those who developed SRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/19\">",
"     19",
"    </a>",
"    ]. In centers where this specific antibody test is not available, a positive test is suggested by fine speckled immunofluorescence pattern of the ANA. By comparison, the presence of anti-centromere antibody was underrepresented in patients SRC (1.8 versus 28.9 percent of systemic sclerosis patients with scleroderma renal crisis; odds ratio 0.05, 95% CI 0.01-0.17).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is anecdotal evidence that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , a renal vasoconstrictor, may accelerate renal disease in systemic sclerosis. In one report, for example, acute renal failure developed in three of eight patients treated with cyclosporine; the causal relation to the drug rather than systemic sclerosis itself could not be determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional factors that may identify patients with systemic sclerosis who are at increased risk for SRC include contractures at the large joints, new onset anemia, new cardiac events (such as heart failure), and pericardial effusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/6,15\">",
"     6,15",
"    </a>",
"    ]. In contrast, preexisting hypertension, elevated serum creatinine, abnormal urinalysis, or antibodies against topoisomerase-1 are not predictive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary histopathologic changes in the kidney are localized in the small arcuate and interlobular arteries and the glomeruli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/6,21\">",
"     6,21",
"    </a>",
"    ]. The characteristic finding is intimal proliferation and thickening that leads to narrowing and obliteration of the vascular lumen, with concentric \"onion-skin\" hypertrophy. These histopathological findings are similar to systemic sclerosis-associated vascular lesions found in other organs (",
"    <a class=\"graphic graphic_picture graphicRef70213 graphicRef54840 graphicRef69687 graphicRef78330 graphicRef75317 \" href=\"mobipreview.htm?43/0/44042\">",
"     picture 2A-E",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    SRC is a thrombotic microangiopathy similar to malignant nephrosclerosis,",
"    <span class=\"nowrap\">",
"     TTP/HUS,",
"    </span>",
"    radiation nephritis, chronic transplantation rejection, and the antiphospholipid antibody syndrome. Because of the similar renal histologic findings, renal biopsy does",
"    <strong>",
"     not",
"    </strong>",
"    definitively establish the diagnosis of SRC.",
"   </p>",
"   <p>",
"    A renal biopsy may be helpful in the diagnosis of SRC by ruling out other diagnoses, and also provides useful prognostic information. In a review of 17 biopsies from patients with SRC, a higher number of thrombosed blood vessels and the presence of severe glomerular ischemic collapse both correlated with persistent renal failure or death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diagnosis and differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of SRC is based upon the characteristic findings in high-risk patients with systemic sclerosis. The following criteria for the diagnosis of scleroderma renal crisis may be helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      New onset of blood pressure",
"      <span class=\"nowrap\">",
"       &gt;150/85",
"      </span>",
"      mmHg, measured at least twice over the preceding 24 hours. However, normotensive scleroderma renal crisis has been described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Progressive decline in renal function with rising serum creatinine.",
"     </li>",
"     <li>",
"      Additional findings may include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Microangiopathic hemolytic anemia and thrombocytopenia",
"     </li>",
"     <li>",
"      Acute retinal changes of malignant hypertension",
"     </li>",
"     <li>",
"      Hypertensive encephalopathy",
"     </li>",
"     <li>",
"      New onset proteinuria or hematuria (excluding other causes)",
"     </li>",
"     <li>",
"      Flash pulmonary edema",
"     </li>",
"     <li>",
"      Progressive oliguria or anuria",
"     </li>",
"     <li>",
"      Characteristic changes on kidney biopsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rarely, severe hypertension associated with acute renal failure may occur in individuals who have features of systemic sclerosis but lack the characteristic skin changes, a disease subset called systemic sclerosis sine scleroderma (",
"    <a class=\"graphic graphic_table graphicRef53984 \" href=\"mobipreview.htm?18/45/19164\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. In this setting, signs of systemic sclerosis should be sought. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Digital tip pitting and scarring, and nailfold microvascular changes with capillary dilatation and drop-out [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Evidence of gastrointestinal involvement (such as esophageal or small bowel dysmotility), interstitial lung disease (interstitial infiltrates in the lower lobes or evidence of restrictive lung disease on pulmonary function testing), or pulmonary arterial hypertension (detected by echocardiography or an isolated reduction in diffusion capacity on pulmonary function testing). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26329?source=see_link\">",
"       \"Clinical manifestations of systemic sclerosis (scleroderma) lung disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of serum autoantibodies against RNA polymerase or a fine speckled immunofluorescence pattern on ANA testing. By contrast, the presence of anti-centromere antibodies appears to be protective against the development of SRC.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Scleroderma renal crisis must be distinguished from other forms of thrombotic microangiopathy, particularly",
"    <span class=\"nowrap\">",
"     TTP/HUS.",
"    </span>",
"    Patients with",
"    <span class=\"nowrap\">",
"     TTP/HUS",
"    </span>",
"    characteristically present with thrombocytopenia, purpura, and prominent microangiopathic hemolysis and may have rapidly progressive renal failure. The clinical manifestations may mimic SRC, but patients with",
"    <span class=\"nowrap\">",
"     TTP/HUS",
"    </span>",
"    have no clinical or serologic signs of scleroderma.",
"   </p>",
"   <p>",
"    Distinguishing TTP from SRC at presentation may present a considerable and urgent diagnostic challenge. The diagnosis of",
"    <span class=\"nowrap\">",
"     TTP/HUS",
"    </span>",
"    is suggested by the presence of a potential inciting event, such as diarrhea in children or certain forms of chemotherapy in adults. In addition, TTP is characterized by an absence or marked reduction in the serum levels of the metalloprotease enzyme ADAMTS13. As noted above, renal biopsy does not distinguish between these disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, patients with systemic sclerosis present with acute renal failure (occasionally with normal blood pressure) due to anti-neutrophil cytoplasmic antibodies (ANCA)-related crescentic glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In some patients, the kidney disease is associated with D-penicillamine therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The diagnosis is confirmed by kidney biopsy showing a pauci-immune crescentic glomerulonephritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scleroderma renal crisis (SRC) is a major complication of systemic sclerosis and represents a medical emergency. Patients with the diffuse cutaneous form of systemic sclerosis and early-stage disease are at greatest risk for SRC, particularly when the skin involvement is advancing. Close monitoring of patients is most important during the first four to five years of systemic sclerosis because SRC most frequently occurs during this phase of the disease.",
"   </p>",
"   <p>",
"    The principal rationale for monitoring for SRC is that its treatment is more likely to be effective when it is initiated early, before irreversible renal injury has occurred. However, there are no studies that have evaluated the effectiveness of any approach for monitoring patients with systemic sclerosis for the development of SRC in terms of reducing morbidity and mortality.",
"   </p>",
"   <p>",
"    We use the following screening regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood pressure measurement on a regular basis for all patients with systemic sclerosis. For high-risk patients (such as those with early-stage diffuse cutaneous disease, rapidly progressive cutaneous involvement, or the presence of autoantibodies to RNA polymerase III), we advocate daily home blood pressure measurements, and, for others, biweekly measurements. In patients with baseline blood pressures of",
"      <span class=\"nowrap\">",
"       &le;120/70",
"      </span>",
"      mmHg, a persistent rise of 20 mmHg in the systolic blood pressure or a 10 mmHg rise in the diastolic blood pressure raises concern and the need for further evaluation. In patients taking antihypertensive medications, sustained hypertension above",
"      <span class=\"nowrap\">",
"       150/90",
"      </span>",
"      mmHg, which is not readily corrected with dose adjustment and modest dietary salt restriction, would trigger further evaluation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Measurement of serum creatinine with estimation of the glomerular filtration rate and dipstick testing or calculation of the urinary protein-to-creatinine ratio on a random urine specimen every three months. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link\">",
"       \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"      </a>",
"      .) An elevation in the serum creatinine (or fall in creatinine clearance, which may need to be measured directly in patients who have lost muscle mass) or new persistent proteinuria &gt;500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      may be a warning sign of impending SRC.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;No prospective studies that demonstrate that the avoidance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    administration of any agent lowers the incidence or severity of SRC have been performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described below, angiotensin converting enzyme (ACE) inhibitors play a major role in the treatment of SRC. In contrast, there is no clear evidence of a preventive effect of ACE inhibitors among patients with systemic sclerosis. We do NOT use ACE inhibitors solely for the purpose of preventing the occurrence of SRC.",
"   </p>",
"   <p>",
"    Retrospective and case-control studies have largely found neither benefit nor harm with ACE inhibitors related to the development of SRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/9,15,17\">",
"     9,15,17",
"    </a>",
"    ]. A multicenter randomized, double-blind, placebo-controlled study of 210 patients evaluated the efficacy of daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/29/24024?source=see_link\">",
"     quinapril",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or the maximum tolerated dosage) for the prevention of vascular damage in systemic sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/29\">",
"     29",
"    </a>",
"    ]. At two to three years, quinapril did not affect the occurrence of SRC or vascular complications, such as Raynaud phenomenon or ischemic digital ulcers, and had no effect on renal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Avoidance of glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, the use of high dose glucocorticoids is associated with a markedly increased risk of SRC. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Glucocorticoid use'",
"    </a>",
"    above.) When glucocorticoid use is unavoidable in patients with systemic sclerosis (eg, when there is concomitant myositis), we recommend limiting the dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    to less than 15",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and limiting use to the shortest possible period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;If left untreated, scleroderma renal crisis (SRC) can progress to end-stage renal disease over a period of one to two months and death usually within one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/2\">",
"     2",
"    </a>",
"    ]. The mainstay of therapy in scleroderma renal crisis is effective and prompt blood pressure control, which improves or stabilizes renal function in up to 70 percent of cases and improves patient survival (survival at one year of 80 percent). The success with antihypertensive therapy in this setting is dependent upon its initiation before irreversible renal damage has occurred.",
"   </p>",
"   <p>",
"    The optimal class of antihypertensive agents is angiotensin converting enzyme (ACE) inhibitors. Among the available ACE inhibitors, the most experience has been with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , which is our preferred ACE inhibitor. Although there are much less data on other ACE inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    , these agents may provide comparable benefit. Captopril has the advantage of rapid onset and short duration of action, which permit rapid dose titration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     ACE inhibitor studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to other antihypertensive agents, a number of nonrandomized, uncontrolled retrospective and prospective studies have shown that the ACE inhibitors are associated with greater antihypertensive efficacy, better preservation of renal function, and improved survival in patients with scleroderma renal crisis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/9,30,31\">",
"     9,30,31",
"    </a>",
"    ]. The principal agent used in these studies was",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    . The following is a survey of some of these studies.",
"   </p>",
"   <p>",
"    A prospective cohort study of 108 patients with SRC seen between 1972 and 1987 noted the following significant benefits in patients treated continuously with ACE inhibitors, compared to those seen before the availability of ACE inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A greater incidence of renal functional recovery, as indicated by discontinuation of dialysis in patients who survived dialysis for more than three months &mdash; 55 versus 0 percent. Renal recovery occurred 3 to 15 months after the onset of scleroderma renal crisis and was dependent upon continued therapy with an ACE inhibitor. Another report from the same investigators found continued improvement in renal function for up to 18 months in patients treated with ACE inhibitors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Renal outcomes'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A higher rate of survival at one year &mdash; 76 percent versus 15 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Scleroderma renal crisis, in essence, is a form of bilateral intrarenal renal artery stenosis. Thus, patients starting ACE inhibitor therapy may show an initial rise in serum creatinine concentrations because of the ACE inhibitor-induced fall in efferent arteriolar resistance and intraglomerular pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19398?source=see_link\">",
"     \"Renal effects of ACE inhibitors in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, careful monitoring of serum creatinine is required when therapy is begun. The serum creatinine concentration is measured daily at the beginning of therapy; small elevations are usually transient and not progressive and would not be an indication to discontinue the ACE inhibitor.",
"   </p>",
"   <p>",
"    A complete blood count, fibrin degradation products, serum lactate dehydrogenase, and the blood smear are also regularly assessed, since the degree of microangiopathic hemolysis often reflects the activity of the disease process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Non-ACE inhibitor therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some centers anecdotally report the use of other drugs in patients with SRC, but we do",
"    <strong>",
"     not",
"    </strong>",
"    recommend use of any of these agents as initial therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other antihypertensive agents have also been used as initial therapy. Although angiotensin II receptor blockers might be expected to be effective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/32\">",
"       32",
"      </a>",
"      ], the efficacy of these drugs in comparison to ACE inhibitors, particularly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      , has not yet been established.",
"     </li>",
"     <li>",
"      Intravenous prostacyclin (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      ), which is believed to help the microvascular lesion without precipitating hypotension, has been administered at the onset of hypertensive renal crisis based upon anecdotal observations of benefit.",
"     </li>",
"     <li>",
"      Fish oil is sometimes prescribed in view of its theoretically beneficial hemodynamic and antiplatelet properties. However, its efficacy is unproven in scleroderma renal disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42679?source=see_link&amp;anchor=H11#H11\">",
"       \"Diet in the treatment and prevention of hypertension\", section on 'Fish oil'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Recommended initial approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommendation for initial therapy with ACE inhibitors for SRC is based upon small numbers of patients in observational studies. Prospective randomized controlled trials have not been performed in SRC.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     Captopril",
"    </a>",
"    has the advantages of rapid onset (peak effect at 60 to 90 minutes) and short duration of action, which permit rapid dose titration. Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/22/20839?source=see_link\">",
"     enalaprilat",
"    </a>",
"    is not routinely used, because it has a long duration of action (up to 36 hours). However, a single dose may be given in patients who have impaired mental status, followed by oral captopril therapy through a nasogastric tube.",
"   </p>",
"   <p>",
"    The therapeutic approach varies with patient's blood pressure and whether the patient has SRC alone or in combination with hypertensive encephalopathy or other manifestation of malignant hypertension. In a review of 145 patients with SRC, 85 percent had new diastolic hypertension with a mean peak blood pressure of",
"    <span class=\"nowrap\">",
"     178/102",
"    </span>",
"    mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/11\">",
"     11",
"    </a>",
"    ]. However, approximately 10 percent are normotensive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/12\">",
"     12",
"    </a>",
"    ]. All patients are treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , which is continued even if the serum creatinine initially continues to rise.",
"   </p>",
"   <p>",
"    The principal goal of initial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    therapy is to return the patient to his or her previous baseline blood pressure within 72 hours. Since the hypertension is acute in SRC, rapid blood pressure reduction to baseline does not usually carry the risks seen with rapid blood pressure lowering in patients with long-standing hypertension. However, some recommend maximum blood pressure reductions of 20 mmHg per day.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among hypertensive patients without evidence of central nervous system involvement (eg, encephalopathy, papilledema),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      is begun at a dose of 6.25 to 12.5 mg. There is progressive dose escalation in 12.5 to 25 mg increments at four- to eight-hour intervals until the goal blood pressure is reached. The maximum captopril dose is 300 to 450",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      Among the infrequent hypertensive patients with evidence of central nervous system involvement (eg, encephalopathy, papilledema), we administer the same",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      dose escalation regimen and add intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      , which has a very short duration of action, for acute blood pressure control. The nitroprusside should be discontinued as soon as possible, as captopril in increasing doses lowers the blood pressure. The goal is to return the patient to his or her previous baseline blood pressure within 72 hours. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/27/41398?source=see_link\">",
"       \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among the approximately 10 percent of patients who have normotensive SRC, we begin",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      at a dose of 6.25 mg and, if tolerated, increase the dose to 12.5 mg at the second dose. Further dose escalation must be done carefully to prevent the induction of hypotension. Some of these patients have blood pressures that, although within the normal range, are still higher than the patient's baseline (eg,",
"      <span class=\"nowrap\">",
"       130/85",
"      </span>",
"      mmHg in a young, thin woman whose baseline value is",
"      <span class=\"nowrap\">",
"       100/70",
"      </span>",
"      mmHg). In such patients, the goal is lowering the blood pressure to the previous baseline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other parameters that can be followed are the platelet count, hemoglobin, haptoglobin, and serum lactate dehydrogenase, which are markers of the degree of intravascular hemolysis. These parameters usually improve fairly quickly, even if the serum creatinine continues to rise.",
"   </p>",
"   <p>",
"    Over the long-term, an ACE inhibitor (longer acting drugs are usually preferred to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    ) is given to maintain normal blood pressure. A low dose of an ACE inhibitor is continued indefinitely, even if not needed for blood pressure control.",
"   </p>",
"   <p>",
"    Some centers in Europe use parenteral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    infusion in addition to ACE inhibitors, but there is no clear evidence supporting this approach. The use of potential nephrotoxins, such as nonsteroidal antiinflammatory drugs and radiocontrast agents, should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Resistant hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies that specifically address the role of other antihypertensive agents in patients with SRC who are resistant to initial ACE inhibitor therapy (ie, fail to show sufficient lowering of the blood pressure with the maximum recommended dose). We prefer addition of a calcium channel blocker (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/5/32848?source=see_link\">",
"     Minoxidil",
"    </a>",
"    may be considered if the resistant hypertension persists. Beta blockers are usually avoided in patients with scleroderma because of the theoretical risk of worsening vasospasm (eg, Raynaud phenomenon). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35256?source=see_link\">",
"     \"Treatment of resistant hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     RENAL OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite treatment with ACE inhibitors, approximately 20 to 50 percent of patients with scleroderma renal crisis (SRC) progress to end-stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/9,11,17\">",
"     9,11,17",
"    </a>",
"    ]. However, among patients with SRC who require dialysis during the acute episode, an appreciable proportion recover sufficient renal function to discontinue dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/9,11\">",
"     9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency and timing with which this occurs and renal outcomes can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study reported patient outcomes in 145 patients with SRC who were continuously treated with ACE inhibitors. The following findings were noted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/11\">",
"       11",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Twenty-eight patients (19 percent) died at a mean of three months, 18 of whom required dialysis.",
"     </li>",
"     <li>",
"      Fifty-five patients (38 percent) did not require dialysis. These patients had a mean peak serum creatinine concentration of 3.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (336",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      that fell to 1.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (159",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      at 7.1 years. Only two had slow deterioration of renal function, requiring dialysis at four and six years.",
"     </li>",
"     <li>",
"      Twenty-eight patients (19 percent) required permanent dialysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thirty-four patients (23 percent overall, 43 percent of all patients requiring early dialysis, and 55 percent of patients requiring early dialysis who did not die) were able to discontinue dialysis after 2 to 18 months (mean eight months). The mean serum creatinine was 2.7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (239",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      when dialysis was discontinued that fell to 2.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (194",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      at 6.1 years. In an earlier report from the same group cited above, there was no recovery of renal function in patients not treated with ACE inhibitors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'ACE inhibitor studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a retrospective single center study of 110 patients with SRC (mean blood pressure of",
"      <span class=\"nowrap\">",
"       193/114",
"      </span>",
"      mmHg), 108 were treated with ACE inhibitors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/9\">",
"       9",
"      </a>",
"      ]. ACE inhibitor therapy was titrated to reduce the systolic blood pressure by 20 mmHg per day. Dialysis was required in 72 patients (64 percent), 24 of whom (33 percent) recovered sufficient renal function to discontinue dialysis. At three years, renal function improved (mean 23",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      among non-dialysis-dependent patients. Approximately 40 percent of patients required permanent dialysis. Overall patient survival at one and five years was 82 and 59 percent, respectively, with the poorest survival seen in those requiring dialysis.",
"     </li>",
"     <li>",
"      Renal biopsy may be helpful in confirming the diagnosis of scleroderma renal crisis, as well as in predicting clinical outcome and reversibility of renal failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, despite the improvement with long-term ACE inhibitor therapy, the outcome of SRC remains suboptimal.",
"   </p>",
"   <p>",
"    Scleroderma renal crisis recurs in 5 percent of patients who receive a renal transplant. The treatment of recurrent scleroderma renal crisis in such patients is the same as that for the initial episode.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If indicated, either hemodialysis or continuous peritoneal dialysis is effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/11\">",
"     11",
"    </a>",
"    ]. However, survival on dialysis of patients with systemic sclerosis is worse than in other forms of end-stage renal disease. In a study of 820 scleroderma patients on dialysis, the two-year survival was 49 percent, compared to 64 percent in all other patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/33\">",
"     33",
"    </a>",
"    ]. Since vascular access is particularly troublesome in these patients, issues surrounding complications with access may have contributed to the higher morbidity and mortality.",
"   </p>",
"   <p>",
"    In the dialysis patient,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    may only be tolerated on non-dialysis days. Given the benefits of ACE inhibitors, it is important to continue ACE inhibitor therapy even if in low doses. The goal remains maintenance of normal blood pressure.",
"   </p>",
"   <p>",
"    As noted in the preceding section, considerable recovery of renal function can occur after scleroderma renal crisis, permitting discontinuation of dialysis in many patients. Since the improvement in renal function can continue for up to 18 months, decisions regarding renal transplantation do not have to be made during or immediately following an episode of scleroderma renal crisis.",
"   </p>",
"   <p>",
"    Based upon these observations, we do not perform renal transplantation for at least one year after the initiation of dialysis. Issues related to wait listing for renal transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11240?source=see_link\">",
"     \"The kidney transplant waiting list\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited experience with renal transplantation in systemic sclerosis. Transplantation is sometimes precluded by the severity of the extrarenal manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The UNOS database (United Network for Organ Sharing) included 260 transplants performed between 1987 and 2004 for the renal diagnosis of systemic sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal allograft survival in patients with systemic sclerosis is reduced compared to transplant recipients with other disorders, but outcomes appear to be better than in patients treated with dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. Reported graft survival rates from the UNOS registry have been 68 to 79 percent at one year, 60 to 70 percent at three years, and 57 percent at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these relatively lower allograft survival rates, patient survival after renal transplantation is superior to that in dialysis patients with systemic sclerosis who remain on the wait list. This was shown in a study of 258 patients with systemic sclerosis who were listed for renal transplantation between the years 1985 to 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/37\">",
"     37",
"    </a>",
"    ]. The one and three year patient survival with transplantation was 90 and 80 percent, respectively, compared to 81 and 55 percent in those who remained on the wait list.",
"   </p>",
"   <p>",
"    As noted above, there is an association between an increased risk of SRC and high-dose glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Glucocorticoid use'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Cyclosporine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    To help reduce the risk of recurrent SRC among patients who undergo kidney transplantation, we avoid calcineurin inhibitors and high-dose glucocorticoids. Instead, the maintenance immunosuppressive regimen includes low-dose glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    We continue ACE inhibitors indefinitely. In one case report, recurrence developed in a patient switched from an ACE inhibitor to an angiotensin II receptor blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/40\">",
"     40",
"    </a>",
"    ]. This supports the view that ACE inhibitors may be superior to angiotensin II receptor blockers and other antihypertensive drugs in patients with systemic sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of recurrent SRC is difficult to ascertain with certainty, because the primary renal histopathologic changes associated with systemic sclerosis (mucoid intimal thickening of the interlobular arteries and fibrinoid necrosis in the glomeruli) may be difficult to differentiate from acute or chronic rejection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12505?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to the widespread use of ACE inhibitors, the recurrence rate of renal damage in the kidney allograft was as high as 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/35,42\">",
"     35,42",
"    </a>",
"    ]. Subsequent reports indicate recurrence rates as low as 2 to 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. As an example, a review from the UNOS database of 260 transplants for SRC performed between 1987 and 2004 noted that recurrent disease developed in five (1.9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/38\">",
"     38",
"    </a>",
"    ]. Most recurrences occur within the first one to two years after transplantation, with many occurring within a few months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early loss of native kidney function due to scleroderma renal crisis appears to be a risk factor for recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/38\">",
"     38",
"    </a>",
"    ]. Progressive skin thickening, new-onset anemia, and cardiac complications may herald recurrent injury and damage to the renal allograft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrent SRC in the transplant may follow a similar course as the primary disease. The treatment of recurrent SRC is the same as that for disease in the native kidney. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114886104\">",
"    <span class=\"h3\">",
"     Minimum wait time for transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recovery of renal function can occur following SRC, permitting discontinuation of dialysis in many patients. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Dialysis'",
"    </a>",
"    above.) Since the improvement in renal function can continue for up to 18 months, decisions regarding renal transplantation do not have to be made during or immediately following an episode of SRC. Based upon these observations, we generally do not perform renal transplantation for at least six months after the initiation of dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scleroderma renal crisis (SRC) is a potentially life-threatening complication. Prior to the widespread use of ACE inhibitors, almost all patients with significant renal involvement died within one year (compared to a 35 percent cumulative seven-year survival in all patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survival of patients with SRC treated with ACE inhibitors is significantly better [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/9,11,17,45\">",
"     9,11,17,45",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 110 patients with SRC, one-year patient survival was 76 percent in patients treated with ACE inhibitors compared to 15 percent in patients treated with other drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a subsequent report from the same investigators of 145 patients with SRC, all of whom were treated with ACE inhibitors, 28 (19 percent) died early at a mean of three months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/11\">",
"       11",
"      </a>",
"      ]. These patients were more likely to have myocardial involvement (43 versus 5 percent in survivors).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Excluding the patients who died early, patient survival was related to dialysis status. The 89 patients who did not require dialysis or required only temporary dialysis had long-term outcomes similar to patients with diffuse systemic sclerosis without renal crisis with survival rates of 90 and 80 to 85 percent at five and eight years. The respective values were approximately 40 and 25 percent in the 28 patients who received permanent dialysis.",
"   </p>",
"   <p>",
"    Another study of 91 patients with SRC found that 21 percent died within six months of the onset of disease. One-, 2-, and 5-year survival rates were 71, 66, and 60 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35801/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As many as 50 percent of systemic sclerosis patients have clinical evidence of renal involvement, such as mild proteinuria, elevated serum creatinine concentration, or hypertension. Renal abnormalities may reflect prerenal failure, direct drug toxicity, effects of chronic hypertension, and, rarely, glomerulonephritis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General renal manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Scleroderma renal crisis (SRC) develops in up to 10 to 20 percent of systemic sclerosis patients, most commonly within 48 months of diagnosis and in those with diffuse cutaneous systemic sclerosis. It is characterized by acute kidney injury, abrupt onset of moderate to marked hypertension, a normal urinalysis or a urine sediment with only mild proteinuria and few cells or casts,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs of microangiopathic hemolytic anemia. It is also important to realize that 10 percent of those with SRC are normotensive. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The characteristic histologic finding in the kidney in SRC is intimal proliferation and thickening that leads to narrowing and obliteration of the vascular lumen, with concentric \"onion-skin\" hypertrophy. These changes are indistinguishable from those in malignant hypertension. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for SRC include early-stage disease with diffuse and advancing skin involvement, glucocorticoid use, autoantibodies directed against RNA polymerase, and administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of SRC is based upon characteristic findings in high-risk patients with systemic sclerosis. These include new onset of blood pressure",
"      <span class=\"nowrap\">",
"       &gt;150/85",
"      </span>",
"      mmHg and progressive decline in renal function, although a few patients are normotensive. Additional findings may include microangiopathic hemolytic anemia and thrombocytopenia, acute retinal changes of malignant hypertension, new onset proteinuria or hematuria (excluding other causes), and other features. Renal biopsy can be helpful in predicting the persistence of renal failure. SRC must be distinguished from other forms of thrombotic microangiopathy, particularly thrombotic thrombocytopenic",
"      <span class=\"nowrap\">",
"       purpura/hemolytic-uremic",
"      </span>",
"      syndrome. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis and differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To permit prompt initiation of treatment of SRC, we recommend close monitoring of all patients with systemic sclerosis. We suggest the following screening regimen (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Monitoring'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For high-risk patients (such as those with early-stage diffuse cutaneous disease or rapidly progressive cutaneous involvement), we advocate daily home blood pressure measurements, and for others, biweekly measurements.",
"     </li>",
"     <li>",
"      Measurement of the plasma creatinine concentration and dipstick testing for protein or calculation of the urinary protein-to-creatinine ratio on a random urine specimen every three months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a paucity of evidence concerning the avoidance",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      administration of any agent that may lower the incidence of SRC. When glucocorticoid use is unavoidable in patients with systemic sclerosis, we recommend limiting the dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      to less than 15",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and limiting use to the shortest possible period (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We do NOT use ACE inhibitors for the purpose of preventing the occurrence of SRC. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The therapeutic approach to the patient with SRC varies with the patient's blood pressure and whether the patient has central nervous system manifestations. We suggest the following general approach (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Recommended initial approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The principal goal of initial",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      therapy is to return the patient to his or her previous baseline blood pressure within 72 hours. Since the hypertension is acute in SRC, rapid blood pressure reduction to baseline does not usually carry the risks seen with rapid blood pressure lowering in patients with long-standing hypertension. However, some recommend maximum blood pressure reductions of 20 mmHg per day.",
"     </li>",
"     <li>",
"      Among patients with SRC, we recommend the administration of ACE inhibitors rather than other antihypertensive agents (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest initial use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      rather than other ACE inhibitors because of extensive clinical experience and its short onset and duration of action, which permit rapid dose escalation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Among hypertensive patients without evidence of central nervous system involvement (eg, encephalopathy, papilledema),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      is begun at a dose of 6.25 to 12.5 mg. There is progressive dose escalation in 12.5 to 25 mg increments at four to eight hour intervals until the goal blood pressure is reached. The maximum captopril dose is 300 to 450",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      Among hypertensive patients with evidence of central nervous system involvement, we administer the same",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      regimen and, for acute blood pressure control, add intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      . The nitroprusside should be discontinued as soon as possible as captopril in increasing doses lowers the blood pressure.",
"     </li>",
"     <li>",
"      Among patients who are normotensive, we begin",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      at a dose of 6.25 mg and, if tolerated, increase the dose to 12.5 mg at the second dose. Further dose escalation must be done carefully to prevent the induction of hypotension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to blood pressure, other parameters that can be followed with treatment are the platelet count, hemoglobin, haptoglobin, and serum lactate dehydrogenase.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite treatment with ACE inhibitors, approximately 20 to 50 percent of patients with scleroderma renal crisis progress to end-stage renal disease. However, among patients with SRC who require dialysis during the acute episode, an appreciable proportion recover sufficient renal function to discontinue dialysis over a period of up to 18 months. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Renal outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based principally upon survival benefits with kidney transplantation among all patients with end-stage renal disease (ESRD), we recommend transplantation rather than hemodialysis or peritoneal dialysis among patients with SRC who require renal replacement therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We do not perform renal transplantation for at least one year after the initiation of dialysis given the chance of recovery of renal function. We continue ACE inhibitors indefinitely in all patients with ESRD, if tolerated. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Renal outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/1\">",
"      Livi R, Teghini L, Pignone A, et al. Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement. Ann Rheum Dis 2002; 61:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/2\">",
"      Traub YM, Shapiro AP, Rodnan GP, et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore) 1983; 62:335.",
"     </a>",
"    </li>",
"    <li>",
"     Shapiro, AP, Medsger, TA Jr. Renal involvement in systemic sclerosis. In: Diseases of Kidney, 4th ed, Schrier, R,Gottschalk, C (Eds), Little, Brown, Boston, 1988, p. 2272.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/4\">",
"      TUFFANELLI DL, WINKELMANN RK. Systemic scleroderma, A clinical study of 727 cases. Arch Dermatol 1961; 84:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/5\">",
"      Steen VD, Syzd A, Johnson JP, et al. Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 2005; 32:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/6\">",
"      Steen VD, Medsger TA Jr, Osial TA Jr, et al. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984; 76:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/7\">",
"      Eason RJ, Tan PL, Gow PJ. Progressive systemic sclerosis in Auckland: a ten year review with emphasis on prognostic features. Aust N Z J Med 1981; 11:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/8\">",
"      O'Callaghan CA. Renal manifestations of systemic autoimmune disease: diagnosis and therapy. Best Pract Res Clin Rheumatol 2004; 18:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/9\">",
"      Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007; 100:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/10\">",
"      Teixeira L, Mouthon L, Mahr A, et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008; 67:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/11\">",
"      Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000; 133:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/12\">",
"      Helfrich DJ, Banner B, Steen VD, Medsger TA Jr. Normotensive renal failure in systemic sclerosis. Arthritis Rheum 1989; 32:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/13\">",
"      Kohno K, Katayama T, Majima K, et al. A case of normotensive scleroderma renal crisis after high-dose methylprednisolone treatment. Clin Nephrol 2000; 53:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/14\">",
"      Guillevin L, B&eacute;rezn&eacute; A, Seror R, et al. Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology (Oxford) 2012; 51:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/15\">",
"      DeMarco PJ, Weisman MH, Seibold JR, et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002; 46:2983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/16\">",
"      Domsic RT, Rodriguez-Reyna T, Lucas M, et al. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 2011; 70:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/17\">",
"      Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/18\">",
"      Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/19\">",
"      Nguyen B, Assassi S, Arnett FC, Mayes MD. Association of RNA polymerase III antibodies with scleroderma renal crisis. J Rheumatol 2010; 37:1068; author reply 1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/20\">",
"      Denton CP, Sweny P, Abdulla A, Black CM. Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol 1994; 33:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/21\">",
"      Donohoe JF. Scleroderma and the kidney. Kidney Int 1992; 41:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/22\">",
"      Batal I, Domsic RT, Shafer A, et al. Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol 2009; 40:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/23\">",
"      Gouge SF, Wilder K, Welch P, et al. Scleroderma renal crisis prior to scleroderma. Am J Kidney Dis 1989; 14:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/24\">",
"      Zwettler U, Andrassy K, Waldherr R, Ritz E. Scleroderma renal crisis as a presenting feature in the absence of skin involvement. Am J Kidney Dis 1993; 22:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/25\">",
"      Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000; 43:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/26\">",
"      Arnaud L, Huart A, Plaisier E, et al. ANCA-related crescentic glomerulonephritis in systemic sclerosis: revisiting the \"normotensive scleroderma renal crisis\". Clin Nephrol 2007; 68:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/27\">",
"      Kamen DL, Wigley FM, Brown AN. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis in scleroderma--a different kind of renal crisis. J Rheumatol 2006; 33:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/28\">",
"      Karpinski J, Jothy S, Radoux V, et al. D-penicillamine-induced crescentic glomerulonephritis and antimyeloperoxidase antibodies in a patient with scleroderma. Case report and review of the literature. Am J Nephrol 1997; 17:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/29\">",
"      Gliddon AE, Dor&eacute; CJ, Black CM, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 2007; 56:3837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/30\">",
"      Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/31\">",
"      Beckett VL, Donadio JV Jr, Brennan LA Jr, et al. Use of captopril as early therapy for renal scleroderma: a prospective study. Mayo Clin Proc 1985; 60:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/32\">",
"      Rajendran PR, Molitor JA. Resolution of hypertensive encephalopathy and scleroderma renal crisis with an angiotensin receptor blocker. J Clin Rheumatol 2005; 11:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/33\">",
"      Abbott KC, Trespalacios FC, Welch PG, Agodoa LY. Scleroderma at end stage renal disease in the United States: patient characteristics and survival. J Nephrol 2002; 15:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/34\">",
"      Paul M, Bear RA, Sugar L. Renal transplantation in scleroderma. J Rheumatol 1984; 11:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/35\">",
"      Merino GE, Sutherland DE, Kjellstrand CM, et al. Renal transplantation for progressive systemic sclerosis with renal failure: case report and review of previous experience. Am J Surg 1977; 133:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/36\">",
"      Bleyer AJ, Donaldson LA, McIntosh M, Adams PL. Relationship between underlying renal disease and renal transplantation outcome. Am J Kidney Dis 2001; 37:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/37\">",
"      Gibney EM, Parikh CR, Jani A, et al. Kidney transplantation for systemic sclerosis improves survival and may modulate disease activity. Am J Transplant 2004; 4:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/38\">",
"      Pham PT, Pham PC, Danovitch GM, et al. Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature. Am J Transplant 2005; 5:2565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/39\">",
"      Chang YJ, Spiera H. Renal transplantation in scleroderma. Medicine (Baltimore) 1999; 78:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/40\">",
"      Cheung WY, Gibson IW, Rush D, et al. Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade. Am J Kidney Dis 2005; 45:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/41\">",
"      Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001; 44:2828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/42\">",
"      Woodhall PB, McCoy RC, Gunnells JC, Seigler HF. Apparent recurrence of progressive systemic sclerosis in a renal allograft. JAMA 1976; 236:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/43\">",
"      Medsger TA Jr, Masi AT, Rodnan GP, et al. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971; 75:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/44\">",
"      Medsger TA Jr, Masi AT. Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis 1973; 26:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35801/abstract/45\">",
"      Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43:2437.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7183 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-189.2.19.178-DF24B1B659-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_61_35801=[""].join("\n");
var outline_f34_61_35801=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL RENAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SCLERODERMA RENAL CRISIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Diffuse skin involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Glucocorticoid use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diagnosis and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Avoidance of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - ACE inhibitor studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Non-ACE inhibitor therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Recommended initial approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Resistant hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      RENAL OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H114886104\">",
"      - Minimum wait time for transplant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7183\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7183|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/50/38694\" title=\"picture 1\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/33/6681\" title=\"picture 2A\">",
"      Scleroderma glomerulus light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/61/12246\" title=\"picture 2B\">",
"      HUS Vascular I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/49/26389\" title=\"picture 2C\">",
"      HUS Vascular II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/19/34099\" title=\"picture 2D\">",
"      HUS vascular III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/3/8255\" title=\"picture 2E\">",
"      HUS IF IV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7183|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/45/19164\" title=\"table 1\">",
"      Classification of scleroderma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12505?source=related_link\">",
"      Clinical manifestations and diagnosis of acute renal allograft rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26329?source=related_link\">",
"      Clinical manifestations of systemic sclerosis (scleroderma) lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42679?source=related_link\">",
"      Diet in the treatment and prevention of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21859?source=related_link\">",
"      Ocular effects of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/63/19450?source=related_link\">",
"      Pathogenesis of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19398?source=related_link\">",
"      Renal effects of ACE inhibitors in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11240?source=related_link\">",
"      The kidney transplant waiting list",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35256?source=related_link\">",
"      Treatment of resistant hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_61_35802="Management of Barrett's esophagus";
var content_f34_61_35802=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of Barrett's esophagus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/61/35802/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35802/contributors\">",
"     Stuart J Spechler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/61/35802/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35802/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/61/35802/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/61/35802/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/61/35802/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barrett's esophagus is the condition in which a metaplastic columnar epithelium that predisposes to cancer development replaces the stratified squamous epithelium that normally lines the distal esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/1\">",
"     1",
"    </a>",
"    ]. The metaplastic epithelium is acquired as a consequence of chronic gastroesophageal reflux disease (GERD).",
"   </p>",
"   <p>",
"    The management of patients with Barrett's esophagus involves three major components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatment of the associated GERD",
"     </li>",
"     <li>",
"      Endoscopic surveillance to detect dysplasia",
"     </li>",
"     <li>",
"      Treatment of dysplasia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, chemoprevention to reduce the rate of malignant transformation has also been evaluated.",
"   </p>",
"   <p>",
"    These issues will be reviewed here. Many remain controversial with considerable disagreement among experts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The pathogenesis, malignant transformation, clinical manifestations, and diagnosis of Barrett's esophagus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8391?source=see_link\">",
"     \"Pathogenesis of Barrett's esophagus and its malignant transformation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1161?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These issues have also been addressed in guidelines issued by the American College of Gastroenterology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/4\">",
"     4",
"    </a>",
"    ], the American Gastroenterological Association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/3\">",
"     3",
"    </a>",
"    ], and the American Society for Gastrointestinal Endoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/5\">",
"     5",
"    </a>",
"    ]. Guidelines from the American Gastroenterological Association are summarized below. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT OF GERD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of gastroesophageal reflux disease (GERD) in patients with Barrett's esophagus involves similar principles to the treatment of patients who have GERD without Barrett's esophagus. One important difference is that many authorities advocate initial therapy with a proton pump inhibitor (PPI), rather than incremental \"step up\" therapy based upon symptom response, for patients with Barrett's esophagus. In addition to controlling reflux symptoms, the goal of PPI therapy is to prevent cancer development. However, the efficacy of PPI therapy for cancer prevention in Barrett's esophagus has not been established in clinical trials.",
"   </p>",
"   <p>",
"    A medical position statement from the American Gastroenterological Association (AGA) supports the use of GERD therapy to treat GERD symptoms and to heal reflux esophagitis for patients with Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/3\">",
"     3",
"    </a>",
"    ]. Since most patients with Barrett's esophagus have symptoms or endoscopic signs of GERD, whether to treat with a PPI is not usually a question. However, for patients with no GERD symptoms and no endoscopic signs of reflux esophagitis, the use of PPIs would be solely to reduce the risk of progression to dysplasia or cancer.&nbsp;The AGA statement notes that the evidence supporting the use of PPIs in patients with Barrett's esophagus solely to reduce the risk of progression to dysplasia or cancer is indirect and has not been proven in long-term controlled trials.&nbsp;As a result, the AGA suggests that the risks and potential benefits of long-term PPI therapy be discussed carefully with patients with Barrett's esophagus in the context of their overall health status and medication use. Generally, we suggest the use of PPIs in such patients after a discussion of the potential risks and benefits. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5136088\">",
"     'American Gastroenterological Association'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Antireflux surgery (fundoplication) is another option for controlling GERD in patients with Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/6\">",
"     6",
"    </a>",
"    ], although fundoplication does not appear to be more effective at preventing esophageal adenocarcinoma than medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42905?source=see_link\">",
"     \"Surgical management of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PPI therapy reduces, but does not eliminate, gastric acid secretion in patients with Barrett's esophagus. PPIs usually eliminate the symptoms of GERD, but symptom relief does not accurately reflect the level of acid suppression achieved. Esophageal pH monitoring studies frequently reveal pathological levels of acid reflux in patients with Barrett's esophagus rendered asymptomatic by PPIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/11\">",
"     11",
"    </a>",
"    ]. In an illustrative study of 48 patients with Barrett's esophagus, 50 percent had persistently abnormal esophageal acid exposure documented by pH monitoring while they were receiving dosages of PPIs that abolished GERD symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/12\">",
"     12",
"    </a>",
"    ]. Approximately 80 percent of patients with Barrett's esophagus treated with a PPI twice daily experience the phenomenon of nocturnal gastric acid breakthrough (defined as a fall in gastric pH below 4 for more than one hour at night), which is often associated with episodes of acid reflux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/13\">",
"     13",
"    </a>",
"    ]. Reliable clinical predictors of persistent abnormal esophageal acid exposure in patients with Barrett's esophagus treated with PPIs have not been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that patients with Barrett's esophagus are unusually resistant to PPI treatment. However, such resistance may be a consequence of a profound reflux diathesis rather than gastric resistance to the antisecretory effects of PPIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/15\">",
"     15",
"    </a>",
"    ]. In other words, PPIs appear to reduce gastric acid secretion appropriately in patients with Barrett's esophagus, but the little acid that remains in the stomach refluxes into the esophagus because of the strong reflux diathesis, so pathological levels of acid reflux persist despite the considerable acid suppression.",
"   </p>",
"   <p>",
"    In some individuals, it may be possible to achieve better control of gastric acid secretion by administering PPIs in high dosages. Adding a bedtime dose of an H2RA to a regimen of a PPI administered twice daily has also been suggested for patients with nocturnal acid breakthrough [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/16\">",
"     16",
"    </a>",
"    ], but the long-term efficacy of this approach is unclear since tachyphylaxis to the H2RA appears to develop within one week in most patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/17\">",
"     17",
"    </a>",
"    ]. Authorities debate the advisability of prescribing aggressive antireflux therapy for all patients with Barrett's esophagus, irrespective of the severity of their underlying GERD. The AGA recommends against such an approach. (See",
"    <a class=\"local\" href=\"#H5136088\">",
"     'American Gastroenterological Association'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because GERD is a well established risk factor for esophageal adenocarcinoma, it has been hypothesized that aggressive GERD therapy might prevent the tumor. However, it is not clear whether GERD predisposes to malignancy by causing the initial esophageal metaplasia (ie, by causing Barrett's esophagus itself), by promoting carcinogenesis in established Barrett's esophagus, or both.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Does aggressive treatment of reflux prevent progression to cancer?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of anti-reflux therapy for patients with Barrett's esophagus is to control their reflux symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/4\">",
"     4",
"    </a>",
"    ]. Available data suggest, but do not prove, that aggressive antireflux therapy might also prevent cancer in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     In vitro studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro observations suggest that the episodic esophageal acid exposure typical of GERD might stimulate hyperproliferation, suppress apoptosis, and, by inference, promote carcinogenesis in Barrett's esophagus. As an example, biopsy specimens of specialized intestinal metaplasia (the metaplastic epithelium characteristic of Barrett's esophagus) maintained in organ culture show hyperproliferation and increased expression of cyclooxygenase-2 (a mediator of proliferation) when exposed to pulses of acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Brief esophageal acid exposure also activates the mitogen-activated protein kinase (MAPK) pathways that can increase proliferation and decrease apoptosis in Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study, biopsy specimens were taken from 39 patients with Barrett's esophagus at baseline and after six months of therapy with PPIs given only in doses sufficient to eliminate GERD symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/21\">",
"     21",
"    </a>",
"    ]. The expression of proliferating cell nuclear antigen (PCNA, a proliferation marker) decreased, and the expression of villin (a differentiation marker) increased significantly in biopsy specimens from the 24 patients in whom PPIs normalized esophageal acid exposure, but not in the 15 with persistent acid reflux during PPI therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Clinical studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials suggest that treatment of reflux sometimes results in limited regression of Barrett's esophagus, and observational studies suggest that antireflux therapy prevents progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma in these patients.",
"   </p>",
"   <p>",
"    Aggressive antireflux therapy can cause partial regression of the specialized intestinal metaplasia in Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In a randomized trial, 68 patients with proven Barrett's esophagus and acid reflux were assigned to receive profound acid suppression with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    (40 mg twice daily) or mild acid suppression (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    150 mg twice daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/22\">",
"     22",
"    </a>",
"    ]. Symptoms of acid reflux improved in both groups, but the degree of acid suppression was greater with omeprazole. Omeprazole produced a small but statistically significant regression of Barrett's esophagus compared to no change with ranitidine.",
"   </p>",
"   <p>",
"    The degree of reversal might be important clinically since some studies have shown that completely reversed squamous epithelium is biologically similar to normal squamous epithelium and, presumably, at low cancer risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/24\">",
"     24",
"    </a>",
"    ]. By contrast, partial reversal, as manifested by squamous islands (",
"    <a class=\"graphic graphic_picture graphicRef78238 \" href=\"mobipreview.htm?22/17/22806\">",
"     picture 1",
"    </a>",
"    ), is associated with persistent abnormalities in worrisome biomarkers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regression of Barrett's epithelium has also been observed with fundoplication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/26\">",
"     26",
"    </a>",
"    ], and some authorities have suggested that fundoplication might be more effective than antisecretory therapy for preventing cancer in Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/7,8,27-29\">",
"     7,8,27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of 25 surgical studies (mainly observational) found a significantly lower rate of adenocarcinoma among surgical patients compared with patients treated medically only in uncontrolled studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/30\">",
"     30",
"    </a>",
"    ]. In controlled trials, the incidence rates were similar (4.8 versus 6.5 per 1000 patient years in surgical versus medical groups, respectively, p = NS). The authors concluded that the evidence suggesting that surgery reduces the incidence of adenocarcinoma compared with medical therapy is largely driven by uncontrolled studies. Thus, the available data suggest that antireflux surgery should not be advised with the expectation that the procedure will prolong life by preventing esophageal cancer.",
"   </p>",
"   <p>",
"    Observational studies suggest that proton pump inhibitors (PPIs) can protect patients with Barrett's esophagus from developing neoplasia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective observational study of 540 patients with Barrett's esophagus followed for a median of 5.2 years, HGD developed in 28 (5 percent) and esophageal adenocarcinoma developed in 12 (2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/31\">",
"       31",
"      </a>",
"      ]. Patients who used PPIs during follow-up were significantly less likely to develop HGD or esophageal adenocarcinoma than those who did not (3.6 per 100 person-years versus 17 per 100 person-years; adjusted hazard ratio [HR] 0.21, 95% confidence interval [CI] 0.07-0.66). H2 receptor antagonist use was not associated with a decreased risk.",
"     </li>",
"     <li>",
"      An observational study in a VA population suggested that patients with Barrett's esophagus who had received a prescription for a PPI were less likely to develop dysplasia compared with those who received no therapy or an H2 receptor antagonist [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/32\">",
"       32",
"      </a>",
"      ]. The authors hypothesized that the timing of acid suppression relative to the course of the disease may have an important influence on potential benefits, possibly explaining the heterogeneity among studies.",
"     </li>",
"     <li>",
"      In another retrospective observational study of 344 patients with Barrett's esophagus, PPI treatment after diagnosis of Barrett's esophagus also was associated with a reduced risk of high grade dysplasia or cancer (adjusted HR 0.39; 95% CI 0.19-0.80) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommendation that patients with Barrett's esophagus undergo endoscopic surveillance is based upon the assumptions that Barrett's esophagus adversely influences survival and that surveillance can reduce mortality. However, a survival benefit in patients undergoing surveillance has not been demonstrated in randomized prospective trials. It has been argued that such trials would be prohibitively large and costly to perform, and their design would raise a number of practical and ethical problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/2,34\">",
"     2,34",
"    </a>",
"    ]. The following discussion will review the major issues related to surveillance; major society recommendations and our approach are presented below. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Guidelines'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H27\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Influence of Barrett's esophagus on mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the annual cancer incidence in patients with Barrett's esophagus have ranged from 0.1 to 2.0 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/35-45\">",
"     35-45",
"    </a>",
"    ]. Although the risk of developing esophageal cancer is increased at least 30-fold above that of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/46\">",
"     46",
"    </a>",
"    ], the absolute risk of developing cancer is low.",
"   </p>",
"   <p>",
"    Estimates of cancer incidence and mortality in patients with Barrett's esophagus were reported in a 2010 meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/47\">",
"     47",
"    </a>",
"    ]. Fifty studies in the analysis reported on the incidence of esophageal adenocarcinoma and included 14,109 patients with 61,804 person-years of follow-up. The meta-analysis found:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pooled estimate for cancer incidence was 6.3 per 1000 person-years. When only studies with well defined criteria for the diagnosis of Barrett's esophagus were included, the rate was 5.0 per 1000 person-years.",
"     </li>",
"     <li>",
"      For high-grade dysplasia or cancer, the corresponding pooled estimate for cancer incidence was 10.2 per 1000 person-years.",
"     </li>",
"     <li>",
"      The incidence of mortality was 3.0 per 1000 person-years due to esophageal adenocarcinoma and 37.1 per 1000 person-years due to other causes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the study mentioned above did not report on the incidence of cancer based on gender, a prior meta-analysis from 2008 found that the rates of progression to cancer or high-grade dysplasia were twice as high for men as they were for women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/48\">",
"     48",
"    </a>",
"    ]. Studies published after the 2010 meta-analysis suggest lower rates of esophageal adenocarcinoma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 42,207 patients with Barrett's esophagus with 78,131 person-years of follow-up, the incidence rate of esophageal cancer was 4.3 per 1000 person-years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/49\">",
"       49",
"      </a>",
"      ]. The incidence rate for developing either high-grade dysplasia or esophageal cancer was 5.8 per 1000 person-years. Risk factors for developing high-grade dysplasia or esophageal cancer included age &gt;75 years, male sex, and the presence of low-grade dysplasia at baseline.",
"     </li>",
"     <li>",
"      A study using the Danish Cancer Registry with 11,028 patients and a median follow-up of 5.2 years found a much lower incidence rate of esophageal cancer (1.2 cases per 1000 person-years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/43\">",
"       43",
"      </a>",
"      ]. Patients with low-grade dysplasia detected at their index endoscopy had an incidence rate of 5.1 cases per 1000 person-years, whereas those without dysplasia had an incidence rate of 1.0 case per 1000 person-years.",
"     </li>",
"     <li>",
"      In a multicenter study of 1204 patients with nondysplastic Barrett's esophagus and at least one year of follow-up, there was a low-risk of progressing to esophageal cancer (0.27",
"      <span class=\"nowrap\">",
"       percent/year),",
"      </span>",
"      high-grade dysplasia (0.48",
"      <span class=\"nowrap\">",
"       percent/year),",
"      </span>",
"      or low-grade dysplasia (3.6",
"      <span class=\"nowrap\">",
"       percent/year)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/50\">",
"       50",
"      </a>",
"      ]. After five years, 99 percent of patients (n = 540) were cancer free, and after ten years, 97 percent of patients (n = 155) were cancer free.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The finding that esophageal cancer is an uncommon cause of death in patients with Barrett's esophagus is likely related to the fact that many patients with Barrett's esophagus are elderly and succumb to common diseases, such as coronary artery disease, before developing adenocarcinoma in their Barrett's esophagus.",
"   </p>",
"   <p>",
"    The low incidence of death related to esophageal cancer has led some authors to question the value of surveillance in patients with Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/42,47\">",
"     42,47",
"    </a>",
"    ]. However, many of the studies reporting on the incidence of mortality did not account for the possibility that Barrett's esophagus may have more of an effect on mortality in younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/46,51-54\">",
"     46,51-54",
"    </a>",
"    ]. In addition, the value of surveillance should also be considered in light of the unexplained dramatic rise in the incidence of esophageal adenocarcinoma during the past three decades. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=see_link\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The issue of surveillance is further complicated by the many variables that are involved in deciding upon a benefit. Examples include the variable incidence of dysplasia or esophageal carcinoma in Barrett's esophagus, the decrease in quality of life and risk of the procedure in patients who are subjected to the worry and bother of endoscopic surveillance, the risks of invasive therapies, the quality of life after invasive therapies, and the risk of increased life and health insurance premiums for patients diagnosed with Barrett's esophagus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Evidence supporting surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have shown that endoscopic surveillance can detect curable dysplasia in Barrett's esophagus, and that asymptomatic cancers discovered during surveillance are less advanced than those found in patients who present with cancer symptoms like dysphagia and weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/55-59\">",
"     55-59",
"    </a>",
"    ]. However, these studies are highly susceptible to a number of biases (eg, lead-time bias, healthy volunteer bias). As a result, it is not appropriate to conclude that surveillance is beneficial based solely on the observation that patients with asymptomatic neoplasms discovered by surveillance endoscopy survive longer than patients who first present with symptoms of esophageal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/60\">",
"     60",
"    </a>",
"    ]. No study has established the reliability of surveillance in detecting curable dysplasia, while a number of reports have documented the development of incurable malignancies in some patients despite adherence to endoscopic surveillance programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Furthermore, hazardous invasive therapies for dysplasia like esophagectomy might ultimately do more harm than good.",
"   </p>",
"   <p>",
"    Some cost-effectiveness models have suggested that endoscopic screening and surveillance for Barrett's esophagus can be beneficial under certain conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/34,61,62\">",
"     34,61,62",
"    </a>",
"    ]. It is important to appreciate that these models do not provide a single definitive answer, but rather a range of possible outcomes that vary with changes in baseline assumptions. One group used a Markov model to construct a simulation of 10,000 middle-aged patients with Barrett's esophagus and assumed that esophagectomy would be performed for those whose surveillance endoscopies showed high-grade dysplasia. For an annual cancer incidence rate of 0.4 percent, the analysis suggested that endoscopic surveillance performed every five years was the preferred strategy, costing $98,000 per quality-adjusted life year gained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/34\">",
"     34",
"    </a>",
"    ]. Another analysis contradicted the findings of this model, concluding that while screening for Barrett's esophagus appeared to be cost-effective, surveillance did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/62\">",
"     62",
"    </a>",
"    ]. None of these models can be considered definitive, because all incorporate numerous layers of uncertain parameters and questionable assumptions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dysplasia as a marker of risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic surveillance is performed primarily to detect dysplasia in Barrett's esophagus. Cancers in this condition are judged to evolve through a sequence of genetic alterations that are associated with dysplastic changes of progressive severity. However, few studies document the natural history of dysplasia; thus the rate at which metaplasia progresses to dysplasia and cancer is unclear.",
"   </p>",
"   <p>",
"    Furthermore, low-grade dysplasia in Barrett's esophagus is not diagnosed reliably, complicating the interpretation of all studies of this condition. It is recommended that a diagnosis of low-grade dysplasia be confirmed by a second pathologist with expertise in esophageal histopathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnostic difficulties may underlie the large disparities among published series regarding the prevalence and incidence of low-grade dysplasia in Barrett's esophagus. In one large series, low-grade dysplasia was described in approximately 70 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/63\">",
"     63",
"    </a>",
"    ]. However, a more recent study that reviewed the pathology archives of three large university hospitals using strict diagnostic criteria for dysplasia identified low-grade dysplasia in only 37 (4.7 percent) of 790 cases of Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/64\">",
"     64",
"    </a>",
"    ]. For comparison, high-grade dysplasia was found in 20 (2.5 percent) of the 790 cases.",
"   </p>",
"   <p>",
"    The following illustrate the variable findings from studies on dysplasia progression:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study followed 618 patients with Barrett's esophagus for a total of 2546 patient-years (mean follow-up 4.1 years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/41\">",
"       41",
"      </a>",
"      ]. During follow-up, 100 patients (16 percent) developed low-grade dysplasia, 22 patients (3.6 percent) developed high-grade dysplasia, and 12 patients (1.9 percent) developed cancer. The annual incidences of low-grade dysplasia, high-grade dysplasia, and cancer were 4.3, 0.9, and 0.5 percent per year, respectively. Outcomes in patients with low-grade dysplasia included regression to no dysplasia in 66 percent, persistent low-grade dysplasia in 21 percent, development of high-grade dysplasia in 10 percent, and development of cancer in 3.2 percent. The incidence of cancer in those with low-grade dysplasia was 0.6 percent per year.",
"     </li>",
"     <li>",
"      In a study of 210 patients with Barrett's esophagus and low-grade dysplasia, 21 patients (10 percent) developed high-grade dysplasia during a mean follow-up of 6.2 years, for an incidence of 1.6 percent per year. Six patients (3 percent) developed adenocarcinoma, for an incidence of 0.4 percent per year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 48 patients with low-grade dysplasia, five (10 percent) progressed to high-grade dysplasia (four patients) or adenocarcinoma (one patient) during a mean follow-up of 41 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another report described a 12 percent cumulative incidence of adenocarcinoma at five years in 43 patients with low-grade dysplasia on baseline endoscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective study with 713 patients found that the presence of low-grade dysplasia was the strongest predictor of the subsequent development of high-grade dysplasia or esophageal cancer (risk ratio 9.7) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 25 patients with low-grade dysplasia followed for a mean duration of 26 months found that seven (28 percent) progressed to high-grade dysplasia (five patients) or adenocarcinoma (two patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/69\">",
"       69",
"      </a>",
"      ]. In this series, the degree of agreement among pathologists in the diagnosis of low-grade dysplasia was correlated with neoplastic progression. Seven of the 17 patients (41 percent) in whom at least two of the three study pathologists agreed on the diagnosis of low-grade dysplasia exhibited progression, while progression was seen in four of the five patients (80 percent) for whom there was unanimous agreement among the study pathologists.",
"     </li>",
"     <li>",
"      In a study of 147 patients diagnosed with low-grade dysplasia at six non-university hospitals, the diagnosis was down-staged to nondysplastic Barrett's esophagus or to indefinite for dysplasia in 85 percent of the patients when the biopsies were reviewed by two expert pathologists [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/70\">",
"       70",
"      </a>",
"      ]. The risk of progression was low in patients who were down-staged to nondysplastic Barrett's esophagus (incidence rate of 0.5 percent per patient per year). However, the risk was significantly higher in patients whose diagnoses of low-grade dysplasia were confirmed (incidence rate of 13 percent per patient per year).",
"     </li>",
"     <li>",
"      The extent of low-grade dysplasia (the mean number and proportion of crypts with low grade dysplasia) was associated with progression to adenocarcinoma in a study of 77 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is also considerable variation among reported estimates on the rate at which high-grade dysplasia in Barrett's esophagus progresses to cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report described eight patients with high-grade dysplasia in Barrett's esophagus, five (63 percent) of whom were found to have adenocarcinoma on repeat endoscopic examinations performed within one year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another group reported a 59 percent five-year cumulative cancer incidence among 76 patients with high-grade dysplasia in Barrett's esophagus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cancer was detected in 32 percent of 100 consecutive patients with high-grade dysplasia found by surveillance endoscopy and followed for up to eight years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      By contrast, another group reported that only 12 of 75 patients (16 percent) with high-grade dysplasia in Barrett's esophagus developed adenocarcinoma during a mean follow-up period of 7.3 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one of the larger studies that included 827 patients with Barrett's esophagus and high-grade dysplasia, early esophageal adenocarcinoma was detected at a rate of 14.1 cases per 100 person-years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/73\">",
"       73",
"      </a>",
"      ]. When prevalent cases of cancer were excluded (ie, cancer detected within six months following the diagnosis of high-grade dysplasia), the rate of cancer development was 4.2 cases per 100 person-years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reasons underlying the large disparities in the results of these studies are unsettled but may at least in part be due to referral bias and inclusion of patients with prevalent cancers in some of the reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/63,67\">",
"     63,67",
"    </a>",
"    ]. One group found that the extent of high-grade dysplasia in Barrett's esophagus correlated with the risk for adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/72\">",
"     72",
"    </a>",
"    ], but other investigators have not confirmed this observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following are our estimates of cancer risk for patients with Barrett's esophagus based upon available reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the general population of patients with Barrett's esophagus, the risk of esophageal adenocarcinoma is approximately 0.25 percent per year.",
"     </li>",
"     <li>",
"      For patients with high-grade dysplasia, the rate of cancer development is 4 to 8 percent per year.",
"     </li>",
"     <li>",
"      For patients with low-grade dysplasia, the risk of cancer is so poorly defined that it is not possible to provide a precise estimate. Presumably, the risk is greater than that of the general population of patients with Barrett's esophagus (0.25 percent per year) and less than that of patients with high-grade dysplasia (5 to 8 percent per year).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Detecting dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysplasia in Barrett's esophagus is often patchy in extent and severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Endoscopists traditionally have relied on random biopsy sampling techniques to identify dysplasia and, consequently, dysplastic areas can easily be missed because of biopsy sampling error. Furthermore, even when dysplasia is detected, foci of invasive cancer can be missed. In studies of patients who had esophagectomies because endoscopic examination revealed high-grade dysplasia in Barrett's esophagus with no apparent tumor mass, cancer (missed because of biopsy sampling error) was present in approximately 40 percent of resection specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. However, one meta-analysis of these studies found that only 13 percent of the resection specimens had invasive cancer, while most of those classified as having \"cancer\" in fact had intramucosal carcinoma, which is not considered invasive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/78\">",
"     78",
"    </a>",
"    ]. In a subsequent study of 68 patients undergoing esophagectomy for high-grade dysplasia, 12 (18 percent) had adenocarcinoma detected in the resected esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/81\">",
"     81",
"    </a>",
"    ]. Four of the cancers were intramucosal, and eight were invasive.",
"   </p>",
"   <p>",
"    Extensive biopsy sampling of the Barrett's esophagus can reduce biopsy sampling error, but cannot eliminate the problem entirely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/82-84\">",
"     82-84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For endoscopic surveillance of Barrett's esophagus, random biopsy sampling techniques have been used because dysplasia in Barrett's epithelium traditionally had been considered an endoscopically inconspicuous lesion. With the recent availability of high-resolution white light endoscopy, however, it has been appreciated that dysplasia is associated with visible abnormalities, albeit subtle ones, in most cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/85\">",
"     85",
"    </a>",
"    ]. Therefore, it is now recommended that endoscopists should carefully inspect the Barrett's epithelium and biopsy any visible abnormalities in addition to obtaining random biopsy specimens. In addition, the American Society for Gastrointestinal Endoscopy has issued guidelines that recommend endoscopic resection for the treatment and staging of nodular BE and suspected intramucosal adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Endoscopic resection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Molecular markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of molecular markers for cancer risk have been proposed as alternatives to random biopsy sampling to seek dysplasia in Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/87-90\">",
"     87-90",
"    </a>",
"    ]. Promising molecular markers include abnormalities in p53 and cyclin D1 expression, and abnormal cellular DNA content demonstrable by flow cytometry or methylation arrays, all of which have been associated with carcinogenesis in Barrett's esophagus. None has been sufficiently proven for routine clinical use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Endoscopic techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endoscopic surveillance of Barrett's esophagus should include a careful inspection of the Barrett's epithelium with high-resolution, white light endoscopy. Techniques that have been proposed to enhance the identification of dysplastic areas for biopsy sampling during endoscopy include mucosal staining with vital dyes (chromoendoscopy), endosonography, optical coherence tomography, high resolution endoscopy, confocal microendoscopy, and spectroscopy using reflectance, absorption, light-scattering, fluorescence, narrow band imaging, and Raman detection methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/91-96\">",
"     91-96",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15370?source=see_link\">",
"     \"Chromoendoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/27/13750?source=see_link\">",
"     \"Autofluorescence endoscopy for Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/40/29316?source=see_link\">",
"     \"Narrow band imaging in Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although initial studies are promising, none of these techniques has yet been shown to provide sufficient additional clinical information (beyond that of high-resolution, white light endoscopy) to justify its routine application for surveillance purposes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Long versus short segment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective data strongly suggest that the risk of cancer for patients with short-segment Barrett's esophagus is less than that for patients with long-segment disease. A prospective study with 713 patients with Barrett's esophagus of 2 cm in length or longer found that the risk of developing high-grade dysplasia or cancer was higher with longer segments of Barrett's esophagus (risk ratio of 1.1 for every centimeter increase in length) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/68\">",
"     68",
"    </a>",
"    ]. However, at present, patients with short- and long-segment Barrett's esophagus presently are managed similarly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1161?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus\", section on 'Differences between long- and short-segment Barrett's'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT OF HIGH-GRADE DYSPLASIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with verified high-grade dysplasia (also called intraepithelial neoplasia) in Barrett's esophagus, there are generally four proposed management options:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Esophagectomy",
"     </li>",
"     <li>",
"      Endoscopic therapies that ablate the neoplastic tissue",
"     </li>",
"     <li>",
"      Endoscopic mucosal resection",
"     </li>",
"     <li>",
"      Intensive endoscopic surveillance in which invasive therapies are withheld until biopsy specimens reveal adenocarcinoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All four choices are associated with substantial risks and unclear benefits. The follow-up duration in most studies on treatments for dysplasia in Barrett's esophagus is considerably less than five years. As a result, the efficacy of these therapies in reducing cancer deaths is not established, although at least two cost-effectiveness analyses concluded that endoscopic ablation provided the longest quality adjusted life expectancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In guidelines issued in 2011, the American Gastroenterological Association (AGA) recommended that patients with high-grade dysplasia within Barrett's esophagus undergo endoscopic eradication therapy with radiofrequency ablation, photodynamic therapy, or endoscopic mucosa resection. This recommendation varies from prior guidelines that suggested either esophagectomy or endoscopic therapies for the majority of patients with high-grade dysplasia. We agree with the AGA guidelines regarding the treatment of high-grade dysplasia. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Esophagectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophagectomy is the only therapy for high-grade dysplasia that clearly removes all of the neoplastic epithelium along with any occult malignancy and regional lymph nodes. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Detecting dysplasia'",
"    </a>",
"    above.) However, this definitive therapy also has the highest rates of procedure-related mortality and long-term morbidity. The mortality rates for esophagectomy among institutions vary inversely with the frequency with which the operation is performed. In one study of 340 esophagectomies performed at 25 different hospitals, the mortality rate was 3.0 percent for patients who had the operation at institutions that did five or more esophagectomies per year, compared with 12.2 percent for patients treated at institutions where the operation was performed less frequently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of data from the Dutch National Medical Registry, the mortality rates for esophagectomy were 12.1, 7.5, and 4.9 percent at centers performing 1 to 10, 11 to 20, and more than 50 esophagectomies per year, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/100\">",
"     100",
"    </a>",
"    ]. The average hospital stay for open esophagectomy is approximately two weeks, and 30 to 50 percent of patients develop at least one serious postoperative complication such as pneumonia, arrhythmia, myocardial infarction, heart failure, wound infection, and anastomotic leak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/99-102\">",
"     99-102",
"    </a>",
"    ]. Esophagectomy is frequently associated with long-term problems such as dysphagia, weight loss, gastroesophageal reflux, and dumping. Some of these complications are related to transection of the vagal nerve and may be reduced with a vagal-sparing esophagectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/103\">",
"     103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20426?source=see_link\">",
"     \"Management of superficial esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Minimally invasive techniques for esophagectomy are being increasingly described. Initial experience (mainly from high volume centers) has suggested that the minimally invasive techniques are associated with similar postoperative morbidity and mortality rates but with reduced blood loss, postoperative pain, and ICU stay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/104\">",
"     104",
"    </a>",
"    ]. Their role in the management of Barrett's esophagus with high-grade dysplasia continues to be defined, although they may be an option in centers with appropriate expertise.",
"   </p>",
"   <p>",
"    Estimated mortality rates for esophagectomy in Barrett's esophagus often have been extrapolated from series of patients who had esophagectomy performed for the treatment of symptomatic, advanced esophageal cancer. Such patients are frequently elderly and debilitated. In addition, those series often have included patients with squamous cell carcinoma of the esophagus, many of whom have had severe co-morbid illnesses caused by cigarette smoking and alcoholism associated with that tumor. Mortality rates for esophagectomy performed to treat dysplasia or early cancer in otherwise healthy patients with Barrett's esophagus are substantially lower. A number of modern, small series have described mortality rates substantially less than 5 percent and excellent survival rates for esophagectomy performed to treat early neoplasia in Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/105,106\">",
"     105,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review on the frequency of lymph node metastases in patients with mucosal neoplasms in Barrett's esophagus has important implications regarding the need for esophagectomy in these cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/107\">",
"     107",
"    </a>",
"    ]. The investigators reviewed the medical literature for studies that included patients who had esophagectomy with lymph node dissection for high-grade dysplasia or intramucosal carcinoma in Barrett's esophagus. They identified 70 relevant with 1874 patients. Overall, lymph node metastases were identified in the resection specimen from 26 of the patients (1.4 percent). When evaluated based upon the final pathologic diagnosis, there were no metastases in the 524 patients with high-grade dysplasia, and metastases were found in 26 of the 1350 patients (1.9 percent) with intramucosal carcinoma. This study suggests that the risk of lymph node metastases for mucosal neoplasms in Barrett's esophagus is approximately 1 to 2 percent. Endoscopic therapy cannot cure neoplasms that have metastasized to lymph nodes, whereas esophagectomy, which usually involves removal of local lymph nodes, does have the potential to cure patients with such metastases. However, the authors argue that the risk of lymph node metastases alone does not warrant the choice of esophagectomy over endoscopic eradication therapy because esophagectomy has a mortality rate that likely exceeds the rate of lymph node metastases. In addition, esophagectomy does not guarantee cure for a tumor that already has metastasized to lymph nodes.",
"   </p>",
"   <p>",
"    With the development of efficacious endoscopic therapies, esophagectomy can now often be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Endoscopic ablative therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ablative therapies (eg, KTP laser, argon laser, Nd:YAG laser, multipolar electrocoagulation, argon plasma coagulation, photodynamic therapy, radiofrequency ablation) use thermal, photochemical, or radiofrequency energy to ablate the abnormal epithelium in Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/108-111\">",
"     108-111",
"    </a>",
"    ]. The most commonly used treatments include radiofrequency ablation and photodynamic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/27/26039?source=see_link\">",
"     \"Photodynamic therapy for ablation of Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/53/41817?source=see_link\">",
"     \"Radiofrequency ablation for Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After the epithelium is ablated, patients are given PPIs so that the injured mucosa heals with the growth of new squamous epithelium. The relative merits of the various endoscopic ablative therapies are disputed. One major concern is that the procedures may not eradicate all of the dysplastic cells. Partially-ablated metaplastic mucosa can heal with an overlying layer of squamous epithelium that hides the \"buried\" metaplastic tissue from the endoscopist, and adenocarcinomas have developed from these residual deposits of metaplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of endoscopic therapy was examined in a retrospective study of 166 patients with high-grade dysplasia or early cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/113\">",
"     113",
"    </a>",
"    ]. Patients were treated with photodynamic therapy, radiofrequency ablation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    argon plasma coagulation. In addition, endoscopic resection was performed for focal nodular Barrett's esophagus, for limited expanses of flat Barrett's esophagus, and for focal residual Barrett's esophagus following ablative therapy. Complete eradication of neoplasia was achieved in 157 patients (95 percent), with complete eradication of intestinal metaplasia in 137 (83 percent). Among those with complete eradication of intestinal metaplasia, recurrent intestinal metaplasia was detected in 48 (35 percent), with dysplasia in 12 (9 percent). Among the patients who had eradication of neoplasia but not complete eradication of intestinal metaplasia, recurrent dysplasia was detected in 6 of 19 (32 percent). Neoplasia (dysplasia or carcinoma) was more likely to recur in patients who had multifocal dysplasia and who were older, whereas neoplasia was less likely to occur in patients who had complete eradication of intestinal metaplasia.",
"   </p>",
"   <p>",
"    The cost-effectiveness of ablative approaches continues to be debated. A meta-analysis of studies involving ablation concluded that ablation may reduce cancer incidence compared with historical reports, particularly in patients with high-grade dysplasia, but the studies were too varied to make definitive conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/114\">",
"     114",
"    </a>",
"    ]. A cost-utility analysis concluded that endoscopic ablation could be preferred in patients with high-grade dysplasia and possibly low-grade or no dysplasia depending upon its effectiveness and whether surveillance endoscopy can be discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Radiofrequency ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiofrequency ablation (RFA) is carried out with the HALO system (B&Acirc;RRX Medical, Sunnyvale, California). The Barrett's mucosa is ablated using radiofrequency energy delivered by a balloon that has a series of closely spaced electrodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/110\">",
"     110",
"    </a>",
"    ]. Proposed advantages of this system are that it rapidly generates a circumferential thermal injury with controlled depth and uniformity. This may result in low rates of stricture formation and buried metaplasia. RFA can be combined with endoscopic mucosal resection in patients with visible lesions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/53/41817?source=see_link\">",
"     \"Radiofrequency ablation for Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H19\">",
"     'Endoscopic resection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Multiple studies have examined RFA for the treatment of Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/110,116-126\">",
"     110,116-126",
"    </a>",
"    ], and analyses suggest it is a cost-effective approach for patients with high-grade dysplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/115,127\">",
"     115,127",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/53/41817?source=see_link&amp;anchor=H23#H23\">",
"     \"Radiofrequency ablation for Barrett's esophagus\", section on 'Cost-effectiveness'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/53/41817?source=see_link&amp;anchor=H12#H12\">",
"     \"Radiofrequency ablation for Barrett's esophagus\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An illustrative trial showed the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized, sham-controlled trial, 127 patients with dysplasia in Barrett's esophagus (64 low-grade, 63 high-grade) were randomized to receive either RFA (ablation group) or a sham procedure (control group) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/121\">",
"       121",
"      </a>",
"      ]. At one year, intention-to-treat analyses revealed the complete eradication of dysplasia in 91 percent of patients with low-grade dysplasia in the ablation group, compared with 3 percent of those in the control group (P&lt;0.001). Similarly, complete eradication was found in 81 percent of patients with high-grade dysplasia in the ablation group, compared with 19 percent of those in the control group (P&lt;0.001). In addition, patients in the ablation group had less progression in their degree of neoplasia (4 versus 16 percent, P = 0.03) and fewer cancers noted at one year (1 versus 9 percent, P = 0.045). Serious complications occurred in six (7 percent) of the 84 patients who received ablation, including one upper gastrointestinal hemorrhage and five esophageal strictures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Photodynamic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photodynamic therapy is based upon the ability of chemical agents, known as photosensitizers, to produce cytotoxicity in the presence of oxygen after stimulation by light of an appropriate wavelength. Several studies of photodynamic therapy have been published. A large controlled trial demonstrated that it was superior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    alone for eradicating dysplasia and preventing cancer in Barrett's esophagus. However, serious complications such as esophageal stricture occurred frequently, and 15 percent of patients who received photodynamic therapy ultimately developed esophageal cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/27/26039?source=see_link\">",
"     \"Photodynamic therapy for ablation of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6989124\">",
"    <span class=\"h3\">",
"     Endoscopic spray cryotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic spray cryotherapy is a newer technique for ablation of Barrett's mucosa. A cryotherapy system is used to apply cold nitrogen or carbon dioxide gas endoscopically to the BE. The tissue is frozen for a total of approximately 40 seconds (two 20-second applications or four 10-second applications).",
"   </p>",
"   <p>",
"    In an analysis of 60 patients with BE and high-grade dysplasia who completed all of their planned cryotherapy sessions, 58 (97 percent) had complete eradication of high-grade dysplasia, 52 (87 percent) had complete eradication of all dysplasia, and 34 (57 percent) had complete eradication of all Barrett's mucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/128\">",
"     128",
"    </a>",
"    ]. Subsquamous (\"buried\") Barrett's mucosa was found in two patients (3 percent). Complications included chest pain (two patients) and strictures (three patients). One patient developed bright red blood per rectum following the procedure. There were no esophageal perforations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Endoscopic resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic resection (ER) includes endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). ER involve the excision of a large segment of esophageal mucosa down to the submucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/129,130\">",
"     129,130",
"    </a>",
"    ]. Unlike the endoscopic ablative techniques, ER provides large tissue specimens that can be examined by the pathologist to determine the character and extent of the lesion, and the adequacy of resection. Therefore, it can provide important staging information (revealing submucosal invasion that might not be apparent by less invasive techniques, which would require esophagectomy or other modalities for cure) and be therapeutic as well (if there is no submucosal extension). ER can also be combined with endoscopic ablative therapies for the eradication of Barrett's mucosa in patients who have visible lesions. The American Society for Gastrointestinal Endoscopy has issued guidelines that recommend ER for the treatment and staging of nodular BE and suspected intramucosal adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/54/4970?source=see_link\">",
"     \"Overview of endoscopic resection of gastrointestinal tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10858?source=see_link\">",
"     \"Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Impressive results have been reported for EMR in the treatment of neoplasia in Barrett's esophagus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 100 patients with early adenocarcinomas in Barrett's esophagus, EMR caused no serious complications, and the calculated five-year survival rate was 98 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/131\">",
"       131",
"      </a>",
"      ]. However, recurrent or metachronous cancers were found in 11 percent of the patients during a mean follow-up period of 37 months. The recurrent tumors were treated successfully with more endoscopic therapy, but this high rate of recurrence suggests that EMR often leaves behind cells with neoplastic potential.",
"     </li>",
"     <li>",
"      Similar results were reported by investigators at the Mayo Clinic, who found that patients with intramucosal carcinoma who were treated either with esophagectomy or with a combination of EMR and PDT had similar long-term survival rates, but 12 percent of the patients treated with PDT and EMR were found to have a metachronous esophageal cancer during a mean follow-up of 43 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another report has described the long-term results of endoscopic therapies in a heterogeneous group of 349 patients who had high-grade dysplasia or mucosal adenocarcinoma in Barrett's esophagus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/132\">",
"       132",
"      </a>",
"      ]. The endoscopic treatments included EMR alone for 279 patients, PDT alone for 55, EMR and PDT combined for 13, and argon plasma coagulation alone for two patients. Serious complications of endoscopic therapy occurred in 5 percent of the 349 patients and included clinically important bleeding (two patients) and esophageal strictures (15 patients). During a mean follow-up period of 64 months, a complete remission was achieved in 97 percent. However, metachronous neoplasms were found during the follow-up period in 21 percent. Risk factors for these metachronous lesions included long-segment Barrett's esophagus, multiple foci of neoplasia in the Barrett's epithelium, piecemeal resection of the tumor, and failure to perform ablation of the residual, non-neoplastic Barrett's epithelium after achieving complete remission. The calculated five-year survival rate was 84 percent, and none of the deaths were from esophageal cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that EMR for dysplasia and early cancers in Barrett's esophagus is safe in experienced hands, and five-year survival rates are excellent. However, EMR alone may not offer a benefit over radiofrequency ablation combined with EMR for visible lesions. In a study of 47 patients with &le;5 cm of Barrett's mucosa containing high-grade dysplasia or early cancer, stepwise radical endoscopic resection (in which endoscopic resections is repeated with the goal of eradicating all of the Barrett's mucosa) was compared with endoscopic resection of visible lesions followed by radiofrequency ablation (RFA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/124\">",
"     124",
"    </a>",
"    ]. Both groups had high rates of complete remission of both neoplasia and intestinal metaplasia (ranging from 96 to 100 percent and 29 to 96 percent, respectively), but the stenosis rate was significantly higher in the patients who underwent stepwise radical endoscopic resection (88 versus 14 percent).",
"   </p>",
"   <p>",
"    In addition, it is important to note that most of the studies of EMR for Barrett's esophagus have come from only a handful of highly specialized centers, and it is not clear that these results can be duplicated in a community setting. Furthermore, recurrent neoplasms develop frequently after endoscopic therapy, especially if the residual Barrett's epithelium is not eradicated. Based on these findings, if endoscopic therapy is chosen for patients with dysplasia or early cancer in Barrett's esophagus, it seems reasonable to attempt to eradicate all of the Barrett's epithelium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10858?source=see_link\">",
"     \"Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Intensive endoscopic surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some authorities recommend a program of expectant management with intensive endoscopic surveillance (ie, endoscopic examinations every three to six months) for patients with high-grade dysplasia in Barrett's esophagus, withholding invasive treatments like esophagectomy until biopsy specimens reveal adenocarcinoma. However, few published data directly support the safety and efficacy of intensive surveillance for high-grade dysplasia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report described 75 patients with high-grade dysplasia who underwent intensive endoscopic surveillance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/63\">",
"       63",
"      </a>",
"      ]. During a mean follow-up of 7.3 years, 12 patients (16 percent) developed adenocarcinomas. The cancers were curable at the time of detection in all 11 patients who were compliant with the surveillance program, but one patient who was lost to follow-up returned years later with an unresectable tumor.",
"     </li>",
"     <li>",
"      In another series of 32 patients with high-grade dysplasia who developed adenocarcinoma during intensive endoscopic surveillance, only one patient had incurable disease (metastases) when the cancer was first detected on surveillance endoscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/133\">",
"       133",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third study, the investigators performed intensive endoscopic surveillance in 15 patients with high-grade dysplasia for a mean duration of 37 months, during which four developed adenocarcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/75\">",
"       75",
"      </a>",
"      ]. One of the four had metastatic disease. The authors concluded that an observational approach to the management of high-grade dysplasia should be discouraged.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73510534\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC TREATMENT OF LOW-GRADE DYSPLASIA AND NONDYSPLASTIC BARRETT'S ESOPHAGUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic techniques for eradication of Barrett's esophagus, including multipolar electrocoagulation, photodynamic therapy (PDT), and radiofrequency ablation (RFA), have also been applied to patients with low-grade dysplasia or nondysplastic Barrett's esophagus. However, the efficacy of endoscopic ablation for the prevention of cancer in such patients has not been established, and there remain many unanswered questions regarding the durability of the ablation procedure and the need for endoscopic surveillance after ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/134,135\">",
"     134,135",
"    </a>",
"    ]. Because of this, we do not recommend routine endoscopic treatment for patients with low-grade dysplasia or nondysplastic Barrett's esophagus. Instead, for most patients with verified low-grade dysplasia after extensive biopsy sampling, we suggest surveillance endoscopy at intervals of 6 to 12 months, and for patients with no dysplasia or endoscopic signs of neoplasia following adequate biopsy sampling, we suggest surveillance endoscopy at an interval of every three to five years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/27/26039?source=see_link\">",
"     \"Photodynamic therapy for ablation of Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/53/41817?source=see_link&amp;anchor=H5#H5\">",
"     \"Radiofrequency ablation for Barrett's esophagus\", section on 'Low-grade dysplasia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/53/41817?source=see_link&amp;anchor=H6#H6\">",
"     \"Radiofrequency ablation for Barrett's esophagus\", section on 'Non-dysplastic BE'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5136088\">",
"     'American Gastroenterological Association'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     CHEMOPREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiological data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit cyclooxygenase (COX), may protect against the development of Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/136\">",
"     136",
"    </a>",
"    ] or, in patients with established Barrett's esophagus, the development of cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/137,138\">",
"     137,138",
"    </a>",
"    ]. The specialized intestinal metaplasia of Barrett's esophagus exhibits increased expression of COX-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/139\">",
"     139",
"    </a>",
"    ], and inhibition of COX-2 has been shown to have anti-proliferative and pro-apoptotic effects in Barrett's-associated esophageal adenocarcinoma cell lines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a case-control study, 434 patients diagnosed with Barrett's esophagus were compared with 434 matched controls. Patients were matched on their indication for endoscopy, year of endoscopy, and endoscopist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/136\">",
"     136",
"    </a>",
"    ]. Compared with patients who did not use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , patients who used aspirin were less likely to be diagnosed with Barrett's esophagus (adjusted odds ratio 0.56, 95% CI 0.39-0.80). When patients were stratified by aspirin dose (&lt;325 mg per day versus &ge;325 mg per day), only patients taking the higher dose had a decreased risk of Barrett's (adjusted odds ratio 0.36, 95% CI 0.20-0.64). Similar results were seen when the analysis was confined to patients with gastroesophageal reflux disease (GERD) (adjusted OR 0.49; 95% CI 0.33-1) and to those with GERD who were taking &ge;325 mg of aspirin per day (adjusted OR 0.30; 95% CI 0.12-0.72).",
"   </p>",
"   <p>",
"    With regard to the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    on the development of esophageal adenocarcinoma in patients with Barrett's, a 2009 meta-analysis of published cohort studies estimated that aspirin use was inversely associated with esophageal adenocarcinoma (OR 0.64, 95% CI 0.52-0.79) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/138\">",
"     138",
"    </a>",
"    ]. A similar reduction in risk was observed for NSAIDs (OR 0.65, 95% CI 0.50-0.85). Subsequent observational studies also demonstrated a reduced risk of adenocarcinoma with NSAID",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aspirin use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/33,141,142\">",
"     33,141,142",
"    </a>",
"    ]. These observations provided the rationale for trials that have evaluated NSAIDs (including COX-2 inhibitors) in cancer prevention in patients with Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/143,144\">",
"     143,144",
"    </a>",
"    ]. One such trial, involving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    given for 48 weeks in 100 patients, found no benefit in preventing the progression of Barrett's esophagus to dysplasia or cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/145\">",
"     145",
"    </a>",
"    ]. However, in a nested case-control study of 11,823 patients with Barrett's esophagus, almost all of whom were taking proton pump inhibitors, a reduced risk of esophageal adenocarcinoma was noted in patients with filled NSAID",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aspirin prescriptions (OR 0.64) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even if NSAIDs are effective in preventing the progression to cancer, it is not clear that the high cost and cardiovascular risks of the COX-2 selective NSAIDs will be justified for routine clinical use.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    , an inexpensive, non-selective NSAID that can prevent cardiovascular as well as neoplastic complications, might be a useful drug if its protective effects can be shown to outweigh its risk of gastrointestinal complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/146\">",
"     146",
"    </a>",
"    ]. A large trial evaluating the efficacy and safety of aspirin for the prevention of cancer in Barrett's esophagus (the ASPECT trial) is being conducted in the United Kingdom, but the results are not expected to be available in the near future.",
"   </p>",
"   <p>",
"    The combination of NSAIDs and statins also appears to provide extra protection against neoplastic progression in patients with Barrett's esophagus. In a prospective study of 570 patients with Barrett's esophagus, 107 used a statin combined with an NSAID [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/142\">",
"     142",
"    </a>",
"    ]. After a mean follow-up of 4.5 years, compared with patients using neither drug, the risk of developing adenocarcinoma or high-grade dysplasia was significantly reduced among patients using NSAIDs and statins (adjusted hazard ratio 0.22; 95% CI 0.06-0.85). By comparison, the adjusted hazard ratio among the 211 patients using only an NSAID was 0.46 (95% CI 0.22-0.99).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;No management strategy for patients with Barrett's esophagus has been proven to prolong life. Although many issues remain unresolved regarding the optimal management, guidelines have been proposed by a number of medical societies and consensus statements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/3,4,147-149\">",
"     3,4,147-149",
"    </a>",
"    ]. The variations in the guidelines underscore the unsettled issues in the management Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/2\">",
"     2",
"    </a>",
"    ]. We follow the 2011 guidelines from the American Gastroenterological Association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/3\">",
"     3",
"    </a>",
"    ]. These guidelines are similar to those issued in 2012 by the American Society for Gastrointestinal Endoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5136088\">",
"    <span class=\"h2\">",
"     American Gastroenterological Association",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2011 the American Gastroenterological Association (AGA) issued guidelines on the management of patients with Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/3\">",
"     3",
"    </a>",
"    ]. They recommend the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening for Barrett's esophagus is suggested in patients with multiple risk factors associated with esophageal adenocarcinoma (age 50 years or older, male sex, white race, chronic GERD, hiatal hernia, elevated body mass index, or intra-abdominal distribution of body fat).",
"     </li>",
"     <li>",
"      The AGA recommends against screening the general population with GERD for Barrett's esophagus.",
"     </li>",
"     <li>",
"      For patients with Barrett's esophagus, GERD therapy with medication effective to treat GERD symptoms and to heal reflux esophagitis is clearly indicated, as it is for patients without Barrett's esophagus.",
"     </li>",
"     <li>",
"      The diagnosis of dysplasia in Barrett's esophagus should be confirmed by at least one additional pathologist, preferably one who is an expert in esophageal histopathology.",
"     </li>",
"     <li>",
"      Endoscopic surveillance is suggested for patients with Barrett's esophagus using the following surveillance intervals:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      No dysplasia: 3 to 5 years",
"     </li>",
"     <li>",
"      Low-grade dysplasia: 6 to 12 months",
"     </li>",
"     <li>",
"      High-grade dysplasia in the absence of eradication therapy: 3 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The AGA recommends against the use of molecular biomarkers to confirm the histologic diagnosis of dysplasia or as a method of risk stratification for patients with Barrett's esophagus.",
"     </li>",
"     <li>",
"      Evidence to support the use of acid-reducing agents, specifically PPIs, in patients with Barrett's esophagus solely to reduce the risk of progression to dysplasia or cancer is indirect and has not been proven in a long-term controlled trial. The risks and potential benefit of long-term PPI therapy should be discussed carefully with patients with Barrett's esophagus in the context of their overall health status and medication use.",
"     </li>",
"     <li>",
"      For patients with Barrett's esophagus who are undergoing surveillance, the AGA recommends:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Endoscopic evaluation using white light endoscopy",
"     </li>",
"     <li>",
"      Four-quadrant biopsy specimens be taken every 2 cm",
"     </li>",
"     <li>",
"      Specific biopsy specimens of any mucosal irregularities be submitted separately to the pathologist",
"     </li>",
"     <li>",
"      Four-quadrant biopsy specimens be obtained every 1 cm in patients with known or suspected dysplasia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The AGA suggests against requiring chromoendoscopy or advanced imaging techniques for the routine surveillance of patients with Barrett's esophagus.",
"     </li>",
"     <li>",
"      The AGA recommends against attempts to eliminate esophageal acid exposure for the prevention of esophageal adenocarcinoma. Such attempts include proton pump inhibitor (PPI) administration in doses greater than once daily, esophageal pH monitoring to titrate PPI dosing, and antireflux surgery.",
"     </li>",
"     <li>",
"      The AGA suggests against the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      solely to prevent esophageal adenocarcinoma in the absence of other indications. However, it recommends screening patients to identify cardiovascular risk factors for which aspirin therapy is indicated.",
"     </li>",
"     <li>",
"      Endoscopic eradication therapy with radiofrequency ablation, photodynamic therapy, or endoscopic mucosal resection (EMR) rather than surveillance is recommended for treatment of patients with confirmed high-grade dysplasia within Barrett's esophagus.",
"     </li>",
"     <li>",
"      EMR is recommended for patients who have dysplasia in Barrett's esophagus associated with a visible mucosal irregularity to determine the T stage of the neoplasia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/29/13778?source=see_link\">",
"       \"Patient information: Barrett's esophagus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/39/2676?source=see_link\">",
"       \"Patient information: Barrett's esophagus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend a surveillance strategy that is consistent with 2011 guidelines from the American Gastroenterologic Association (AGA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/61/35802/abstract/3\">",
"     3",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H5136088\">",
"     'American Gastroenterological Association'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that patients with Barrett's esophagus have regular surveillance endoscopy to obtain esophageal biopsy specimens (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Gastroesophageal reflux should be treated prior to surveillance to minimize confusion caused by inflammation in the interpretation of dysplasia. While not in the AGA guidelines, we suggest that the first surveillance endoscopy be performed within one year of the index diagnosis of Barrett's esophagus if there is any question regarding the adequacy of biopsy sampling (eg, four quadrant biopsies were not obtained) or endoscopic signs of neoplasia during the first endoscopy. For patients with no dysplasia or endoscopic signs of neoplasia following adequate biopsy sampling, we suggest surveillance endoscopy at an interval of every three to five years (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Endoscopic surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The above recommendations apply regardless of whether the patient has long or short-segment Barrett's. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Long versus short segment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If dysplasia is noted, we recommend that it be verified by consultation with a second pathologist with expertise in esophageal histopathology. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Dysplasia as a marker of risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with verified low-grade dysplasia after extensive biopsy sampling, we suggest surveillance endoscopy at intervals of 6 to 12 months (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Extensive biopsy sampling involves taking four-quadrant biopsies at intervals of no more than 1 cm throughout the columnar-lined esophagus.",
"      <br/>",
"      <br/>",
"      Radiofrequency ablation may be an appropriate therapeutic alternative for verified low-grade dysplasia in selected cases if an experienced provider is available. (See",
"      <a class=\"local\" href=\"#H73510534\">",
"       'Endoscopic treatment of low-grade dysplasia and nondysplastic Barrett's esophagus'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/53/41817?source=see_link&amp;anchor=H5#H5\">",
"       \"Radiofrequency ablation for Barrett's esophagus\", section on 'Low-grade dysplasia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Esophagectomy is the only therapy for high-grade dysplasia that clearly removes all of the neoplastic epithelium, but it also has the highest rates of procedure-related mortality and long-term morbidity. On the other hand, endoscopic eradication therapy is available, has proven efficacy (although long-term data are not yet available), and is relatively safe. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Esophagectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Endoscopic ablative therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of treatment for high-grade dysplasia and intramucosal cancer in Barrett's esophagus depends upon:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The patient's age (eg, older patients with Barrett's esophagus are less likely to develop cancer due to their shorter life expectancy compared with younger patients)",
"     </li>",
"     <li>",
"      The patient's comorbidities",
"     </li>",
"     <li>",
"      The extent of dysplasia (short segments or Barrett's esophagus are easier to ablate than longer segments with multifocal dysplasia)",
"     </li>",
"     <li>",
"      Local expertise in surgery and endoscopy",
"     </li>",
"     <li>",
"      The patient's preferences with regard to undergoing surgery, undergoing repeated endoscopies, and accepting the possibility of recurrent neoplasia in the absence of esophagectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients with Barrett's esophagus and high-grade dysplasia who are fit to undergo endoscopy, we suggest endoscopic eradication therapy rather than esophagectomy or intensive endoscopic surveillance (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Endoscopic eradication therapy includes endoscopic mucosal resection for the removal and staging of visible lesions (if present), followed by radiofrequency ablation or photodynamic therapy to ablate the remaining metaplastic epithelium. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Endoscopic resection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Endoscopic ablative therapies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5136088\">",
"       'American Gastroenterological Association'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For younger patients with high-grade dysplasia, especially for those with long-segment Barrett's esophagus and multifocal dysplasia, esophagectomy is a reasonable alternative. After a thorough discussion with the younger patient of the risks and benefits of endoscopic eradication therapy and esophagectomy, the choice between the two should be based on patient preferences and the availability of skilled practitioners. For very elderly or infirm patients for whom invasive endoscopic procedures pose a substantial risk, intensive endoscopic surveillance is reasonable. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Esophagectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Intensive endoscopic surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/1\">",
"      Spechler SJ, Fitzgerald RC, Prasad GA, Wang KK. History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology 2010; 138:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/2\">",
"      Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004; 127:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/3\">",
"      American Gastroenterological Association, Spechler SJ, Sharma P, et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011; 140:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/4\">",
"      Wang KK, Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008; 103:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/5\">",
"      ASGE Standards of Practice Committee, Evans JA, Early DS, et al. The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc 2012; 76:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/6\">",
"      Hofstetter WL, Peters JH, DeMeester TR, et al. Long-term outcome of antireflux surgery in patients with Barrett's esophagus. Ann Surg 2001; 234:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/7\">",
"      Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/8\">",
"      Ye W, Chow WH, Lagergren J, et al. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 2001; 121:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/9\">",
"      Corey KE, Schmitz SM, Shaheen NJ. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol 2003; 98:2390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/10\">",
"      Tran T, Spechler SJ, Richardson P, El-Serag HB. Fundoplication and the risk of esophageal cancer in gastroesophageal reflux disease: a Veterans Affairs cohort study. Am J Gastroenterol 2005; 100:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/11\">",
"      Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1998; 93:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/12\">",
"      Gerson LB, Boparai V, Ullah N, Triadafilopoulos G. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther 2004; 20:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/13\">",
"      Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/14\">",
"      Wani S, Sampliner RE, Weston AP, et al. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus. Aliment Pharmacol Ther 2005; 22:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/15\">",
"      Spechler SJ, Sharma P, Traxler B, et al. Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. Am J Gastroenterol 2006; 101:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/16\">",
"      Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/17\">",
"      Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/18\">",
"      Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996; 98:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/19\">",
"      Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/20\">",
"      Souza RF, Shewmake K, Terada LS, Spechler SJ. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002; 122:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/21\">",
"      Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/22\">",
"      Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999; 45:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/23\">",
"      Horwhat JD, Baroni D, Maydonovitch C, et al. Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: incidence and clinical data. Am J Gastroenterol 2007; 102:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/24\">",
"      Garewal H, Ramsey L, Sharma P, et al. Biomarker studies in reversed Barrett's esophagus. Am J Gastroenterol 1999; 94:2829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/25\">",
"      Dvorak K, Ramsey L, Payne CM, et al. Abnormal expression of biomarkers in incompletely ablated Barrett's esophagus. Ann Surg 2006; 244:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/26\">",
"      Rossi M, Barreca M, de Bortoli N, et al. Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett esophagus: a prospective study. Ann Surg 2006; 243:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/27\">",
"      DeMeester SR, DeMeester TR. Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy. Ann Surg 2000; 231:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/28\">",
"      McCallum RW, Polepalle S, Davenport K, et al. Role of anti-reflux surgery against dysplasia in Barrett's esophagus. Gastroenterology 1991; 100:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/29\">",
"      Katz D, Rothstein R, Schned A, et al. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998; 93:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/30\">",
"      Chang EY, Morris CD, Seltman AK, et al. The effect of antireflux surgery on esophageal carcinogenesis in patients with barrett esophagus: a systematic review. Ann Surg 2007; 246:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/31\">",
"      Kastelein F, Spaander MC, Steyerberg EW, et al. Proton Pump Inhibitors Reduce the Risk of Neoplastic Progression in Patients With Barrett's Esophagus. Clin Gastroenterol Hepatol 2013; 11:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/32\">",
"      El-Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004; 99:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/33\">",
"      Nguyen DM, El-Serag HB, Henderson L, et al. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2009; 7:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/34\">",
"      Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/35\">",
"      Spechler SJ. The frequency of esophageal cancer in patients with Barrett's esophagus. Acta Endoscopica 1992; 22:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/36\">",
"      Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med 2001; 111:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/37\">",
"      Conio M, Blanchi S, Lapertosa G, et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003; 98:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/38\">",
"      Rastogi A, Puli S, El-Serag HB, et al. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 2008; 67:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/39\">",
"      Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/40\">",
"      Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/41\">",
"      Sharma P, Falk GW, Weston AP, et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006; 4:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/42\">",
"      Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011; 103:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/43\">",
"      Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011; 365:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/44\">",
"      Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012; 61:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/45\">",
"      Rugge M, Fassan M, Cavallin F, et al. Re: Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2012; 104:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/46\">",
"      Van der Veen AH, Dees J, Blankensteijn JD, Van Blankenstein M. Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut 1989; 30:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/47\">",
"      Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010; 8:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/48\">",
"      Yousef F, Cardwell C, Cantwell MM, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 2008; 168:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/49\">",
"      de Jonge PJ, van Blankenstein M, Looman CW, et al. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 2010; 59:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/50\">",
"      Wani S, Falk G, Hall M, et al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011; 9:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/51\">",
"      Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/52\">",
"      Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 2000; 321:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/53\">",
"      Solaymani-Dodaran M, Logan RF, West J, et al. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004; 53:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/54\">",
"      Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001; 48:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/55\">",
"      Streitz JM Jr, Andrews CW Jr, Ellis FH Jr. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993; 105:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/56\">",
"      Peters JH, Clark GW, Ireland AP, et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994; 108:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/57\">",
"      Corley DA, Levin TR, Habel LA, et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002; 122:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/58\">",
"      Fountoulakis A, Zafirellis KD, Dolan K, et al. Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer. Br J Surg 2004; 91:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/59\">",
"      Wong T, Tian J, Nagar AB. Barrett's surveillance identifies patients with early esophageal adenocarcinoma. Am J Med 2010; 123:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/60\">",
"      Shaheen NJ, Provenzale D, Sandler RS. Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence. Am J Gastroenterol 2002; 97:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/61\">",
"      Gerson LB, Groeneveld PW, Triadafilopoulos G. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2004; 2:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/62\">",
"      Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003; 138:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/63\">",
"      Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/64\">",
"      Lao CD, Simmons M, Syngal S, et al. Dysplasia in Barrett esophagus. Cancer 2004; 100:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/65\">",
"      Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology 2011; 141:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/66\">",
"      Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/67\">",
"      Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000; 95:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/68\">",
"      Sikkema M, Looman CW, Steyerberg EW, et al. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study. Am J Gastroenterol 2011; 106:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/69\">",
"      Skacel M, Petras RE, Gramlich TL, et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000; 95:3383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/70\">",
"      Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010; 105:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/71\">",
"      Srivastava A, Hornick JL, Li X, et al. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 2007; 102:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/72\">",
"      Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001; 120:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/73\">",
"      Verbeek RE, van Oijen MG, ten Kate FJ, et al. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study. Am J Gastroenterol 2012; 107:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/74\">",
"      Dar MS, Goldblum JR, Rice TW, Falk GW. Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy? Gut 2003; 52:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/75\">",
"      Weston AP, Sharma P, Topalovski M, et al. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol 2000; 95:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/76\">",
"      Reid BJ, Weinstein WM, Lewin KJ, et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology 1988; 94:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/77\">",
"      Cameron AJ, Carpenter HA. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. Am J Gastroenterol 1997; 92:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/78\">",
"      Konda VJ, Ross AS, Ferguson MK, et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? Clin Gastroenterol Hepatol 2008; 6:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/79\">",
"      Collard JM. High-grade dysplasia in Barrett's esophagus. The case for esophagectomy. Chest Surg Clin N Am 2002; 12:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/80\">",
"      Reed MF, Tolis G Jr, Edil BH, et al. Surgical treatment of esophageal high-grade dysplasia. Ann Thorac Surg 2005; 79:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/81\">",
"      Nasr JY, Schoen RE. Prevalence of adenocarcinoma at esophagectomy for Barrett's esophagus with high grade dysplasia. J Gastrointest Oncol 2011; 2:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/82\">",
"      Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993; 105:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/83\">",
"      Falk GW, Rice TW, Goldblum JR, Richter JE. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 1999; 49:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/84\">",
"      Abela JE, Going JJ, Mackenzie JF, et al. Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy. Am J Gastroenterol 2008; 103:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/85\">",
"      Curvers WL, Bansal A, Sharma P, Bergman JJ. Endoscopic work-up of early Barrett's neoplasia. Endoscopy 2008; 40:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/86\">",
"      ASGE Standards of Practice Committee, Evans JA, Early DS, et al. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc 2013; 77:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/87\">",
"      Reid BJ, Blount PL, Rabinovitch PS. Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003; 13:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/88\">",
"      Guindi M, Riddell RH. Dysplasia in barrett's esophagus. New techniques and markers. Chest Surg Clin N Am 2002; 12:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/89\">",
"      Bird-Lieberman EL, Dunn JM, Coleman HG, et al. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. Gastroenterology 2012; 143:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/90\">",
"      Alvi MA, Liu X, O'Donovan M, et al. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus. Clin Cancer Res 2013; 19:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/91\">",
"      Canto MI, Setrakian S, Willis J, et al. Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus. Gastrointest Endosc 2000; 51:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/92\">",
"      Scotiniotis IA, Kochman ML, Lewis JD, et al. Accuracy of EUS in the evaluation of Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma. Gastrointest Endosc 2001; 54:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/93\">",
"      Kobayashi K, Izatt JA, Kulkarni MD, et al. High-resolution cross-sectional imaging of the gastrointestinal tract using optical coherence tomography: preliminary results. Gastrointest Endosc 1998; 47:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/94\">",
"      Georgakoudi I, Jacobson BC, Van Dam J, et al. Fluorescence, reflectance, and light-scattering spectroscopy for evaluating dysplasia in patients with Barrett's esophagus. Gastroenterology 2001; 120:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/95\">",
"      Kendall C, Stone N, Shepherd N, et al. Raman spectroscopy, a potential tool for the objective identification and classification of neoplasia in Barrett's oesophagus. J Pathol 2003; 200:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/96\">",
"      Wallace MB, Sharma P, Lightdale C, et al. Preliminary accuracy and interobserver agreement for the detection of intraepithelial neoplasia in Barrett's esophagus with probe-based confocal laser endomicroscopy. Gastrointest Endosc 2010; 72:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/97\">",
"      Shaheen NJ, Inadomi JM, Overholt BF, Sharma P. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut 2004; 53:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/98\">",
"      Vij R, Triadafilopoulos G, Owens DK, et al. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc 2004; 60:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/99\">",
"      Swisher SG, Deford L, Merriman KW, et al. Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg 2000; 119:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/100\">",
"      van Lanschot JJ, Hulscher JB, Buskens CJ, et al. Hospital volume and hospital mortality for esophagectomy. Cancer 2001; 91:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/101\">",
"      Karl RC, Schreiber R, Boulware D, et al. Factors affecting morbidity, mortality, and survival in patients undergoing Ivor Lewis esophagogastrectomy. Ann Surg 2000; 231:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/102\">",
"      Young MM, Deschamps C, Trastek VF, et al. Esophageal reconstruction for benign disease: early morbidity, mortality, and functional results. Ann Thorac Surg 2000; 70:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/103\">",
"      Peyre CG, DeMeester SR, Rizzetto C, et al. Vagal-sparing esophagectomy: the ideal operation for intramucosal adenocarcinoma and barrett with high-grade dysplasia. Ann Surg 2007; 246:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/104\">",
"      Santillan AA, Farma JM, Meredith KL, et al. Minimally invasive surgery for esophageal cancer. J Natl Compr Canc Netw 2008; 6:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/105\">",
"      Prasad GA, Wu TT, Wigle DA, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology 2009; 137:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/106\">",
"      Wang VS, Hornick JL, Sepulveda JA, et al. Low prevalence of submucosal invasive carcinoma at esophagectomy for high-grade dysplasia or intramucosal adenocarcinoma in Barrett's esophagus: a 20-year experience. Gastrointest Endosc 2009; 69:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/107\">",
"      Dunbar KB, Spechler SJ. The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett's esophagus: a systematic review. Am J Gastroenterol 2012; 107:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/108\">",
"      van den Boogert J, van Hillegersberg R, Siersema PD, et al. Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: a review. Am J Gastroenterol 1999; 94:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/109\">",
"      Sampliner RE. Endoscopic ablative therapy for Barrett's esophagus: current status. Gastrointest Endosc 2004; 59:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/110\">",
"      Sharma VK, Wang KK, Overholt BF, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 2007; 65:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/111\">",
"      Bright T, Watson DI, Tam W, et al. Randomized trial of argon plasma coagulation versus endoscopic surveillance for barrett esophagus after antireflux surgery: late results. Ann Surg 2007; 246:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/112\">",
"      Van Laethem JL, Peny MO, Salmon I, et al. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut 2000; 46:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/113\">",
"      Gastrointest Endosc 2013; 77:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/114\">",
"      Wani S, Puli SR, Shaheen NJ, et al. Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol 2009; 104:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/115\">",
"      Inadomi JM, Somsouk M, Madanick RD, et al. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 2009; 136:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/116\">",
"      Sharma VK, Kim HJ, Das A, et al. A prospective pilot trial of ablation of Barrett's esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system). Endoscopy 2008; 40:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/117\">",
"      Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc 2008; 68:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/118\">",
"      Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy 2010; 42:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/119\">",
"      Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Stepwise circumferential and focal ablation of Barrett's esophagus with high-grade dysplasia: results of the first prospective series of 11 patients. Endoscopy 2008; 40:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/120\">",
"      Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy 2008; 40:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/121\">",
"      Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009; 360:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/122\">",
"      Pouw RE, Wirths K, Eisendrath P, et al. Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol 2010; 8:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/123\">",
"      Sharma VK, Jae Kim H, Das A, et al. Circumferential and focal ablation of Barrett's esophagus containing dysplasia. Am J Gastroenterol 2009; 104:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/124\">",
"      van Vilsteren FG, Pouw RE, Seewald S, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut 2011; 60:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/125\">",
"      Finkelstein SD, Lyday WD. The molecular pathology of radiofrequency mucosal ablation of Barrett's esophagus [abstract]. Gastroenterology 2008; 134:A436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/126\">",
"      Pouw RE, Gondrie JJ, Rygiel AM, et al. Properties of the neosquamous epithelium after radiofrequency ablation of Barrett's esophagus containing neoplasia. Am J Gastroenterol 2009; 104:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/127\">",
"      Hur C, Choi SE, Rubenstein JH, et al. The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology 2012; 143:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/128\">",
"      Shaheen NJ, Greenwald BD, Peery AF, et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 2010; 71:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/129\">",
"      Soetikno RM, Gotoda T, Nakanishi Y, Soehendra N. Endoscopic mucosal resection. Gastrointest Endosc 2003; 57:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/130\">",
"      Pech O, May A, Gossner L, et al. Management of pre-malignant and malignant lesions by endoscopic resection. Best Pract Res Clin Gastroenterol 2004; 18:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/131\">",
"      Ell C, May A, Pech O, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc 2007; 65:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/132\">",
"      Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008; 57:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/133\">",
"      Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 2000; 95:3089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/134\">",
"      Gupta N, Waxman I, Sharma P. A critical look at endoscopic eradication therapy for Barrett's esophagus: are we putting the cart before the horse? Gastrointest Endosc 2011; 73:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/135\">",
"      Spechler SJ. Barrett's Esophagus without dysplasia: wait or ablate? Dig Dis Sci 2011; 56:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/136\">",
"      Omer ZB, Ananthakrishnan AN, Nattinger KJ, et al. Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol 2012; 10:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/137\">",
"      Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/138\">",
"      Abnet CC, Freedman ND, Kamangar F, et al. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 2009; 100:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/139\">",
"      Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58:2929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/140\">",
"      Souza RF, Shewmake K, Beer DG, et al. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000; 60:5767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/141\">",
"      Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010; 138:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/142\">",
"      Kastelein F, Spaander MC, Biermann K, et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology 2011; 141:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/143\">",
"      Heath EI, Canto MI, Wu TT, et al. Chemoprevention for Barrett's esophagus trial. Design and outcome measures. Dis Esophagus 2003; 16:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/144\">",
"      Souza RF, Spechler SJ. Barrett's esophagus: chemoprevention. Gastrointest Endosc Clin N Am 2003; 13:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/145\">",
"      Heath EI, Canto MI, Piantadosi S, et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007; 99:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/146\">",
"      Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 2004; 96:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/147\">",
"      Boyer J, Robaszkiewicz M. Guidelines of the French Society of Digestive Endoscopy: monitoring of Barrett's esophagus. The Council of the French Society of Digestive Endoscopy. Endoscopy 2000; 32:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/148\">",
"      Management of Barrett's esophagus. The Society for Surgery of the Alimentary Tract (SSAT), American Gastroenterological Association (AGA), American Society for Gastrointestinal Endoscopy (ASGE) Consensus Panel. J Gastrointest Surg 2000; 4:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/61/35802/abstract/149\">",
"      Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012; 143:336.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2236 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-23AA9155C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_61_35802=[""].join("\n");
var outline_f34_61_35802=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT OF GERD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Does aggressive treatment of reflux prevent progression to cancer?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - In vitro studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Clinical studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ENDOSCOPIC SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Influence of Barrett's esophagus on mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Evidence supporting surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dysplasia as a marker of risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Detecting dysplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Molecular markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Endoscopic techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Long versus short segment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT OF HIGH-GRADE DYSPLASIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Esophagectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Endoscopic ablative therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Photodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6989124\">",
"      - Endoscopic spray cryotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Endoscopic resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Intensive endoscopic surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H73510534\">",
"      ENDOSCOPIC TREATMENT OF LOW-GRADE DYSPLASIA AND NONDYSPLASTIC BARRETT'S ESOPHAGUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CHEMOPREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5136088\">",
"      American Gastroenterological Association",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2236\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2236|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/17/22806\" title=\"picture 1\">",
"      Barretts squamous island",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/27/13750?source=related_link\">",
"      Autofluorescence endoscopy for Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15370?source=related_link\">",
"      Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10858?source=related_link\">",
"      Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1161?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=related_link\">",
"      Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20426?source=related_link\">",
"      Management of superficial esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/40/29316?source=related_link\">",
"      Narrow band imaging in Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/54/4970?source=related_link\">",
"      Overview of endoscopic resection of gastrointestinal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8391?source=related_link\">",
"      Pathogenesis of Barrett's esophagus and its malignant transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/39/2676?source=related_link\">",
"      Patient information: Barrett's esophagus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/29/13778?source=related_link\">",
"      Patient information: Barrett's esophagus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/27/26039?source=related_link\">",
"      Photodynamic therapy for ablation of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/53/41817?source=related_link\">",
"      Radiofrequency ablation for Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42905?source=related_link\">",
"      Surgical management of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_61_35803="Immunocompromised pyo rx";
var content_f34_61_35803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Empiric antibiotic therapy for pyomyositis in immunocompromised adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Vancomycin should be combined with one of the following regimens for empiric gram-negative and anaerobic coverage:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Monotherapy with a beta-lactam/beta-lactamase inhibitor, such as one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Ampicillin-sulbactam (3 g every six hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Piperacillin/tazobactam (4.5 g every eight hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Ticarcillin-clavulanate (3.1 g every four hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A third generation cephalosporin such as ceftriaxone (1 g IV every 24 hours)",
"       <strong>",
"        PLUS",
"       </strong>",
"       metronidazole (500 mg IV every eight hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Alternative empiric regimens for empiric gram-negative and anaerobic coverage include:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A fluoroquinolone (eg, ciprofloxacin 400 mg IV every 12 hours or levofloxacin 500 mg IV daily)",
"       <strong>",
"        PLUS",
"       </strong>",
"       metronidazole (500 mg IV every eight hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Monotherapy with a carbapenem*, such as one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Imipenem (500 mg every six hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Meropenem (1 g every 8 hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Ertapenem (1 g daily)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Carbapenems should not be used for patients with history of immediate-type hypersensitivity to beta-lactams.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_61_35803=[""].join("\n");
var outline_f34_61_35803=null;
var title_f34_61_35804="Therapeutic goals";
var content_f34_61_35804=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Therapeutic goals for management of metabolic syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Goals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Lifestyle risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Abdominal obesity",
"       </td>",
"       <td>",
"        Year 1: reduce body weight 7 to 10 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continue weight loss thereafter with ultimate goal BMI &lt;25 kg/m2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Physical inactivity",
"       </td>",
"       <td>",
"        At least 30 min (and preferably &ge;60 min) continuous or intermittent moderate intensity exercise 5X/wk, but preferably daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atherogenic diet",
"       </td>",
"       <td>",
"        Reduced intake saturate fat, trans fat, cholesterol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Metabolic risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        Dyslipidemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"3\">",
"        Primary target elevated LDL-C",
"       </td>",
"       <td class=\"sublist_other\">",
"        High risk*: &lt;100 mg/dL (2.6 mmol/&gt;L); optional &lt;70 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Moderate risk: &lt;130 mg/dL (3.4 mmol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Lower risk: &lt;160 mg/dL (4.9 mmol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"3\">",
"        Secondary target elevated non-HDL-C",
"       </td>",
"       <td class=\"sublist_other\">",
"        High risk*: &lt;130 mg/dL (3.4 mmol/L); optional &lt;100 mg/dL (2.6 mmol/L) very high risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Moderate risk: &lt;160 mg/dL (4.1 mmol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Lower risk: &lt;190 mg/dL (4.9 mmol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Tertiary target reduced HDL-C",
"       </td>",
"       <td class=\"sublist_other\">",
"        Raise to extent possible w/weight reduction and exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Elevated bp",
"       </td>",
"       <td>",
"        Reduce to at least &lt;140/90 (&lt;130/80 if diabetic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Elevated glucose",
"       </td>",
"       <td>",
"        For IFG, encourage weight reduction and exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For type 2 DM, target A1C &lt;7 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prothrombotic state",
"       </td>",
"       <td>",
"        Low dose aspirin for high risk patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Proinflammatory state",
"       </td>",
"       <td>",
"        Lifestyle therapies; no specific interventions",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DM: diabetes mellitus; IFG: impaired fasting glucose; bp: blood pressure.",
"     <br/>",
"     * High risk: diabetes, known coronary artery disease.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Grundy S, Cleeman J, Daniels S, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112:2735.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_61_35804=[""].join("\n");
var outline_f34_61_35804=null;
var title_f34_61_35805="Treatment of HCV genotype I telaprevir";
var content_f34_61_35805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Treatment of HCV genotype I with telaprevir, peginterferon, and ribavirin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 287px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TT: triple therapy (telaprevir, peginterferon, weight-based ribavirin); DT: dual therapy (peginterferon, weight-based ribavirin).",
"     <br>",
"      * Time points where HCV RNA should be checked. The HCV RNA should also be checked at the end of therapy and six months after completing therapy in those with an end of treatment response. Treatment should be discontinued if HCV RNA is &gt;1000 IU/mL at week 4 or 12 or if HCV RNA is detectable at week 24.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_61_35805=[""].join("\n");
var outline_f34_61_35805=null;
var title_f34_61_35806="Safety instructions for patients receiving radioiodine treatment";
var content_f34_61_35806=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Safety instructions for patients receiving radioiodine treatment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"2\">",
"        <em>",
"         To be given verbally and in writing and edited as appropriate for the patient.",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dear Patient (name):",
"       </td>",
"       <td>",
"        Date:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        With regard to your radioiodine therapy, please consider the following.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        <strong>",
"         STEP 1:",
"        </strong>",
"        Talk with your doctor or a member of the Radioiodine Treatment Team about:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          Why treated women must avoid pregnancy for a period of time and not breastfeed",
"         </li>",
"         <li>",
"          When treated men can consider fathering a child",
"         </li>",
"         <li>",
"          Who will give you the radioiodine therapy, and where and when this will happen",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        <strong>",
"         STEP 2:",
"        </strong>",
"        Make preparations before treatment and talk with your doctor or a member of the Radioiodine Treatment Team about the following specific items.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"2\">",
"        Obtaining:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          Wipes and/or toilet paper that can be flushed down the toilet",
"         </li>",
"         <li>",
"          Disposable gloves if others will be helping to take care of you",
"         </li>",
"         <li>",
"          Heavy duty (doubled if possible), leak proof, specified plastic trash bags for tissues, paper towels and other things that may be contaminated and trashed",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"2\">",
"        For your travel:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          If you are well enough, it is best to drive yourself",
"         </li>",
"         <li>",
"          If you ride with someone else, confirm she is not pregnant, and maintain a distance of &gt;3 feet (use the back seat on opposite side of the driver)",
"         </li>",
"         <li>",
"          When and where you can take necessary trips",
"         </li>",
"         <li>",
"          When it is safe to use public transportation",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"2\">",
"        For home:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          Living or working with a pregnant woman",
"         </li>",
"         <li>",
"          Associations with children",
"         </li>",
"         <li>",
"          Inability to control your urine or bowels",
"         </li>",
"         <li>",
"          Using special medical equipment, such as catheters, ostomy bags, or anything that could be contaminated by your body fluids",
"         </li>",
"         <li>",
"          Getting sick easily (throwing up or getting woozy)",
"         </li>",
"         <li>",
"          Not being able to go directly home; arrangements must be made through your treatment team. Hotel and motel stays are not recommended.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        <strong>",
"         STEP 3.",
"        </strong>",
"        Your doctor or member of the Radioiodine Treatment Team will discuss with you the following items and fill in the number of days related to each.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          Days that you need to stay &gt;3 feet away from your adult family members and caregivers for at least 18 hours a day, and at least 6 feet away as much as possible: ______________",
"         </li>",
"         <li>",
"          Days that you need to stay &gt;6 feet away from babies, children younger than 16-years-old and pregnant women: ______________",
"         </li>",
"         <li>",
"          Days that you need to stay away from work and close contact with others in public places (movies, shopping, etc): ______________",
"         </li>",
"         <li>",
"          Days that you need to stay away from school or daycare (includes both teachers and students): ______________",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        <strong>",
"         STEP 4.",
"        </strong>",
"        Recommendations for after therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"2\">",
"        At home: specific recommendations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Ask your doctor for the number of days to:",
"        <ul>",
"         <li>",
"          Sleep alone in a bed that is &gt;6 feet away from another person, and, if possible, use a separate bedroom or sleeping room all by yourself",
"         </li>",
"         <li>",
"          Not kiss anyone",
"         </li>",
"         <li>",
"          Not have sexual activity",
"         </li>",
"         <li>",
"          Move your bowels every day and use a laxative if you need help",
"         </li>",
"         <li>",
"          Empty your bladder (urinate) every hour or so during the day of, and day after your radioiodine treatment; follow your doctor's advice on how much to drink",
"         </li>",
"         <li>",
"          Use wipes (preferably flushable) to clean the toilet seat after use; men should sit down to urinate and use wipes to remove splatter of urine; wipe yourself dry after urinating so that you do not drip",
"         </li>",
"         <li>",
"          For a phone you share with others, after use, wipe off the mouthpiece, or, while using, cover the phone with a plastic bag that, after use, is placed in specified plastic trash bag",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"2\">",
"        At home: general recommendations, especially for patients sharing a bathroom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          Flush the toilet after each time you use it; flush toilet paper and wipes",
"         </li>",
"         <li>",
"          Always wash your hands well after using the toilet",
"         </li>",
"         <li>",
"          Rinse the sink and wash your hands after brushing your teeth to wash away the saliva (spit)",
"         </li>",
"         <li>",
"          Do not share your toothbrush, razor, face cloth, towel, food or drinks, spoons, forks, glasses and dishes",
"         </li>",
"         <li>",
"          Shower every day for at least the first 2 days after your treatment",
"         </li>",
"         <li>",
"          Do not cook for other people. If cooking is necessary, use plastic gloves and dispose of in the specified plastic trash bag.",
"         </li>",
"         <li>",
"          Wash your dishes in a dishwasher or by hand; it is better not to use disposable (throw-away) dishes which must be put into a specified plastic trash bag",
"         </li>",
"         <li>",
"          Try to flush any tissues or any other items that contain anything from your body, such as blood, down the toilet; items that cannot be flushed, such as menstrual pads, bandages, paper/plastic dishes, spoons and forks and paper towels, should be put in the specified plastic trash bag",
"         </li>",
"         <li>",
"          Wash your underwear, pajamas, sheets and any clothes that contain sweat, blood or urine by themselves. Use a standard washing machine; you do not need to use bleach and do not need extra rinses.",
"         </li>",
"         <li>",
"          Have anyone who helps you clean up vomit, blood, urine, or stool wear plastic gloves; the gloves should then be put in the specified trash plastic bag",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\" colspan=\"2\">",
"        Trash recommendations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        <ul>",
"         <li>",
"          Keep the specified plastic trash bags separate from other trash; keep the bags away from children and animals",
"         </li>",
"         <li>",
"          A member of your Radioiodine Treatment Team will tell you how and when to get rid of the specified plastic trash bag. You may be asked to bring the bag back to your treatment facility, or, after 80 days, the bag may be removed as other trash bags.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\" colspan=\"2\">",
"        Pets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        <ul>",
"         <li>",
"          Usually pets will not receive enough radiation to harm them. But do not sleep with pets (ask your doctor for how long) since your saliva, perspiration or other secretions may be carried away by the pet.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"2\">",
"        Outside the home",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Ask your doctor or a member of the Radioiodine Treatment Team when:",
"        <ul>",
"         <li>",
"          It will be safe to eat out, go shopping and attend events such as religious services, parties and movies",
"         </li>",
"         <li>",
"          You will be able to return to work and to care for or teach others",
"         </li>",
"         <li>",
"          It would be safe to donate blood",
"         </li>",
"         <li>",
"          Special or longer distance travel is possible. (Note: For up to 3 months or more following radioiodine treatment you may set off radiation detectors at: national borders, airports, bus and train stations, tunnels, bridges, trash collection sites and even your place of employment. A member of your Radioiodine Treatment Team will issue you a letter or card describing the therapy and the phone number of a person knowledgeable about your treatment (usually at the treating facility) in case local law enforcement agents need to check on this information. You should keep the letter or card containing the information with you whenever you are traveling for at least 3 months.)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"2\">",
"        Emergency care",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          You will get an information card or letter at the time of your treatment that will show the date, type and amount of radioiodine that you were treated with; carry this card with you at all times for at least 3 months following your treatment",
"         </li>",
"         <li>",
"          If you are in a traffic accident or any other medical emergency during the first week after your treatment, you should show this card to the medical people to let them know about the date and dose of your radioiodine treatment",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        <strong>",
"         IMPORTANT INFORMATION FOR PATIENTS ON RISKS OF RADIATION",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <p>",
"         Radiation exposure to others should always be as low as reasonably achievable, a goal often abbreviated as ALARA. If you follow the above advice, the radiation from you to others is likely to be less than what they receive from radiation in nature over a year's time.",
"        </p>",
"        <p>",
"         Please phone us if you have any questions, and particularly if:",
"        </p>",
"        <ul>",
"         <li>",
"          Any of the above instructions cannot be followed and/or if",
"         </li>",
"         <li>",
"          You see anything that may have accidentally or unavoidably increased exposure of others to radiation",
"         </li>",
"        </ul>",
"        <br/>",
"        <p>",
"         We welcome your input on how we can improve our methods and advice to patients.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        Phone:",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        Sincerely yours,",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The American Thyroid Association Taskforce on Radioiodine Safety. Radiation Safety in the Treatment of Patients with Thyroid Diseases by Radioiodine 131-I: Practice Recommendations of the American Thyroid Association. Thyroid 2011; 21:335. Copyright &copy; 2011 Mary Ann Liebert Publishers.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_61_35806=[""].join("\n");
var outline_f34_61_35806=null;
var title_f34_61_35807="Bergmeister papilla";
var content_f34_61_35807=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bergmeister papilla",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A white glial remnant overlies the central portion of the disc, obscuring the retinal vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl C Golnik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_61_35807=[""].join("\n");
var outline_f34_61_35807=null;
